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Summary 
The South African ostrich industry is currently being threatened by respiratory disease in feedlot ostriches 
with dramatic production losses.  Three ostrich-specific mycoplasmas, Ms01, Ms02 and Ms03 were 
identified to be associated with respiratory disease in ostriches in South Africa.  There is currently no 
registered mycoplasma vaccine available for use in ostriches.  In order to prevent mycoplasma infections 
in South African ostriches, the ostrich industry has launched an investigation into possible strategies for 
vaccine development.  This thesis describes different strategies for the establishment of immunity in 
ostriches against the ostrich-specific mycoplasmas.  Firstly, the effectiveness of existing poultry 
mycoplasma vaccines to provide protection in ostriches against ostrich mycoplasma infections was tested.  
To this end, ostriches received primary and secondary vaccinations with poultry mycoplasma vaccines 
against Mycoplasma synoviae or Mycoplasma gallicepticum, respectively, after which protection against 
ostrich-specific mycoplasma was evaluated.  Even though the specific identity of the ostrich-specific 
mycoplasmas (Ms01, Ms02, and/or Ms03) responsible for subsequent infection of immunized ostriches 
was not determined, it was concluded that poultry mycoplasma vaccines do not provide protection against 
these mycoplasma infections in ostriches.  This appears to be the result of low levels of antibody cross-
reactivity between mycoplasmas, highlighting the necessity for the development of specific vaccines 
against each of the individual ostrich-specific mycoplasmas. 
Secondly, the development of a DNA vaccine against Ms01 was investigated.  With the aim of 
developing an Ms01-specific DNA vaccine, the entire Ms01 genome was sequenced using GS20 
sequencing technology.  Bioinformatic searches were launched for the identification of an appropriate 
vaccine candidate gene in the Ms01 genome.  The P100 gene, showing a high degree of homology with 
the P100 gene of the human pathogen M. hominis, was subsequently identified.  After successful cloning, 
and modification of ten specific codons within the gene to correct for alternative codon usage, the 
modified P100 gene of Ms01 is now ready for insertion into a suitable DNA vaccine vector, for 
subsequent use as a DNA vaccine in ostriches. 
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Opsomming 
Die Suid-Afrikaanse volstruisbedryf word huidiglik bedreig deur respiratoriese siektes in voerkraal 
volstruise wat aansienlike produksieverliese tot gevolg het.  Drie volstruis-spesifieke mikoplasmas, Ms01, 
Ms02 en Ms03 is geïdentifiseer wat ‘n rol te speel in respiratoriese siektes in volstruise in Suid-Afrika.  
Daar is huidiglik geen geregistreerde mikoplasma entstof beskikbaar vir gebruik in volstruise nie.  Ten 
einde mikoplasma infeksies in volstruise te voorkom, het die Suid-Afrikaanse volstruisbedryf ‘n 
ondersoek geloods na moontlike strategieë vir entstof ontwikkeling.  Hierdie tesis handel oor benaderinge 
om immuniteit in volstuise teen die volstruis-spesifieke mikoplasmas te induseer.  Eerstens is die 
effektiwiteit van bestaande pluimvee mikoplasma entstowwe getoets vir beskerming in volstruise teen 
volstruis-spesifieke mikoplasmas.  Met dit ten doel, is volstruise twee maal met pluimvee entstowwe teen 
Mycoplasma synoviae of Mycoplasma gallisepticum onderskeidelik geënt, waarna die beskerming teen 
Ms01 geëvalueer is.  Alhoewel die presiese identiteit van die volstruis-spesifieke mikoplasmas (Ms01, 
Ms02 en/of Ms03) verantwoordelik vir die daaropvolgende infeksies in geïmmuniseerde volstruise nie 
bepaal is nie, is dit gevind dat die toediening van pluimvee entstowwe nie beskerming gebied het teen 
hierdie mikoplasma infeksies in volstruise nie.  Dit blyk die gevolg te wees van die lae vlakke van 
antiliggaam kruis-reaktiwiteit tussen mikoplasmas, en beklemtoon dat die ontwikkeling van spesifieke 
entstowwe vir elk van die volstruis-spesifieke mikoplasmas individueel uitgevoer sal moet word. 
Tweedens is die ontwikkeling van ‘n DNA entstof teen Ms01 ondersoek.  Met die doel om ‘n Ms01-
spesifieke DNA entstof te ontwikkel, is die volledige Ms01 genoomvolgorde bepaal deur gebruik te maak 
van “GS20” volgordebepalingtegnologie.  Daarna is bioinformatika soektogte geloods vir die 
identifisering van ‘n geskikte entstof kandidaat geen in die Ms01 genoom.  Die P100 geen, wat hoë 
homologie toon met die menslike patogeen M. hominis se P100 geen, is geïdentifiseer in Ms01.  Na 
suksesvolle klonering, en die modifisering van tien spesifieke kodons in die geen, is die gemodifiseerde 
P100 geen van Ms01 nou geskik vir invoeging in ‘n geskikte DNA entstof vektor, vir daaropvolgende 
gebruik as DNA entstof in volstruise. 
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Chapter 1 – Introduction 
South Africa is the undisputed world leader in the ostrich trade.  Large scale commercial ostrich farming 
originated in South Africa in the mid-eighteen hundreds (1864), reaching a peak in the early nineteen 
hundreds (1913) when ostrich feathers became South Africa’s fourth largest export product, closely 
behind gold, diamonds and wool (History Of: Ostriches and Oudtshoorn, 2004).  In 1986, South Africa 
exported a record high of 90 000 ostrich hides to the United States alone, and by 1992, 95% of the 
ostriches slaughtered worldwide were processed in South Africa.  Today, ostrich farming is still regarded 
as one of the top trades in South Africa, ranking in the top twenty agro-based industries, with the total 
investment in ostrich production and processing activities exceeding R2.1 billion.  The industry is mainly 
export driven, with 90% of all leather and meat products being exported, amounting to an annual export 
income of R1.2 billion.  Currently, South Africa has 558 registered export farms producing 300 000 
slaughter birds annually, and creating employment for more than 20 000 workers, lending to the 
significant economic and socio-economic value of the industry (The South African Ostrich Industry, 
2004). 
A major attribute of the ostrich industry, is its high profit potential brought about by the variety of 
products obtained from a bird.  Initially the focus of the ostrich trade was on the production of feathers 
only, much later the skin was included, and only relatively recently meat (Huchzermeyer, 2002).  The 
value of a slaughter bird in South Africa can generally be broken down as 10% feathers, 20% meat, and 
70% skin.  Ostrich feathers are commonly used for cleaning purposes, and also serve as decorations and 
are quite popular in the fashion industry.  Ostrich meat is regarded the healthiest of all red meats with low 
fat (<2%), cholesterol and calorie content, while still retaining a high protein content.  Therefore, ostrich 
meat has gained considerable popularity in recent years with increased consumer awareness concerning a 
healthy lifestyle.  Furthermore, ostrich leather is considered to be one of the most luxurious leathers, on a 
par with other exotic leathers such as crocodile and snake leather (Ostrich products, 2004). 
Owing to South Africa’s historic advantage, as well as the favorable natural conditions, South Africa 
should be able to maintain its world leadership in the ostrich trade provided that certain conditions, such 
as disease control and export regulations, are met.  The South African ostrich industry is currently being 
threatened by respiratory disease in feedlot ostriches resulting in up to 30% production losses (personal 
communication, Dr. A. Olivier).  Other than the dramatic production losses, a further concern involves 
the transmission of mycoplasmas to other countries via contaminated products.  Therefore mycoplasma 
infections may place constraints on the export of ostrich products, thereby potentially having a 
considerable economic impact.  Recently, three ostrich-specific mycoplasmas, Ms01, Ms02 and Ms03 
(Ms, Mycoplasma struthionis after their host, Struthio camelus) were identified to be associated with 
respiratory disease in ostriches in South Africa (Botes et al., 2005).  Strategies for the control of 
mycoplasma infections in ostriches include prevention by strict biosecurity practices, and treatment with a 
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limited range of antibiotics.  However, there is currently no registered mycoplasma vaccine available for 
use in ostriches. 
In order to prevent mycoplasma infections in South African ostriches, the ostrich industry has launched 
an investigation into possible strategies for vaccine development.  Their investigation includes 
conventional approaches to vaccine development (whole-organism vaccines), undertaken at 
Onderstepoort Veterinary Institute, Pretoria (not part of this study), as well as a more novel approach to 
vaccine development, namely DNA vaccine development (described in this study).  As alternative to 
vaccine development, the use of existing poultry mycoplasma vaccines to provide protection against 
mycoplasma infections in ostriches has been suggested. 
The objectives of this study were: 
• Testing the effectiveness of poultry mycoplasma vaccines against Mycoplasma synoviae and 
Mycoplasma gallisepticum in providing protection in ostriches against the ostrich-specific 
mycoplasmas Ms01, Ms02 and Ms03. 
• The identification, isolation and modification of a DNA vaccine candidate gene in the ostrich 
mycoplasma Ms01 for subsequent DNA vaccine development against this mycoplasma. 
In this thesis, Chapter 2 contains a literature review of the classification, evolution, phylogeny, genome 
characteristics, morphology, biochemistry, distribution, and pathogenesis of mycoplasmas.  An overview 
of poultry and ostrich-specific mycoplasmas is given, as well as strategies for the development of new 
vaccines.  Vaccine trials with existing poultry mycoplasma vaccines in ostriches are described in Chapter 
3.  In Chapter 4, the identification, isolation and modification of a possible DNA vaccine candidate gene 
of the ostrich-specific mycoplasma, Ms01, is described.  A conclusion and future perspectives are given 
in Chapter 5, followed by a reference list and appropriate addenda including the statistical analysis of the 
ELISA results using the Statistical Analysis System (SAS), the nucleotide/amino acid sequence of the 
P100 gene of Ms01, and the alignment of the P100 gene sequence after site-directed mutagenesis (SDM). 
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Chapter 2 – Characteristics, pathogenicity and host specificity of 
mycoplasmas, and general approaches to vaccine development 
2.1 Introduction 
Mycoplasmas are cell wall-less bacteria known to be the smallest cellular organisms capable of self-
reproduction.  They are commensals as well as parasites of a wide range of hosts, in many cases causing 
disease (Razin, 1985).  In order to develop new strategies for the prevention and control of infection with 
pathogenic mycoplasma species, it is necessary to have a clear understanding of their cellular 
mechanisms, and in particular, their mode of pathogenesis.  In this literature review, the characteristics of 
mycoplasmas in general, including their classification, evolution, phylogenetic relationships, genome 
characteristics, morphology, biochemistry, distribution, as well as their pathogenicity, will be discussed.  
The focus will then be shifted to avian mycoplasmas, more specifically the two major pathogens of 
commercial poultry Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS), as well as the 
recently identified pathogenic ostrich-specific mycoplasmas Ms01, Ms02 and Ms03.  The epidemiology 
of these pathogens, as well as currently available treatments will be outlined, followed by a summary of 
strategies for the development of vaccines against mycoplasmas. 
2.2 Taxonomy 
Phenotypically, mycoplasmas are mainly distinguished from other bacteria by their complete lack of a 
cell wall (Razin, 1985).  Furthermore, mycoplasmas are known for their minute size and uniquely small 
genome with their low guanine-and-cytosine (G+C) content, as well as a strict requirement for exogenous 
sterol (Weisburg et al., 1989; Razin et al., 1998; Bradbury, 2005).  It is these most distinctive features 
that form the basis for the classification of mycoplasmas.  Taxonomically, the lack of a cell wall is used to 
separate them from other bacteria, into a distinct class of prokaryotes named Mollicutes (derived from the 
Latin words ‘mollis’, meaning soft, and ‘cutes’, meaning skin) (Weisburg et al., 1989; Razin et al., 1998).  
Based on differences in morphology, genome size, and nutritional requirements, members of the class 
Mollicutes comprise five orders with the best studied genera being found in Acholeplasmatales 
(Acholeplasma), Anaeroplasmatales (Anaeroplasma, Asteroleplasma), Entomoplasmatales 
(Entomoplasma, Mesoplasma, Spiroplasma), and Mycoplasmatales (Mycoplasma, Ureaplasma) 
(Weisburg et al., 1989; Razin et al., 1998; Bradbury, 2005).  A summary of the classification of the genus 
Mycoplasma within the class Mollicutes is given in Table 2.1.  As a general rule, members of the orders 
Acholeplasmatales, Anaeroplasmatales and Entoplasmatales are considered phylogenetically early 
mollicutes and accordingly have larger genome sizes than the phylogenetically more recently evolved 
Mycoplasmatales which often possess smaller genomes (Razin et al., 1998).  Furthermore, the 
requirement for exogenous sterol served as an important taxonomic criterion to distinguish the sterol-
nonrequiring mollicutes, Acholeplasma and Asteroleplasma, from the sterol-requiring ones (Razin et al., 
1998; Weisburg et al., 1989). 
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The majority of mollicutes that are of veterinary importance belong to the genus Mycoplasma (derived 
from the Greek words ‘mykes’ for fungus, which is ironic since mycoplasmas’ are not fungi, and ‘plasma’ 
for something formed or molded) (Bradbury, 2005).  To date, more than 100 mycoplasma species have 
been identified, making this the largest genus within the class Mollicutes.  It is therefore not surprising 
that the terms ‘mycoplasma’ and ‘mollicute’ are often used interchangeably to refer to any member within 
the class Mollicutes (Razin et al., 1998).  To avoid confusion, and since the genus Mycoplasma is the 
focus of this study, the term ‘mycoplasma’, and not ‘mollicute’, will be used for the remainder of this 
thesis. 
2.3 Evolution 
The origin of mycoplasmas was, for many years, quite a controversial topic.  Given their unusually small 
size, both physically and genomically, along with the general simplicity they exhibit, it is understandable 
that some scientists proposed them to be a primitive life form, possibly preceeding present-day bacteria in 
evolution.  Others however, suggest that mycoplasmas were simply wall-less variants of typical bacteria 
(Woese et al., 1980; Weisburg et al., 1989).  However, from nucleic acid hybridization and sequencing 
studies, it is known today that mycoplasmas originated by degenerate evolution from a low G+C content 
Gram-positive branch of walled eubacteria. This mode of mycoplasma evolution was accompanied by the 
loss of a substantial amount genomic sequence, ultimately resulting in the dramatic reduction in the 
genome size of mycoplasmas, and their consequent obligate parasitic lifestyle (Dubvig and Voelker, 
1996; Razin et al., 1998; Rocha and Blanchard, 2000). 
Comparative genomics confirmed that the reduction in genome size associated with the degenerate 
evolution of mycoplasmas did not result from increased gene density or reduction in gene size, but did 
indeed result form the loss of ‘non-essential’ genes, an event often referred to as ‘gene-saving’.  Genes 
involved in the gene-savings event included those encoding proteins involved in bacterial cell wall 
synthesis, as well as genes encoding enzymes involved in many anabolic pathways (Razin et al., 1998).  
This resulted in the two main events of mycoplasma evolution; (i) the loss of a cell wall, (ii) and the loss 
of various metabolic capabilities (Woese et al., 1980).  The number of genes encoding enzymes involved 
in DNA replication and repair, transcription and translation and cellular processes such as cell division, 
cell killing, and protein secretion were also reduced.  However, the amount of gene-saving in these 
categories was more restricted in order for mycoplasmas to preserve their own ‘housekeeping’ 
capabilities (Razin et al., 1998).  Accordingly it has been suggested that degenerate evolution of 
mycoplasmas, has resulted in a model for the minimum number of genes required for sustaining self-
replicating life (Razin, 1985; Maniloff, 1992; Dubvig and Voelker, 1996; Maniloff, 1996).  Examining 
the genomic data of mycoplasmas may therefore help to define the genes which are essential for life 
(Razin et al., 1998). 
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TABLE 2.1 Summary of the major characteristics of members of the class Mollicutes, illustrating the classification of the genus Mycoplasmas within the class Mollicutes 
Classification 
Class: Mollicutes 
No. of species 
Genome size 
(kb) 
Mol% G+C Unique nutritional requirements / special 
features 
Sterol 
requirement 
Habitat 
 
Order:  Acholeplasmatales 
               Family:  Acholeplasmataceae 
                         Genus:  Acholeplasma 
 
 
 
13 
 
 
 
1500-1650 
 
 
 
26-36 
 
Optimum growth at 30˚C-37˚C 
 
No 
 
Animals, insects and plant surfaces 
 
 
 
Order:  Anaeroplasmatales 
               Family:  Anaeroplasmataceae 
                         Genus:  Anaeroplasma 
                                      Asteroleplasma 
 
 
 
4 
1 
 
 
 
1500-1600 
1500 
 
 
 
29-34 
40 
 
Oxygen sensitive anaerobes 
 
Sometimes 
 
Yes 
No 
 
Rumens of cattle and sheep 
 
Order:  Entomoplasmatales 
                Family:  Spiroplasmataceae 
                         Genus:  Spiroplasma 
                                      Entomoplasma 
                                      Mesoplasma 
 
 
 
22 
5 
12 
 
 
 
780-2220 
790-1140 
870-1100 
 
 
 
24-31 
27-29 
27-30 
 
Optimum growth at 30˚C 
 
Yes 
 
Plants and insects 
 
Order:   Mycoplasmatales 
               Family:  Mycoplasmataceae 
                         Genus:  Mycoplasma* 
                                       Ureaplasma 
 
 
 
120< 
6 
 
 
 
580-1350 
760-1170 
 
 
 
23-41 
27-30 
 
Optimum growth at 37˚C 
 
 
Uses urea as energy source 
 
Yes 
 
Humans and animals 
Undefined 
                                     Phytoplasma 
 
Not defined 
 
530-1350 
 
23-29 
 
Optimum growth at 30˚C 
 
No 
 
Plants and insects 
*Class:  Mollicutes, on basis of lack of a cell wall; Oder: Mycoplasmatales, based on exogenous sterol requirement; Family: Mycoplasmataceae, based on genome size; Genus:  Mycoplasma 
(Table adapted from:  Robinson and Freundt, 1987; Razin et al., 1998; Prescott et al., 2002; Kleven, 2008) 
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2.4 Phylogeny 
Based on sequence analysis of the conserved 16S ribosomal RNA (rRNA) genes, the phylogenetic 
relationship between mycoplasmas and bacteria has been established (Woese et al., 1980).  These 
analyses revealed mycoplasmas to be related to a branch of Gram-positive eubacteria with low G+C 
composition, and a clostridial phenotype (Clostridium innocuum, and C. ramosum) (Razin, 1985; 
Weisburg et al., 1989).  The genus Mycoplasma is further subdivided into four phylogenetic groups based 
on 16S rRNA gene sequence analysis; (i) the anaeroplasma group, (ii) the spiroplasma group, (iii) the 
pneumoniae group, and (iv) the hominis group (Dubvig and Voelker, 1996), which was also retrieved in 
our phylogenetic analysis as is shown in Figure 2.1. 
2.5 Characteristics of the mycoplasmal genome 
2.5.1 Genome size 
The circular double-stranded genome of mycoplasmas is the smallest reported of all self-replicating 
cellular organisms, ranging in size from 580 kilobases (kb) in M. genitalium to 1380 kb in M. mycoides 
subsp. mycoides (Dubvig and Voelker, 1996; Razin et al., 1998).  The considerable amount of variability 
that exists in the genome sizes of different mycoplasma species, is possibly a result of high number of 
repetitive DNA elements found in mycoplasma genomes (Razin et al., 1998). 
2.5.2 Repetitive elements 
Although repetitive DNA elements is not a feature expected to be found in a minimal genome, many 
mycoplasma species have been shown to harbour a high frequency of such elements.  Repeated DNA 
sequences in the mycoplasmal genome include both multiple copies of protein-coding regions, as well as 
insertion sequence elements.  Interestingly many of these repetitive elements are homologous to genes 
encoding major surface antigens, and may therefore promote DNA rearrangements associated with 
antigenic variation (see Antigenic variation, section 2.8.2.1) (Dubvig and Voelker, 1996; Razin et al., 
1998). 
2.5.3 Base composition and codon usage 
The mycoplasma genome is further known for its extremely low G+C content typically ranging from 23 
to 41 mol%.  The distribution of G+C along the mycoplasma genome is uneven, with coding regions 
generally being more G-C rich than the non-coding regions (Weisburg et al., 1989; Razin et al., 1998). 
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Figure 2.1 Phylogenetic tree of mycoplasmas based on analysis of 16S rRNA gene sequences.  This tree represents 
one of twelve of the shortest trees retrieved in a heuristic search (CI = 0.401, RI = 0.703).  Those branches that 
collapse in the strict consensus tree are indicated with arrows.  Branch lengths and bootstrap values are indicated 
above and below the line respectively. 
This characteristic base composition of the mycoplasmal genome is manifested in their unique codon 
usage.  Accoringly, mycoplasmas have evolved to preferentially use adenine (A)- and thymine (T)-rich 
codons (Razin, 1985).  Indeed, codon usage data indicate that approximately 90% of codons in the 
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majority of mycoplasma genomes have an A or T in the third nucleotide position.  This has the result 
that during translation, most mycoplasmas employ the alternative genetic code, known as the mold 
mitochondrial genetic code.  In this code, the universally assigned termination codon TGA, encodes 
tryptophan instead, encoded by TGG in the universal genetic code (Dubvig and Voelker, 1996; Razin et 
al., 1998; Söll and RajBhandary, 2006).  Such an adaptation in codon usage has obvious practical 
implications when cloned mycoplasma genes are expressed in heterologous systems, as premature 
truncation of gene products will occur where the mycoplasma tryptophan codon will be read as a 
termination codon (Dubvig and Voelker, 1996; Razin et al., 1998).  Codon bias is not limited to the third 
nucleotide position, and is also evident in the first and second codon position, where it has a considerable 
effect on amino acid composition.  For instance, relative to an organism such as Escherichia coli with a 
G+C content approximately 50 mol%, mycoplasmas have fewer GGN, CCN, GCN, and CGN codons.  
Therefore, mycoplasma proteins generally contain fewer glycine, proline, alanine and arginine residues.  
In contrast, mycoplasmas tend to have a high percentage AAN, TTY, TAY and ATN codons, resulting in 
an abundance of asparagine, lysine, phenylalanine, tyrosine, and isoleucine residues in mycoplasma 
proteins.  In highly conserved proteins, mycoplasmas often have lysine residues (codons AAA and AAG) 
at animo acid positions that have arginine (codons AGA and AGG and CGN) in other organisms (Dubvig 
and Voelker, 1996). 
2.5.4 DNA methylation 
As is the case in other prokaryotic genomes, some of the adenine and cytosine residues in the 
mycoplasma genome may be methylated, resulting in 6-methyladenine and 5-methylcytosine (Razin et 
al., 1998).  In mycoplasmas, the adenine residue (A) at the GATC site is often methylated, while in others 
the cytosine residue (C) is methylated.  Even though the exact biological function of DNA methylation is 
not clear, this phenomenon in prokaryotic genomes is suggested to provide protection of their DNA 
against the endonuclease activity of competing microbes within a given environment (Razin, 1985; 
Dubvig and Voelker, 1996; Xai, 2003). 
2.5.5 Gene arrangement 
Comparative analysis of the gene order in the genomes of M. gallisepticum, M. hyopneumoniae and M. 
pulmonis, revealed that there was no fixed arrangement of genes in these genomes.  It was found 
however, that the order of genes within an operon encoding the cytadhesin proteins GapA, CrmA, CrmB 
and CrmC, remained the same between the respective species, with only the genes adjacent to the operon 
varying (Van der Merwe, 2006). 
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2.5.6 Regulation of gene expression 
2.5.6.1 Regulation of transcription 
During the transcription of mycoplasma genes, expression signals largely resemble those of Gram-
positive bacteria.  Two RNA polymerase promoter areas, known as the -10 (Pribnow box) (TATAAT) 
and -35 regions (TTGACA/TTGNNN), have been identified in mycoplasma, both of which are similar to 
bacterial promoter consensus sequences recognized by the vegetative sigma factor σA.  In addition, 
mycoplasma RNA polymerases show structural similarity to other prokaryote polymerases, although its 
activity is relatively insensitive to the antibiotic rifampin (Dubvig and Voelker, 1996). 
2.5.6.2 Regulation of translation 
With the exception of the stop codon TGA encoding tryptophan in most mycoplasmas, the translation of 
messenger RNA (mRNA) of mycoplasmas otherwise resembles that of Gram-positive bacteria.  
Nucleotide sequence data indicate that coding regions of most mycoplasma genes begin with an ATG 
start codon, with GTG and TTG serving as alternative start codons (Dubvig and Voelker, 1996).  This is 
in agreement with most prokaryotes, as the translation initiation codon ATG interacts more tightly with 
the initiation transcript RNA (tRNA) than to the other initiation codons, therefore being the preferred 
initiation codon in frequently expressed genes (Sakai et al., 2001).  Furthermore, the mRNA of most 
mycoplasma genes contains a ribosome-binding site (RBS) similar to the Shine-Dalgarno (SD) sequence 
of Gram-positive bacteria.  The typical mycoplasmal RBS has the sequence 5’-AGAAAGGAGG-3’ (SD-
like sequence) and is usually located four to ten bases upstream of the start codon, (Chen et al., 1994; 
Dubvig and Voelker, 1996).  The extent to which the SD sequence is conserved correlates with the 
translation efficiency of a gene.  For frequently expressed genes, the ribosome needs to recognise the SD 
sequence more efficiently than in the case of rarely expressed genes.  It should be mentioned that no SD-
like sequence has been identified in M. genitalium or M. pneumoniae, suggesting that the translation 
process of these species does not depend heavily on these factors (Sakai et al., 2001; Madeira and 
Gabriel, 2007). 
2.5.6.3 Nature and posttranslational modification of expressed proteins 
As mycoplasmas lack a cell wall and are bound by a plasma membrane only, there is no periplasmic 
space and proteins that are not cytoplasmic are either membrane bound or secreted.  For protein secretion, 
mycoplasmas possess a typical eubacterial signal sequence ((-4)-VAASC-(+1)) that directs proteins into a 
secretory pathway to transport them across the plasma membrane (Henrich et al., 1999).  Posttranslational 
modification of mycoplasma proteins includes phosphorylation and isoprenylation, the function of which 
is not completely clear.  In general, protein phosphorylation, through the action of kinases, 
phosphotransferases and phosphatases, is a mechanism for regulating intracellular signalling, modulating 
cellular events by interconverting between active and inactive protein forms.  Therefore, in mycoplasmas, 
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the phosphorylation of cytoskeletal proteins may regulate activities such as cytadherence, gliding 
motility, and cell division in the same manner (Razin et al., 1998). 
2.6 Morphology and Biochemistry 
2.6.1 Cell size, shape and motility and reproduction 
One of mycoplasmas’ most distinctive features is their unusually small cell size, ranging from 0.3-0.8 μm 
in diameter (Weisburg et al., 1989; Prescott et al., 2002).  Their lack of a cell wall and inability to 
synthesize peptidoglycan precursors render mycoplasmas completely resistant to penicillin and other 
antibiotics targeting cell wall synthesis, but susceptible to lysis by osmotic shock and detergent treatment 
(Prescott et al., 2002).  Since mycoplasmas are bound by a plasma membrane only, they are pleomorphic, 
varying in shape from spherical or pear-shaped organisms, to branched or helical filaments.  An important 
group of pathogenic mycoplasmas have a flask shape with a protruding tip structure that mediates 
attachment to the host (see Host cell attachment and ABC transporters as virulence factors, section 
2.8.1).  The ability of mycoplasmas to maintain their respective cell shapes in the absence of a rigid cell 
wall is suggested to be made possible by a network of interconnected cytoskeleton-associated proteins, as 
well as by the incorporation of exogenous sterols into the plasma membrane as a stabilizing factor.  The 
cytoskeleton is also thought to participate in cell division, motility, as well as the asymmetric distribution 
of adhesins and other membrane proteins along the cell surface (Razin et al., 1998).  Although 
mycoplasmas are generally considered to be non-motile, some species have been shown to exhibit gliding 
motility on liquid-covered solid surfaces.  The exact mechanism of their motility has not been described, 
however some kind of chemotactic behaviour with a protruding structure in the direction of movement, 
has been suggested (Dybvig and Voelker, 1996; Razin et al., 1998).  The mode of reproduction of 
mycoplasmas is essentially not different from that of other prokaryotes dividing by binary fission.  For 
typical binary fission to occur, cytoplasmic division must be fully synchronized with genome replication, 
and in mycoplasmas the cytoplasmic division may lag behind genome replication, resulting in the 
formation of multinucleated filaments.  The factors coordinating the cell division process in mycoplasmas 
are to date not clearly understood (Razin et al., 1998). 
2.6.2 Metabolism 
The loss of many of their biosynthetic pathways during degenerative evolution accounts for 
mycoplasmas’ parasitic lifestyle (Prescott et al., 2002).  Analysis of sequenced mycoplasma genomes 
indicate that mycoplasmal genes encode a large number of proteins with functions related to catabolism 
and to metabolite transport, with few proteins related to anabolic pathways.  Accordingly, mycoplasmas 
lack the capacity to synthesize molecules such as cholesterol, fatty acids, some amino acids, purines and 
pyrimidines, and therefore need to acquire these and other nutrients from their host (Dybvig and Voelker, 
1996; Henrich et al., 1999; Prescott et al., 2002).  As far as catabolic metabolism is concerned, 
mycoplasmas depend largely on glycolysis and lactic acid fermentation as a means of synthesizing ATP, 
Stellenbosch University  https://scholar.sun.ac.za
  
11
 
while others catabolize arginine or urea.  The pentose phosphate pathway seems functional in at least 
some mycoplasmas, while none appear to have the complete tricarboxylic acid cycle.  The electron 
transport system is flavin terminated, thus ATP is produced by substrate-level phosphorylation, a less 
efficient mechanism than oxidative phosphorylation (Prescott et al., 2002; Razin et al., 1998). 
2.6.3 ABC transporters 
Knowledge of the transport proteins of an organism can aid in the understanding of the metabolic 
capabilities of the organism.  For example, the combination of transporters in a given organism can shed 
light on its lifestyle (Ren and Paulsen, 2005).  Not surprisingly then, for a parasitic organism that must 
acquire most of its cellular building blocks from its host, a substantial number of transport proteins are 
encoded by the mycoplasma genome.  Three types of transport systems have been identified to be 
involved in transport across the mycoplasma cell membrane, namely the ATP-binding cassette (ABC) 
transporter system, the phosphotransferase transport system, and facilitated diffusion by transmembrane 
proteins functioning as specific carriers.  Of these, mycoplasmas depend mainly on ABC transporters 
which are involved in the import and export of a large variety of substrates, including sugars, peptides, 
proteins and toxins (Razin et al., 1998). 
2.6.3.1 Structure and assembly of ABC transporters 
ABC transporters are widespread among living organisms, comprising one of the largest protein families.  
Structurally, ABC transporters are remarkably conserved in terms of the primary sequence and the 
organization of domains.  Characteristic to ABC transporters is a highly conserved ATPase domain which 
binds and hydrolyzes ATP to provide energy for the import and export of a wide variety of substrates.  
This ATP-binding domain, also known as an ATP-binding cassette, forms the defining structural feature 
of ABC transporters, and contains two highly conserved motifs, the Walker A or P-loop 
(GXXXXGKT/S) and Walker B (RXXXGXXXLZZZD) motifs (were X is any amino acid, and Z 
represents a hydrophobic residue), which together form a structure for ATP binding.  The ATP-binding 
domain further contains a highly conserved signature sequence known as the C motif of linker peptide 
(LSGGQ/R/KQR) that is specific to ABC transporters and is located at the N-terminal with respect to the 
Walker B motif.  The ATP-binding domain is further associated with a hydrophobic membrane-spanning 
domain, typically consisting of six putative α-helix membrane-spanning segments that constitute the 
channel through which substrate may be transported (Henrich et al., 1999).  In addition, ABC transporters 
may also include additional proteins with specific functions.  In the case of Gram-positive bacteria and 
mycoplasmas, such proteins include substrate-binding proteins anchored to the outside of the cell via lipid 
groups, binding substrate and then delivering it to the membrane-spanning import complex (Garmory and 
Titball, 2004). 
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2.6.3.2 The physiological role of ABC transporters 
This superfamily of ABC transporters has a wide range of functions in bacteria, allowing them to survive 
in many different environments.  Some ABC transporters are importers responsible for the uptake a wide 
variety of substrates, including sugars and other carbohydrates, amino acids, di-, tri- and oligopeptides, 
polyamines, and inorganic ions.  Others function as exporters and are responsible for the export of 
proteins, such as proteases and hemolysin, polysaccharides, and toxins, as well as the secretion of 
antibiotics in antibiotic-producing and drug-resistant bacteria (Razin et al., 1998; Garmory and Titball, 
2004; Davidson and Maloney, 2007). 
2.6.3.3 The oligopeptide permease system of M. hominis 
The oligopeptide permease (Opp) system is an ABC transporter responsible for the import of 
oligopeptides into bacteria (Henrich et al., 1999).  In M. hominis, the Opp system consists of four core 
domains, the OppBCDF domains, and a cytadherence-associated lipoprotein, P100, functioning as the 
substrate-binding domain OppA.  The OppB and OppC subunits are integral membrane-spanning 
domains and possess conserved hydrophobic motifs characteristic to bacterial permeases (RTAK-
KGLXXXI/VZXXHZLR in the OppB domain, and XAAXXZGAXXXRXIFXHILP in the OppC 
domain).  Each domain typically contains six membrane-spanning α-helices forming the permease 
pathway for the transport of oligopeptides through the membrane.  The OppD and OppF subunits are the 
peripheral ATPase domains that bind and hydrolyze ATP for the active transport of oligopeptides 
(Henrich et al., 1999; Hopfe and Henrich, 2004).  Uncharacteristic of a substrate-binding domain, the 
P100/OppA domain of M. hominis has been shown to contain the highly conserved Walker A and Walker 
B motifs, characteristic of the ATP-binding (OppD and OppF) domains.  Therefore, in addition to the 
substrate-binding role, as well as its association with cytadherence, the P100/OppA domain is also 
described as the main ecto-ATPase of M. hominis.  The role of the ecto-ATPase activity of the 
P100/OppA domain is unclear, however, several hypotheses for its physiological function excist.  These 
include: (i) protection from the cytolytic effect of extracellular ATP by allowing splitting of the ATP 
released in the vicinity by the colonized cells, (ii) regulation of ecto-kinase substrate concentration, (iii) 
involvement in signal transduction, as well as (iv) possible involvement in cytadhesion (Hopfe and 
Henrich, 2004).  Although the physiological role of the P100/OppA protein in M. hominis is largely 
speculative, no P100/OppA-deficient mutants have been identified to date, suggesting that P100/OppA 
plays an essential role in the vitality of the organism (Hopfe and Henrich, 2004). 
2.6.4 In vitro cultivation 
The difficulty with which mycoplasmas are cultivated in vitro is a major impediment in mycoplasma 
research.  The most common explanation for mycoplasmas’ weak cultivation properties are their 
numerous nutritional requirements brought about by the scarcity of genes involved in their biosynthetic 
pathways (Dubvig and Voelker, 1996; Razin et al., 1998).  To overcome these deficiencies, mycoplasmas 
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generally require a complex protein-rich growth medium containing serum, which provides the fatty 
acids and cholesterol required for membrane synthesis.  In addition, mycoplasma growth medium often 
contain yeast derived components, as well as various sugars or arginine as primary energy source.  
Penicillin and thallium acetate are also often included to inhibit contaminant growth (Razin et al., 1998; 
Kleven, 2008).  Mycoplasmas demonstrate optimal growth at 37˚C-38˚C, and exhibit markedly diverse 
atmospheric requirements.  Most mycoplasma species are facultative anaerobes usually favoring an 
anaerobic state, while many species also flourish in aerobic environments, with yet another group being 
obligate anaerobes (Razin et al., 1998; Weisburg et al., 1989; Prescott et al., 2002). 
Even in the most complex growth media, mycoplasmas still exhibit poor and slow growth rates (Kleven, 
1998), raising the question whether the lack of growth in a rich medium is not rather due to the presence 
of a component or components that are toxic to mycoplasmas, thereby inhibiting their growth.  However, 
the reason for mycoplasmas problematic in vitro cultivation remains unresolved (Razin et al., 1998).  
When grown on agar, mycoplasmas form colonies with a characteristic “fried egg” appearance; growing 
into the medium surface at the centre while spreading outward on the surface at the colony edges, 
possibly reflecting their facultative anaerobic atmospheric requirements (Kleven, 1998). 
2.7 Distribution and host specificity 
Mycoplasmas are widely distributed in nature as saprophytes, as well as commensals and parasites of a 
broad range of mammalian, bird, reptile, insect, plant and fish hosts, with the list of hosts known to 
harbour mycoplasmas continuously increasing.  In general, mycoplasmas tend to exhibit rather strict host 
and tissue specificity, a feature thought to reflect their nutritionally fastidious nature and obligate parasitic 
lifestyle.  However, numerous reports of mycoplasmas crossing species barriers, as well as mycoplasmas 
being isolated from sites other than their normal specified niches, reflect a greater than expected 
adaptability of mycoplasmas to different environments (Dybvig and Voelker, 1996; Razin et al., 1998; 
Pitcher and Nicholas, 2005).  The primary habitats of mycoplasmas in animals are the mucous surfaces of 
the respiratory and urogenital tracts, the eyes, alimentary canal, mammary glands, and joints (Razin et al., 
1998; Rocha and Blanchard, 2000). 
2.8 Pathogenicity of mycoplasmas 
Despite mycoplasmas’ small size and general simplicity, many species have the ability to cause adverse 
effects in their hosts (Bradbury, 2005).  Relatively little is known about the pathogenesis of mycoplasma 
infections, however, it is thought to be a complex and multifactorial process (Lockaby et al., 1998; 
Kleven, 2008). 
2.8.1 Host cell attachment and ABC transporters as virulence factor 
Many mycoplasma species are well-recognized respiratory pathogens.  As a first step to pathogenesis, 
mycoplasmas must adhere to and colonize the epithelial linings of the host they infect (Razin et al., 
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1998), in many cases resulting in diseases, such as contagious bovine pleuropneumoniae in cattle 
caused by M. mycoides, chronic respiratory disease in chickens caused by M. gallisepticum, and 
pneumoniae in swine caused by M. hyopneumoniae.  Attachment of mycoplasmas to the epithelial 
surfaces of their host is regarded to be a critical step during mycoplasma infections.  This event, often 
also referred to as cytadherence or adhesion, plays a key role as virulence factor during mycoplasma 
infection, particularly in cases where the pathogens are confined to the mucosal surfaces of their host 
(Kleven, 2008).  Mycoplasma cytadhesins are generally large integral membrane proteins having regions 
exposed on the mycoplasma cell surface (Henrich et al., 1993; Dybvig and Voelker, 1996; Razin et al, 
1998; Evans et al., 2005).  Some mycoplasma species related to the human pathogen M. pneumoniae, 
including M. genitalium and M. gallisepticum, possess a specialized attachment organelle or tip structure 
that facilitates attachment to host cells (Henrich et al., 1993; Dybvig and Voelker, 1996; Razin et al., 
1998).  The best studied cytadhesin is the P1 protein of M. pneumoniae (Dybvig and Voelker, 1996).  The 
P1 protein is surface-localized, 165 kilodalton (kDa), trypsin-sensitive protein that clusters at the terminus 
of the attachment organelle of M. pneumoniae (Su et al., 1987).  Other well-known attachment proteins in 
mycoplasmas include the MgPa adhesin of M. genitalium, the GapA adhesin of M. gallisepticum, as well 
as the cytadherence associated P100 protein of M. hominis.  Like the majority of mycoplasmas, M. 
hominis lacks a well-defined attachment tip structure.  The cytadherence properties of such species are 
not well understood (Henrich et al., 1993; Dybvig and Voelker, 1996).  In addition, little is known about 
the ligand-receptor interactions that promote attachment to host cells.  Two different types of receptors, 
sialoglycoproteins and sulfated glycolipids, have however been implicated (Razin et al., 1998). 
Since loss of cytadherence have been shown to prevent infecting mycoplasmas from colonizing their 
target tissue and causing disease, attachment of mycoplamas to their respective host cells is considered an 
initial and crucial step for colonisation and subsequent infection.  Therefore, the membrane proteins that 
mediate this adhesion are regarded to be a crucial part of mycoplasmas’ pathogenicity (Henrich et al., 
1993; Lockaby et al., 1998). 
ABC transporters have also been suggested to play an important role in the virulence of pathogenic 
organisms.  Their association with virulence is most likely a reflection of their involvement in nutrient 
uptake, but may also indirectly result from associated substrate and/or host cell attachment (Garmory and 
Titball, 2004). 
2.8.2 Evasion of the host’s immune system 
The immune system functions to protect an organism from foreign invading agents that may cause 
damage to the host.  In order to persist and cause disease, some pathogens have developed means to evade 
the humoral immune system of their host (Evans et al., 2005).  Two well-known routes of evading the 
host’s immune system are (i) antigenic variation, and (ii) internalization of the microbe into non-
phagocytic host cells. 
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2.8.2.1 Antigenic variation 
The pathogenesis of mycoplasmas is complicated by their ability to alter their antigenic profile by varying 
the expression of major immunogenic surface proteins, thereby evading the host’s immune system, 
(Evans et al., 2005; Kleven, 2008).  Multiple surface exposed membrane proteins have been implicated in 
antigenic variation (Dybvig and Voelker, 1996; Evans et al., 2005).  Of these, lipoproteins are regarded 
the primary source of variation.  The membranes of mycoplasmas contain an unusually high number of 
lipoproteins that are attached to the membrane via a lipid moiety or via hydrophobic amino acids, with a 
portion of the protein on the outer surface of the cell.  Although the function of most lipoproteins in 
mycoplasmas is unknown, some, at least, are thought to undergo antigenic variation, resulting in a 
changing mosaic of antigenic structures of the cell surface (Dybvig and Voelker, 1996; Kleven, 1998; 
Rocha and Blanchard, 2002).  Antigenic variation may be achieved by the on/off switching of multiple 
copies within a gene family, thereby resulting in alternate expression of the genes encoding antigens 
(Dybvig and Voelker, 1996; Kleven, 1998).  Furthermore, genes encoding attachment proteins often 
contain repetitive elements that allow homologous recombination and genomic rearrangements, thereby 
also contributing to antigenic variation (Dubvig and Voelker, 1996; Razin et al., 1998).  This feature of 
mycoplasmas provides one possible explanation for how mycoplasmas manage to persist in a host and 
cause disease, often in spite of strong immune responses (Dybvig and Voelker, 1996; Kleven, 1998; 
Rocha and Blanchard, 2002). 
2.8.2.2 Intracellular location 
Most animal mycoplasmas are considered to be non-invasive surface parasites.  Some species, such as M. 
fermentans, M. genitalium, M. hominis and M. penetrans, however, have the ability to penetrate and 
survive within the cells of their respective hosts (Razin et al., 1998; Evans et al., 2005).  The suggested 
mechanism by which mycoplasmas enter their host cells involves initial attachment of the pathogen to the 
surface of the host cell.  Host cell attachement is followed by certain cytoskeletal changes including; 
rearrangement of the microtubule and microfilament proteins, aggregation of tubulin and α-actinin, and 
condensation of phosphorylated proteins.  This demonstrates yet another example of where adherence to 
their host cells plays a key role in mycoplasma pathogenesis, being the signal that prompts cytoskeletal 
changes (Razin et al., 1998). 
Entry into host cells allows mycoplasmas to persist in their host by evading the humoral immune system 
of the host, as well as exposure to antibiotics, promoting the establishment of chronic infection states.  
This may account, to some extent, for the difficulty with which mycoplasmas are eradicated from infected 
hosts (Razin et al., 1998; Kleven, 2008). 
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2.8.3 Other possible virulence causal factors 
2.8.3.1 Cell damage and disruption 
During respiratory disease, mycoplasma colonization of the tracheal epithelial surface results in the loss 
of cilia movement, erosion of ciliated epithelial cells, and hypertrophy of nonciliated basal epithelial cells.  
Factors suggested to play a role in the cell damage and disruption include (i) the production of hydrogen 
peroxide and other toxic metabolic end products of mycoplasmas, and (ii) possible toxic extracellular 
components of the mycoplasma membrane (Lockaby et al., 1998).  In the case of invasive mycoplasmas, 
entry into the host cells may affect the normal cell function and integrity of the host cell, resulting in 
potential cell lysis, cell disruption and necrosis.  In addition, exposure of the host cells’ cytoplasma and 
nucleus to mycoplasmal endonucleases may cause chromosomal damage (Razin et al., 1998).  A less-
documented factor also suggested to contribute to the pathogenesis of mycoplasmas is immune-mediated 
host injury through the stimulation of the hosts’ autoimmune responses (Lockaby et al., 1998). 
2.8.3.2 Concurrent infections 
Mycoplasmas are well-known for their tendency to have single or multiple interactions with other disease 
causing organisms such as Newcastle disease virus (NDV), Infectious bronchitis virus, and/or bacteria 
such as E. coli.  These interactions often have the result that mild or even subclinical mycoplasma 
infections are aggravated, resulting in severe disease (Kleven, 1998). 
2.8.3.3 Environmental factors 
Mycoplasma infections, especially respiratory infections, are known to be notably affected by 
environmental factors, increasing the severity of diseases.  Temperature fluctuation, as typically 
experienced during the change of seasons, humidity, atmospheric ammonia, and dust, have all been found 
to have important interactions with infecting mycoplasmas in producing respiratory disease (Kleven, 
1998). 
2.9 Mycoplasmas infecting domestic poultry 
More than a dozen mycoplasma species are known to infect commercial poultry, of which the most 
prominent pathogenic species are MG, MS, M. meleagridis, and M. iowae (Kleven, 1998).  Of these, MG 
and MS are considered the most important as they are the most widespread in commercial poultry, and as 
such are being the only ones listed by the World Organisation for Animal Health (OIE) (Kleven, 2008). 
2.9.1 Epidemiology 
2.9.1.1 Natural host 
In general, poultry mycoplasmas tend to be host-specific and are not known to infect mammalian or other 
avian hosts (Kleven, 1998).  However, MG is known to infect a wide range of bird species, of which 
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gallinaceous birds are most susceptible, while MS are almost exclusively restricted to chickens and 
turkeys (Kleven, 1998; Evans et al., 2005). 
2.9.1.2 Infection and transmission 
MG is regarded the most economically important mycoplasma infecting commercial poultry, and is the 
leading cause of respiratory disease in chickens and infectious sinusitis in turkeys (Kleven, 1998; Evans 
et al., 2005).  MS is known to cause respiratory disease in chickens and turkeys that may result in 
airsacculitis and synovitis where spreading to the joints is thought to occur through the bloodstream 
(Kleven, 1998; Lockaby et al., 1998).  Both MG and MS infections are highly transmissible, being both 
spread vertically by egg-transmission, and horizontally through close contact between birds (Kleven, 
1998; Evans et al., 2005). 
2.9.2 Clinical signs 
Poultry mycoplasmas vary widely in virulence, displaying a wide variety of clinical manifestations, 
making them difficult to diagnose.  A possible explanation for this is the high incidence of intraspecies 
variability that exists among different strains, as well as mycoplasmas’ ability to interact with other 
disease-causing organsisms and environmental factors (Kleven, 1998).  The clinical signs of MG in 
infected poultry vary from subclinical to obvious respiratory signs including coryza, conjunctivitis (nasal 
exudate and swollen eyelids), rales, sinusitis, and severe air sac lesions ultimately resulting in increased 
mortality, downgrading of meat-type birds, reduced egg production and hatchability, higher feed usage 
and slow growth rates (Evans et al., 2005).  Birds infected with MS display signs of infectious synovitis 
manifested by pale combs, lameness and slow growth.  Swelling may occur around the joints with viscous 
exudate in the joints and along the tendon sheaths, as well as greenish droppings containing large amounts 
of urates commonly being observed.  In addition, milder clinical signs and lesions of respiratory disease, 
similar to those observed with MG, are often observed during MS infections (Kleven, 1998). 
2.9.3 Diagnosis 
MG and MS disease in chickens and turkeys may superficially resemble respiratory disease caused by 
other pathogens such as NDV and avian infectious bronchitis.  For diagnostic purposes, MG and MS can 
be identified by immunological methods after isolation from mycoplasma media, immunofluorescence of 
colonies on agar, detection of their DNA in field samples and/or cultures by species-specific PCR, or 
isolated from other or unknown species by sequencing of the 16S rRNA gene (Kleven, 2008). 
2.9.4 Prevention, treatment and control 
Control of poultry mycoplasma infections is based on three general aspects: prevention, treatment, and 
vaccination.  The preferred method for the control of mycoplasma infections in poultry is the maintenance 
of a mycoplasma-free flock as mycoplasmas pathogenic for poultry are transmitted vertically between 
birds.  Although an affective biosecurity program in combination with consistent monitoring for signs of 
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infection should be adequate, ever increasing population density is however a common cause of lapses 
in biosecurity (Kleven, 2008). 
Even though mycoplasmas are completely resistant to antibiotics that affect cell wall synthesis (Kleven, 
1998), a limited range of antibiotics affecting protein production can be used to reduce the effects of MG 
and MS infections (Evans et al., 2005).  The two most commonly used antibiotics in poultry are tylosin 
and tetracycline.  These antibiotics are employed as prophylactic treatment to respiratory disease 
associated with MG and MS in chickens and turkeys, and to reduce egg transmission of mycoplasma 
infection.  A treatment program in infected birds typically consists of continuous medication in the feed, 
or treatment for 5-7 days each month.  Although antibiotic treatment has proved to be an effective tool in 
preventing production losses associated with poultry mycoplasma infections, it has been shown to be 
ineffective at clearing mycoplasma infections, and should not be considered as a long-term solution as 
resistance may develop (Evans et al., 2005; Kleven, 2008). 
In situations where maintaining flocks free of MG and/or MS infection is not feasible, vaccination can be 
a viable option (Kleven, 2008).  There are currently several live attenuated MG vaccines approved and 
commercially available (including F strain (FVAX-MG, Schering-Plough Animal Health), 6/85 
(Mycovac-L, Intervet Inc), and ts-11 (MG vaccine, Merial Select)), to prevent egg-production losses in 
commercial layers, and to reduce egg transmission in breeding stock (Evans et al., 2005).  It is important 
that vaccination take place before field challenge occurs; one dose often being sufficient for vaccinated 
birds to remain permanent carriers.  Administration of the vaccines may vary from vaccine to vaccine, 
and different methods including intramuscular or subcutaneous injection, intranasal or eyedrop 
administration, as well as aerosol and drinking water administration are employed.  A number of 
inactivated, oil-emulsion bacterins against MG and MS respectively, reported to prevent respiratory 
disease, airsacculitis, egg production losses, and reducing egg transmission in poultry, are also 
commercially available.  In the case of these bacterins, two doses, subcutaneously administered, are 
necessary to provide longterm protection (Kleven, 2008). 
2.10 Mycoplasmas infecting ostriches 
Mycoplasmas have been implicated, together with other pathogens such as E. coli, Pseudomonas 
aeruginosa, Pasteurella species, and Avibacterium paragallinarum, in certain clinical syndromes in 
feedlot ostriches in South Africa (Botes et al., 2005; Verwoerd, 2000).  Based on earlier research, poultry 
mycoplasmas were believed to be responsible for mycoplasma associated diseases in ostriches 
(Verwoerd, 2000).  However, recent analysis of the 16S rRNA gene sequenses of mycoplasmas isolated 
from ostriches in the Oudtshoorn district, revealed that ostriches in this district harbour three unique 
ostrich-specific mycoplasmas, named Ms01, Ms02 and Ms03 (until formally described) (Botes et al., 
2005).  Phylogenetic analysis of the 16S rRNA gene sequences of these ostrich-specific mycoplasmas 
revealed them to be rather divergent from each other, falling in two different phylogenetic mycoplasma 
groupings (Figure 2.1, section 2.4).  Ms01 appears to be distinct from Ms02 and Ms03, falling in a 
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different clade of the phylogenetic tree with M. falconis being its closest relative.  On the other hand, 
Ms02 and Ms03 were found to be grouped together, and in the same clade as M. synoviae. 
2.10.1 Ostrich-specific mycoplasmas 
2.10.1.1 Infection and contributing factors 
Ostrich-specific mycoplasmas are primarily associated with infections of the respiratory tract, causing 
inflammation of the nose, trachea and air sacs, as well as severe lung lesions.  Infection of the respiratory 
tract of ostriches may have many direct and indirect consequences, including increased treatment costs, 
erosion disease, downgrading of carcasses, and increased susceptibility to secondary infections with 
pathogens such as E. coli, Pseudomonas aeruginosa, Pasteurella species, Bordetella avium and 
Avibacterium paragallinarum.   These secondary infections commonly results in the build-up of pus in 
the sinuses and air sacs, fever, pneumoniae and septic infection results, which ultimately leads to higher 
mortality rates and productions losses (Botes et al., 2005). 
2.10.1.2 Clinical signs 
Clinical signs of ostrich-specific mycoplasma infection in ostriches include nasal exudates, swollen 
sinuses, foamy eyes, rattle sounds in the throat, shaking of the head as well as excessive swallowing 
(Respiratory sickness in ostriches: Air sac infection, 2006). 
2.10.1.3 Contributing factors 
Factors that contribute to the incidence of ostrich-specific mycoplasma infections in ostriches include 
adverse weather conditions, stress, poor hygiene and lack of biosecurity.  A higher incidence of 
mycoplasma infections in ostriches is recorded annually during the months of autumn and spring when 
temperature fluctuations occur.  Furthermore, windy and wet weather, as typically experienced during the 
winter months in the Western Cape, causes an increase in the severity of mycoplasma infections by 
increasing the susceptibility of ostriches to secondary infections.  Stress, brought about by transport of the 
birds, change in feed and high population density, as well as poor hygiene, such as dirty water troughs 
and moldy feed, are also said to be contributing factors to mycoplasma infections.  Finally, poor 
biosecurity programs, such as mixing birds from different sources, presents the risk of mycoplasma 
spreading from infected to non-infected birds (Kleven, 1998; Respiratory sickness in ostriches: Air sac 
infection, 2006). 
2.10.1.4 Prevention, treatment and control 
Apart from good farming and biosecurity practises, there are currently no means of preventing infections 
of ostriches with ostrich-specific mycoplasmas.  Furthermore, control of mycoplasma infections in 
ostriches is complicated by the fact that carrier conditions exist, that is, ostriches infected with 
mycoplasmas often do not show any symptoms.  In addition, concealing tactics employed by these 
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pathogens allow them to evade the host’s immune system, thereby rendering them difficult to eradicate.  
A number of antibiotics, such as tylosin, oxytetracycline, doxycycline, and advocin, are currently being 
employed to control Ms01, Ms02 and Ms03 infections in ostriches (Respiratory sickness in ostriches: Air 
sac infection, 2006).  Although the use of these antibiotics has been shown to be effective in managing 
mycoplasma infections in ostriches, the mycoplasmas cannot be eradicated.  For this reason, there is an 
urgent need for the development of a vaccine(s) against the ostrich-specific mycoplasmas Ms01, Ms02 
and Ms03. 
2.11 Strategies in mycoplasma vaccine development 
The concept of vaccination was first demonstrated over 200 years ago when Edward Jenner showed that 
prior exposure to cowpox could prevent infection by smallpox in humans.  Over the last century, vaccines 
against a wide variety of infectious agents have been developed (Gurunathan et al., 2000).  Presently, 
numerous types of vaccines exist, including conventional whole-organism vaccines, as well as toxoids 
and protein-subunit vaccines.  More innovative vaccines include conjugate and recombinant vector 
vaccines, as well as the more recently developed DNA vaccines. 
2.11.1 Conventional vaccines 
Most vaccines today are still whole-organism vaccines, being either (i) killed organism vaccines, typically 
consisting of a chemically or heat inactivated form of a previously virulent pathogen, or (ii) live, 
attenuated organism vaccines, consisting of disabled previously virulent organisms, or closely related less 
virulent strains of an organism.  Live attenuated vaccines have the advantage of producing potent and 
long-lasting cell-mediated and humoral immunity, as these vaccines resemble natural infection closely.  
However, the risk for attenuated pathogens to mutate back to virulent wild-type strains exists.  In contrast, 
killed organism vaccines are non-infectious, but also less immunogenic than attenuated vaccines, and 
produce humoral immunity only (Lechmann and Liang, 2000). 
Whole-organism vaccine development requires the in vitro cultivation of the pathogen in large quantities.  
This approach has been successful in the development of whole-organism vaccines against the 
economically important poultry mycoplasmas MS and MG.  These vaccines were used in the 
immunization trials in ostriches in this study to assess their efficacy in providing cross-protection against 
ostrich-specific mycoplasmas (see Chapter 3).  However, the feasibility of whole-organism vaccine 
development against the ostrich-specific mycoplasmas is hindered due to the weak in vitro cultivation 
properties of mycoplasmas in general.  For this reason, the alternative of DNA vaccine development was 
pursued in this study (see Chapter 4), and will be outlined in the following section. 
2.11.2 DNA vaccines 
The use of DNA rather than whole organisms to provide immunity against invading pathogens is a 
relatively new approach to vaccine development (Razin, 1985; Robinson and Torres, 1997; Garmory et 
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al., 2003).  Historically, DNA vaccination is based on the influential study by Wolff and colleagues 
demonstrating that direct immunization with naked DNA resulted in the in vivo expression of the foreign 
protein within the muscle cells of mice (Wolff et al., 1990).  Present day DNA vaccines are constructed 
using recombinant DNA technology where a gene encoding a desired antigen is cloned into a eukaryotic 
expression vector.  The recombinant plasmid is subsequenctly amplified in bacteria, followed by 
purification of the plasmid, after which the plasmid DNA is inoculated directly into the animal to be 
vaccinated.  The plasmid DNA is taken up by the cells of the vaccinated animal, expressed, and the 
resulting foreign protein processed and presented to the immune system, thereby eliciting an immune 
response (Robinson and Torres, 1997; Garmory et al., 2003). 
2.11.2.1 Basic requirements for a DNA vaccine expression vector 
The efficacy of a DNA vaccine greatly relies on the components of the expression vector employed.  
Therefore, an important first consideration when optimising the efficacy of a DNA vaccine is the choice 
of an appropriate expression vector that would allow optimal expression of the foreign DNA in eukaryotic 
cells (Gurunathan et al., 2000).  An example of a typical DNA vaccine expression vector is shown in 
Figure 2.2.  The basic requirements of a DNA vaccine expression vector include: (i) a strong eukaryotic 
promoter, such as the most commonly employed virally derived promoters from the immediate-early 
region of the cytomegalovirus (CMV), (ii) a cloning site downstream of the promoter for insertion of the 
antigenic gene or genes, (iii) a polyadenylation signal, such as that isolated from the simian virus 40 
(SV40), to provide stabilization of the mRNA transcripts, (iv) a selectable marker, such as a bacterial 
antibiotic resistance gene, which allows for plasmid selection during growth in bacterial cells, and (v) a 
bacterial origin of replication (ori) with a high copy number, enabling high yields of plasmid DNA upon 
purification from transformed cultures (Robinson and Torres, 1997; Garmory et al., 2003; Gurunathan et 
al., 2000). 
 
Figure 2.2 Example of a mammalian expression vector (pCI-neo, Promega) used in a typical DNA vaccine strategy. 
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2.11.2.2 Optimization of immunogenicity of DNA vaccines 
A further important consideration when optimising the efficacy of a DNA vaccine is the optimization of 
the immunogenicity following administration.  A number of components have been found to play an 
important role in the immunogenicity of DNA vaccines, one being the presence of unmethylated cytidine-
phosphate-guanosine (CpG) motifs.  These motifs are present at 20-fold higher frequencies in bacterial 
DNA than mammalian DNA, and are known to stimulate monocytes and macrophages to produce a 
variety of cytokines including interleukin (IL)-12, tumor necrosis factor (TNF)-α, and interferon (IFN)-
α/β.  These cytokines then act on natural killer cells to induce lytic activity and IFN-γ secretion.  The CpG 
motifs can also stimulate the production of IL-6 that in turn promotes B-cell activation and subsequent 
antibody secretion.  In addition, T-cells are also stimulated directly or indirectly by CpG motifs, 
depending on their baseline activation state.  Since CpG motifs play such a prominent immunostimulatory 
role, incorporation of these motifs into the backbone of a vaccine vector, could serve to mobilize the 
immune response against the DNA-expressed antigen (Robinson and Torres, 1997; Gurunathan et al., 
2000; Garmory et al., 2003). 
The Kozak sequence is a consensus sequence flanking the AUG initiation codon within mRNA shown to 
play a role in the optimal translation efficiency of expressed mammalian genes, by influencing its 
recognition by eukaryotic ribosomes.  Therefore, since many prokaryotic genes and some eukaryotic 
genes do not possess such a Kozak sequence, the expression level of these genes might be increased by 
the insertion of such a sequence (Garmory et al., 2003). 
Furthermore, the route of administration of DNA vaccines is also an important consideration as it plays a 
crucial role in determining the type of immune response elicited.  Administration includes intramuscular 
(IM), intradermal (ID), subcutaneous, intravenous, intraperitoneal, oral, vaginal, intranasal, as well as 
non-invasive gene-gun delivery to the skin.  The most commonly used methods are IM or ID saline 
injection, as well as gene-gun delivery; where the skin of the host is bombarded with DNA-coated gold 
beads (Robinson and Torres, 1997; Garmory et al., 2003).  Vaccination via gene-gun delivery initiates an 
immune response by transfecting epidermal Langerhans cells that move in the lymph from the skin to 
draining lymph nodes.  Although this type of delivery is considered to be the best as it results in the 
transfection of the largest number of cells, it has obvious practical implications concerning the cost 
effectiveness of DNA vaccination, and does not seem practical for large scale implementation.  Following 
IM injection, most DNA expression occurs in skeletal muscle, whereas following ID inoculations, most 
expression occurs in keratinocytes.  In addition, DNA appears to move as free DNA through the blood to 
the spleen where professional antigen presenting cells (APCs) initiate an immune response (Robinson and 
Torres, 1997).  Administration of DNA to the mucosal surfaces of their hosts as DNA drops in liposomes 
or in microspheres has been found to be less consistent and successful than IM, ID or gene-gun delivery.  
However, mucosal methods of DNA delivery hold promise for raising responses that selectively protect 
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the respiratory and intestinal surfaces that are major portals for the entry of pathogens (Robinson and 
Torres, 1997). 
2.11.2.3 Dosage 
The amount of DNA needed for IM and ID inoculation, DNA being introduced outside the cell, is up to 
100 to 1000 times more that than needed to raise an immune response during gene-gun bombardments, 
when DNA is shot directly into the cells (Robinson and Torres, 1997).  Interestingly, the amount of DNA 
required to raise an immune response is suggested to be independent of the size of the vaccinated animal, 
with fairly similar doses of DNA being used to raise responses in mice, calves, and monkeys.  Most 
immunizations of DNA into mice have used between 1 and 100 μg of DNA, while immunizations into 
monkeys and calves range from 10 μg to 1 mg of DNA.  Gene-gun inoculation requires the least amount 
of DNA ranging from 10ng to 10 μg in mice.  Although much remains to be determined regarding the 
dosage of DNA vaccines, the relative independence of the dosage and the size of the animal suggest that 
similar numbers of APCs are able to induce immune responses throughout the animal kingdom (Robinson 
and Torres, 1997). 
2.11.2.4 DNA vaccine raised immune responses 
Many factors may affect the efficiency and nature of a DNA-induced immune response, including the 
type of expression vector employed, the method of DNA delivery, as well as the type of antigen 
presentation (B lymphocyte, T lymphocyte, or both) to the hosts’ immune system (Robinson and Torres, 
1997).  An illustration of the suggested mechanism by which DNA vaccines elicit immunity upon IM 
administration, is shown in Figure 2.3. 
Once a gene encoding an appropriate antigenic protein has been identified and isolated, it is subsequently 
inserted into a suitable eukaryotic expression vector.  This is followed by mass production in bacteria, 
plasmid DNA isolation, and subsequent innoculation of the purified recombinant plasmid DNA directly 
into the animal to be vaccinated.  The mechanisms by which the antigen is produced within the cells of 
the immunized animal, is unclear.  However, following the processes of antigen production and 
processing, the pathogen-derived peptides are suggested to be presented to the immune system by both 
the major histocompatibility complex (MHC) class I molecules (stimulating CD8+ T-cells) as well as 
MHC class II molecules (stimulating CD4+ T-cells) of local APCs, thereby inducing both cellular and 
humoral immunity (Oshop et al., 2002).  It should be noted that even though the principle of DNA 
vaccination is relatively simple, many details regarding the mechanisms of action are still unknown. 
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Figure 2.3 Principle mechanism of induced immunity by DNA vaccines (Oshop et al., 2002). 
2.11.3 Advantages of DNA vaccinology 
A major advantage of immunization with DNA vaccines stems from their ability to activate both humoral 
and cellular immunity.  In the case of extracellular viral and bacterial infections, protection is mediated by 
the humoral immune response, i.e. through the production of antibodies blocking the activity of 
extracellular forms of invading pathogens.  On the other hand, intracellular pathogens are controlled by 
cell-mediated immunity, killing off pathogen-infected cells.  However, in some cases (such as malaria, 
and possibly mycoplasmas) both humoral and cellular immune responses may be required to provide 
protection against the given pathogen.  Accordingly, the ability of DNA vaccines to induce both humoral 
and cellular immunity is the major attribute of this strategy.  Although DNA vaccines mimic the effects of 
live attenuated vaccines in this way, DNA vaccines have the advantage of not posing risk of infection, 
thereby undermining the safety concerns associated with live vaccines (Robinson and Torres, 1997; 
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Gurunathan et al., 2000).  Another advantage of DNA vaccines is the elimination of the need for large-
scale in vitro cultivation of pathogens for the development of the vaccine (Rappuoli, 2001).  Therefore, 
the route of DNA vaccine development is especially attractive for use against fastidious or non-
cultivatable pathogens, a problem often associated with mycoplasmas.  Furthermore, DNA vaccines are 
relatively simple and cost-effective to develop, and require greatly simplified transport and storage needs 
due to the stability of DNA over a wide temperature range (Gurunathan et al., 2000; Robinson and 
Torres, 1997). 
2.11.4 Candidate genes for DNA vaccine development 
The first step in DNA vaccine development is the identification of an appropriate candidate gene, i.e. a 
gene encoding a protein with good immunogenic properties.  Structures of a pathogen interacting with the 
host, as well as proteins associated with the virulence of pathogens, are thought to be especially 
immunogenic (Henrich et al., 1993).  Accordingly, genes encoding membrane proteins, such as proteins 
mediating attachment of mycoplasmas to their host cells, and ABC-transporters responsible for the uptake 
of various nutrients from their host, are generally considered as good candidates for DNA vaccine 
development (Garmory and Titball, 2004). 
In order to identify such DNA vaccine candidate genes, information concerning the genetic makeup of the 
target pathogen is required.  To this end, the genetic information of a wide range of organisms, including 
many pathogens, for which genomes have been completely or partly sequenced, are available on genetic 
databases such as GenBank, which contains an annotated collection of all publicly available DNA 
sequences.  A combination of bioinformatic approaches and recombinant DNA technology can then used 
to identify and isolate genes to serve as vaccine candidates.  Genomic libraries (also known as DNA 
libraries) are commonly employed in cases where little or no genetic information is available for a given 
pathogen.  In order to construct a genomic library, the genomic DNA is fragmented, each fragment cloned 
and replicated seperately in bacteria, and the clones screened to identify individual genes.  Where the 
construction of a genomic library is not possible, as was the case in this study, alternative techniques for 
generating genomic data, such as whole genome sequencing, can be considered. 
2.11.5 Whole-genome sequencing of mycoplasma genomes 
The sequencing of whole bacterial and viral genomes can potentially play an important role in the 
development of new antibiotics and vaccines.  Comparison of the entire genome sequences of pathogens 
can lead to the identification of conserved antigenic regions, and therefore the identification of possible 
candidate genes to be used in subunit vaccine development (Leamon et al., 2007).  Whole-genome 
sequencing usually requires the cloning of DNA fragments into bacterial vectors, amplification and 
purification of individual templates, followed by Sanger sequencing, using fluorescent chain-terminating 
nucleotide analogues, and either slab gel or capillary electrophoresis (Margulies et al., 2005). 
Stellenbosch University  https://scholar.sun.ac.za
  
26
 
Since the late 1980s, several laboratories initiated independent projects focusing on the sequencing and 
genetic mapping of different mycoplasma genomes.  The first large-scale studies directed at sequencing 
entire mycoplasma genomes were initiated in the early nineties.  One of the first mycoplasma genomes to 
enter such a study was that of M. capricolum.  However, by 1995, less than a quarter of the 1000 kb 
genome of M. capricolum had been sequenced succesfully.  The genome of M. pneumoniae was 
sequenced by first constructing a cosmid library, followed by sequencing both DNA strands in a directed 
fashion by primer walking, limiting random (shotgun) sequencing to a minimum.  The 800 kb genome of 
M. pneumoniae was subsequently sequenced successfully over a period of three years.  For the 
sequencing of the 580 kb genome of M. genitalium, an application of whole-genome shotgun sequencing 
was employed.  Random fragmentation of genomic DNA (gDNA), followed by cloning and sequencing 
of the individual fragments, and the subsequent reassembly of the overlapping sequenced fragments, 
resulted in the entire M. genitalium genome being sequenced in under 6 months (Razin et al., 1998). 
It is evident that whole-genome sequencing can become a rather time consuming, strenuous and 
expensive process, and although alternative sequencing methods have been described, no technology had 
displaced the use of bacterial vectors and Sanger sequencing as the main generators of sequence 
information (Margulies et al., 2005).  Recently however, Margulies and colleagues (2005) described the 
novel 454 Sequencing System that circumvents subcloning into bacteria, as well as the handling of 
individual clones (Leamon et al., 2007). 
2.11.5.1 The 454 Sequencing System using GS20 sequencing technology 
The 454 Sequencing System is based on GS20 sequencing technology that allows high-throughput, 
sequencing-by-synthesis to be performed in parallel.  The system combines an emulsion-based method to 
isolate and clonally amplify DNA fragments in vitro, with modified pyrosequencing in picoliter-sized 
wells.  Consequently, the 454 Sequencing System provides significantly higher throughput than any of 
the other existing sequencing technologies (Rogers and Venter, 2005), and allows high accuracy whole-
genome sequencing at relatively low cost and with reduced effort and time (Margulies et al., 2005). 
An illustration of the GS20 sequencing method is shown in Figure 2.4.  In order to sequence the entire 
genome of an organism, a DNA library is first created by shearing the isolated gDNA of the organism to 
be sequenced into fragments between 300 and 800 bp in length (Figure 2.4 A).  Next, specialized A- and 
B-adaptors carrying priming sequences are ligated to the ends of the fragments (Figure 2.4 B).  The B-
adaptor carries a biotin tag that allows binding of the individual fragments to the surface of streptavidin 
coated capture beads in a water-in-oil emulsion.  The simultaneous amplification of fragments is achieved 
by isolating individual DNA-carrying beads in separate aqueous droplets, each droplet serving as a 
separate microreactor in which parallel DNA amplification takes place (Figure 2.4 C).  Each individual 
fragment is subsequently clonally amplified by emulsion PCR (emPCR), yielding approximately 107 
copies of a template per bead (Figure 2.4 D).  Following emPCR, the capture beads containing clonally 
amplified fragments, together with enzyme beads containing immobilized ATP, sulphurylase and 
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luciferase necessary for pyrosequencing, are loaded into the open wells of a fiber optic picotitre slide.  
The slide is subsequently mounted in a flow chamber through which sequencing reagent containing the 
individual nucleotides (A, T, G and C) flow cyclically (Figure 2.4 E).  Upon incorporation of a nucleotide 
into the growing DNA strand, inorganic pyrophosphate is released and converted to ATP by the 
sulfurylase.  ATP in turn serves as substrate for luciferase, which generates photons proportional to the 
quantity of nucleotides incorporated in the elongating DNA strand (Figure 2.4 F). 
     
A. B. C. D. 
   
E. F. 
Figure 2.4 Schematic illustration of the GS20 method.  (A). Shearing of the isolated gDNA into 300-800 bp 
fragments.  (B). Ligation of specialized A- and B-adaptors to individual fragments.  (C). Water-in-oil emulsion 
forming the microreactor for emPCR.  (D). Multiple clonally amplified copies of a single fragment contained on an 
individual capture bead to be sequenced. (E). Overview of the 454 Sequencing system. (F). The sequencing-by-
synthesis process based on pyroseqencing (Margulies et al., 2005; Leamon et al., 2007). 
The resulting light signal is captured by a charge-coupled device (CCD) camera, allowing the capture of 
emitted photons from the bottom of each individual well, and the signal to be converted into nucleotide 
sequence.  The resulting nucleotide sequences are subsequently subjected to assembly using a de novo 
shotgun sequence assembler program that forms part of the GS20 data processing software package.  The 
assembler consists of a series of modules:  the ‘Overlapper’, which finds and creates overlaps between 
reads; the ‘Unitigger’, which constructs larger contigs (contiguous sequences) of overlapping sequence 
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reads; and the ‘Multialigner’, which generates consensus calls and quality scores for the bases within 
each contig (Margulies et al., 2005). 
GS20 sequencing is an effective method through which whole genomes of organisms can be sequenced, 
and was employed in this study for the sequencing of the genome of the ostrich-specific mycoplasma 
Ms01, and suitable DNA vaccine candidate genes were subsequently identified in the whole genome 
sequence data (see Chapter 4). 
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Chapter 3 – Poultry Mycoplasma Vaccine Trials in Ostriches 
3.1 Introduction 
Of the more than a dozen mycoplasma species known to infect poultry, the most widespread and 
prominent mycoplasmas infecting commercial poultry are MG and MS.  Vaccines available for the 
control of MG and MS infections in chickens and turkeys include inactivated, oil-emulsified bacterins, 
live vaccines, as well as recombinant vaccines, all of which have been shown to prevent airsacculitis, 
respiratory disease, egg production losses, as well as vertical transmission of disease between birds 
(Kleven, 2008). 
There are currently no mycoplasma vaccines available for use in ostriches.  For this reason, a new 
strategy based on the close phylogenetic relationship of the two ostrich-specific mycoplasmas Ms02 and 
Ms03, to the poultry mycoplasma MS (Botes et al., 2005) was developed.  This entails the use of a 
vaccine against MS to provide possible protection against mycoplasma infections in ostriches.  This 
approach was further supported by a preliminary study using immunofluorescence, in which it was found 
that the natural anti-mycoplasma antibodies in ostriches showed cross-reactivity with MS (Morley, 
personal communication, 1999).  For these reasons, a preliminary study using commercially available 
poultry mycoplasma vaccines to prevent mycoplasma infections in ostriches, was launched (Van der 
Merwe, 2006).  The study showed that MS and MG vaccines did elicit immune responses in three 
different groups of ostrich chicks aged three months, four to five months and six to seven months.  
However protection could not be assessed as only one vaccination was given, and the vaccinated birds 
were not challenged. 
In this study, trials, using vaccines against MG and MS, were again launched in order to determine 
whether commercially available poultry mycoplasma vaccines can provide protection against 
mycoplasma infections in ostriches.  To this end, 8-10 week old ostrich chicks received initial and booster 
vaccinations, followed by assessment of the resulting antibody responses by an enzyme-linked 
immunosorbent assay (ELISA).  Resistance to infection with ostrich mycoplasmas was assessed by field 
challenge of the immunized ostriches after booster vaccinations, followed by visual inspection of the 
birds. 
3.2 Materials and Methods 
3.2.1 Poultry mycoplasma vaccine trials at Oudtshoorn 
In these vaccine trials, the two inactivated oil-emulsion vaccines “Mycoplasma Synoviae Bacterin” (MS-
Bac), and “Mycoplasma Gallisepticum Bacterin” (MG-Bac) were used.  MS-Bac is commonly 
administered to laying and breeding birds to prevent egg production losses, as well as respiratory disease, 
and leg abnormalities associated with MS in chickens and turkeys.  MG-Bac, on the other hand, prevents 
egg production losses and respiratory disease associated with MG in many bird species, especially 
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gallinaceous birds.  Prior to use, the oil was removed by centrifugation to prevent the occurrence of 
granulomas and abscesses following subcutaneous immunization as oil-emulsion vaccines are known to 
cause these unacceptable side-effects in ostriches. 
Ostriches from two farms in the Oudtshoorn district, the Kwessie and the Schoeman farmstead, where a 
high annual incidence of mycoplasma infections was reported, were included in the trials.  A total of 140 
and 77 ostrich chicks (8-10 weeks old, 15-20 kg), none of which showed symptoms of mycoplasma 
infection, were selected from the Kwessie and Schoeman farms, respectively.  Chicks from the Kwessie 
farm were in a better condition than chicks from the Schoeman farm, where in many cases the masses of 
chicks from the Kwessie farm exceeded 20 kg.  On each farm, ostriches were divided into three groups: 
group A and group B were vaccinated with MS-Bac and MG-Bac respectively, while ostriches in the 
control group underwent no vaccination. 
The general strategy that was followed was to vaccinate the ostrich chicks in the summer months during 
which there is generally a low risk of natural mycoplasma infections.  Immunity was then assessed in 
autumn when there is a much higher risk of mycoplasma infections. 
3.2.2 Immunizing schedule and serum sample collection 
On the first day of the vaccine trials, designated day 0, pre-immunization serum samples were collected 
from all of the ostriches in all the groups, followed by subcutaneous immunization in group A and group 
B with 1 ml oil-free MS-Bac and MG-Bac respectively, while the control group received no vaccine. 
Trials were influenced by adverse weather condition in the Oudtshoorn vicinity during the trial period, 
which made access to these farms impossible on the dates that were originally planned for serum sample 
collection.  As a result, serum collection dates had to be adjusted, and were not taken at weekly intervals 
as originally planned.  In some instances, the collection dates of serum samples were missed, which 
subsequently influenced the interpretation of the results. 
Serum samples were collected from each ostrich in each group on days 6, 14, and 21 on the Kwessie 
farm, and on day 7 on the Schoeman farm, after the first immunization.  Thirty-eight days after the 
commencement of the vaccine trial, the ostriches in group A and B on the Kwessie farm received a 
second subcutaneous vaccination with 1 ml oil-free MS-Bac and MG-Bac respectively, following serum 
samples being collected.  Ostriches in the control group received no vaccine.  Serum samples were 
subsequently collected from each ostrich in each group on day 52, 62, 83 and 111 on the Kwessie farm.  
Twenty-seven days after the commencement of the vaccine trial, the ostriches in groups A and B on the 
Schoeman farm received a second subcutaneous vaccination with 1 ml oil-free MS-Bac and MG-Bac 
respectively, following serum samples being collected.  Ostriches in the control group once again 
received no vaccine.  Serum samples were subsequently collected from each ostrich in each group on day 
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34, 45, 53 and 83 on the Schoeman farm. The collected serum samples were stored at 4˚C for 
immediate use, and at -20˚C for long-term storage. 
3.2.3 Field challenge with ostrich mycoplasmas Ms01, Ms02 and Ms03 
After the final serum samples were collected, immunized ostriches and those in the control group were 
mixed with unimmunized flock on the respective farms during the high risk autumn period.  The reason 
for this approach of challenging immunized birds was that re-infection with cultivated mycoplasmas was 
not possible due to the poor cultivation properties of mycoplasmas.  Thus, the infection of the vaccinated 
and control birds was based on natural horizontal transfer of mycoplasmas from one bird to another in a 
natural field situation.  Eight weeks after exposure to unimmunized flock, the ostriches were visually 
inspected for symptoms usually associated with mycoplasma infections such as nasal exudates, foamy 
eyes and swollen sinuses. 
3.2.4 Enzyme-linked immunosorbent assay 
In order to assess the serum antibody production in response to vaccination, the ELISA technique was 
employed.  This technique can provide the relative antibody concentration of a sample, and was chosen 
for its simplicity, specificity, sensitivity, commercial availability and adaptability.  Two commercially 
available ELISA kits for the detection of MS and MG antibodies in chicken and turkey serum were used.  
The microtitre plates were coated with the respective antigen by the manufacturer.  In the ELISA, 
antibodies present in the serum of the vaccinated ostriches were allowed to bind to the immobilized 
antigen in the wells of the microtitre plate.  For the detection of the bound antibodies, labeled specific 
secondary antibodies, i.e. biotinylated rabbit anti-ostrich immunoglobulin (Ig) antibodies, were used.  
These secondary antibodies were used since the use of antibodies raised against poultry 
immunoglobulins, as those supplied in the kits, do not react well with ostrich antibodies (Blignaut et al., 
2000).  A horse radish peroxidase (HRP) - Streptavidin conjugate was used for the detection of the bound 
biotinylated rabbit anti-ostrich Ig antibodies.  This system was chosen for its high sensitivity and the low 
background levels.  The colorless substrate 2,2’-Azino-di(3-ethylbenzthiazoline sulphonic acid-6) 
(ABTS) is converted to a green product in the presence of hydrogen peroxide (H2O2), which was then 
measured spectrophotometrically to determine the antibody concentration of a serum sample. 
For use in the ELISA, rabbit anti-ostrich Ig was first isolated and biotinylated, followed by a modified 
protocol of the ELISA technique with MS and MG Antibody Test kits, FlockChek Ms and Mg 
respectively (IDEXX Laboratories, Dehteq), after which the results were analyzed statistically. 
3.2.4.1 Isolation and biotinylation of rabbit anti-ostrich Ig 
To precipitate the Ig fraction, 500 μl of high titre rabbit anti-ostrich Ig serum was added to 1 ml of 
phosphate buffered saline (PBS, pH 7.2) in a 50 ml JA-20 centrifuge tube.  A volume of 1.5 ml saturated 
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ammonium sulphate was added, and the mixture kept at 4˚C for 20 min followed by centrifugation at 
27 200 x g for 20 min.  After centrifugation, the supernatant was decanted and the pellet redissolved in 1 
ml PBS.  A volume of 1 ml saturated ammonium sulphate was again added, and the mixture kept at 4˚C 
for 20 min followed by centrifugation at 27 200 x g for 20 min.  The supernatant was decanted and the 
remaining pellet redissolved in 500 μl PBS.  The resulting Ig fraction was dialyzed overnight against 
carbonate buffer (0.1 M, pH 8.3) at 4˚C, replacing the buffer with fresh carbonate buffer approximately 8 
hours after starting dialysis. 
Following isolation, the Ig concentration was determined by measuring the absorbance at 280 nm.  To 
this end, the Ig sample was diluted 1:10 in carbonate buffer.  The rabbit anti-ostrich Ig solution was 
subsequently diluted with carbonate buffer to a final concentration of 5 mg/ml.  For biotinylation, 2 mg 
biotinamidocaproate N-hydroxysuccinimide ester (Sigma) was dissolved in 1 ml N,N-dimethylformamide 
(DMF).  The solution was then slowly added to the Ig fraction (250 μl biotinylation reagent per 1 ml Ig 
fraction) while stirring gently for 2 hours at room temperature.  The prepared conjugate was subsequently 
dialyzed overnight against PBS at 4˚C, replacing the solution with fresh PBS approximately 8 hours after 
starting dialysis.  Finally, glycerol was added in a 1:1 ratio to the biotinylated rabbit anti-ostrich Ig 
preparation, mixed thoroughly and stored at -20˚C. 
3.2.4.2 Detection of humoral Ig antibodies to MS and MG in ostrich serum 
Only the 96-well microtitre antigen coated plates and sample diluent buffer (Reagent 5) of the MS and 
MG Antibody Test kits were used (for reasons previously stated reasons in section 3.2.4).  All serum 
samples from ostriches immunized with MS-Bac or MG-Bac, as well as unimmunized control birds, were 
assayed with both the MS and MG antigen coated plates. 
Serum samples collected on days 0, 6, 14, 21, 38, 52, 62, 83 and 111 (Kwessie farm), and days 0, 7, 27, 
34, 45, 53, 83 (Schoeman farm) were diluted 1:500 with diluent buffer from the respective kits.  The first 
column on each plate served as a control; containing all reagents except the ostrich serum to be analyzed.  
Furthermore, to assess the efficacy of the isolated rabbit anti-ostrich Ig (section 3.2.4.1) a positive control 
of ostrich serum previously shown to possess a strong antibody titre was included (results not shown).  Of 
the diluted sera, 100 μl was pipetted in duplicate into the wells of each MS and MG antigen coated 
microtitre plates respectively, and the plates incubated at 37˚C for 3 hours.  Following incubation, the 
serum was decanted and the wells washed three times with PBS-Tween (200 μl/well, PBS buffer with 
0.1% Tween-20). 
Biotinylated rabbit anti-ostrich Ig was diluted 1:100 in Casein-Tween buffer (0.01 M Tris-HCl, pH 7.6, 
containing 0.5% casein, 0.15 M NaCl, 0.02% thiomersal, 0.1% Tween) and added to the microtitre plates, 
100 μl/well, followed by incubation of the plates at 37˚C for 1 hour.  After incubation, the contents of the 
plates were decanted and the wells washed with PBS-Tween as described above. 
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Streptavidin horse radish peroxidase (AVPO) was diluted 1:100 in Casein-Tween buffer and added to 
the microtitre plates, 100 μl/well, followed by incubation of the plates at 37˚C for 1 hour.  After 
incubation, the contents of the plates were once again decanted and the wells washed with PBS-Tween as 
described above. 
Finally, substrate solution (0.05% ABTS, 0.015% H2O2 in 0.1 M citrate buffer, pH5) was added to all 
wells of the microtitre plates, 100 μl/well, followed by incubation of the plates at 37˚C for 30 min.  The 
absorbance of each well of the microtitre plates was subsequently measured spectrophotometrically at 405 
nm on a Labsystems Multiskan MS microtitre plate readier. 
3.2.4.3 Statistical analysis 
The antibody titres in response to the different vaccines as measured by ELISA were followed over time 
and these results were analyzed using the General Linear Models procedure in the Statistical Analysis 
System (SAS, Cary, NC) program (v 6.2) and a least significant differences (LSD) value was calculated. 
3.3 Results 
3.3.1 Antibody responses to MS and MG vaccines in ostriches 
The average titre value of each of the immunized groups of ostriches was plotted against time.  In the 
interpretation of the immune response data, a minimum antibody level sufficient to provide protection 
against mycoplasma infections in ostriches has not been determined. However, a cut-off value of 0.2 
proved to be a good indicator of protection against NDV in the vaccination trials in ostriches done by 
Blignaut et al. (2000).  This cut-off value was also arbitrarily used in these vaccine trials, and was used to 
calculate the fraction and percentages of birds that showed a positive antibody response (titre ≥ 0.2) in 
each group at each time point. 
3.3.2.1 Antibody response obtained from the vaccine trials conducted on the Kwessie farm 
The average titre values representing the antibody response elicited in the ostriches on the Kwessie farm 
following immunization with the poultry mycoplasma vaccines against MS and MG as obtained from the 
MS Antibody Test kit plates are shown in Figure 3.1. 
Ostriches in group A, responded to immunization with the MS vaccine with both a primary and secondary 
antibody response, while no antibodies could be detected in the serum samples from ostriches in group B, 
immunized with the MG vaccine and analysed with the MS Antibody Test kit plates.  Three weeks after 
the initial immunization, a peak of serum antibody productions was observed in ostriches from Group A, 
with 16% of birds responding with titres higher than 0.2 (see Table 3.1, day 21).  The responses of Group 
B and the control group did not differ significantly from each other, showing very little response, 
differing significantly from Group A at 21 days after the first immunization. 
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Figure 3.1 Antibody responses, as determined with MS Antibody Test kit plates, elicited in ostriches from the 
Kwessie farm after immunization with poultry mycoplasma vaccines.  Groups A and B were vaccinated with 1 ml 
oil-free MS-Bac and MG-Bac respectively, and the control group received no vaccine.  The days on which the initial 
(day 0) and second (day 38) immunizations took place, are indicated with arrows.  The LSD value for this trial was 
0.022. 
After the second immunization titre values of birds in group A increased rapidly, reaching a peak after 52 
days with 92% of birds responding with titres higher than 0.2 (see Table 3.1, day 52).  Although serum 
antibody levels dropped after 111 days, ostriches in group A still showed high levels of circulating 
antibody with 39% of birds maintaining a positive, presumably protective, antibody response (see Table 
3.1, day 111).  No immune response was detected in ostriches in the control group and group B, 
immunized with MG vaccine. 
Table 3.1 Antibody responses detected in serum samples of ostriches from the Kwessie farm as detected with the 
MS Antibody Test kit plates.  Positive responses (0.2 ≤ titre) are indicated as fractions and percentages for group A 
immunized with MS-Bac, group G immunized with MG-Bac, and the control group which received no vaccine. 
Group A Group B Control group Day 
Fraction % Fraction % Fraction % 
0 0/50 0 0/50 0 0/40 0 
6 0/50 0 0/50 0 0/40 0 
14 2/50 4 2/50 4 0/40 0 
21 6/50 16 2/50 4 0/40 0 
38 5/50 10 1/50 2 0/40 0 
52 33/37 89 1/39 2.6 0/33 0 
62 33/36 89 0/37 0 0/30 0 
83 23/36 64 0/33 0 0/27 0 
111 14/36 39 0/34 0 0/30 0 
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The average titre values representing the antibody response elicited in the ostriches on the Kwessie 
farm following immunization with the poultry mycoplasma vaccines against MS and MG as obtained 
from the MG Antibody Test kit plates are shown in Figure 3.2. 
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Figure 3.2 Antibody responses, as determined with MG Antibody Test kit plates, elicited in ostriches from the 
Kwessie farm after immunization with poultry mycoplasma vaccines.  Groups A and B were vaccinated with 1 ml 
oil-free MS-Bac and MG-Bac respectively, and the control group received no vaccine.  The days on which the initial 
(day 0) and second (day 38) immunizations took place, are indicated with arrows.  The LSD value for this trial was 
0.052. 
Ostriches in group B, responded to immunization with the MG vaccine with both a primary and 
secondary antibody response, while no antibodies could be detected in the serum samples from ostriches 
in group A, immunized with the MS vaccine and analysed with the MG Antibody Test kit plates.  Two 
weeks after the initial immunization, more than half (56%) of birds in group B showed a positive 
antibody response, reaching a peak after 21 days when 86% of the birds responded with titres higher than 
0.2 (see Table 3.2, day 21).  The responses of Group A and the control group did not differ significantly 
from each other, showing very little response, differing significantly from Group B from 14 days after the 
first immunization.  After the second immunization, titre values of birds in group B increased rapidly 
reaching a peak after 62 days with 97% of birds responding with titres higher that 0.2 (see Table 3.2, day 
62).  Although serum antibody levels dropped after 111 days, ostriches in group B still showed high 
levels of circulating antibody with 91% of birds maintaining a positive antibody response (see Table 3.2, 
day 111).  No immune response was detected in ostriches in the control group and group A, immunized 
with MS vaccine. 
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Table 3.2 Antibody responses detected in serum samples of ostriches from the Kwessie farm as detected with the 
MG Antibody Test kit plates.  Positive responses (0.2 ≤ titre) are indicated as fractions and percentages for group A 
immunized with MS-Bac, group G immunized with MG-Bac, and the control group which received no vaccine. 
Group A Group B Control group Day 
Fraction % Fraction % Fraction % 
0 0/50 0 0/50 0 0/40 0 
6 0/50 0 0/50 0 0/40 0 
14 0/50 0 28/50 56 0/40 0 
21 0/50 0 44/50 88 0/40 0 
38 0/50 0 41/50 82 1/40 2.5 
52 0/37 0 36/39 92 0/33 0 
62 0/36 0 36/37 97 0/30 0 
83 0/36 0 32/33 97 0/27 0 
111 0/36 0 31/34 91 0/30 0 
 
Thus both vaccines elicited antibody responses in the immunized ostriches.  It is tempting to wish to 
make a comparison between the antibody responses of ostriches immunized with the MS and MG vaccine 
and measured with ELISAs against MS and MG respectively (comparison of group A in Figure 3.1 with 
group B in Figure 3.2).  However, this is not statistically comparable due to the fact that two different 
ELISAs were used for the detection of these antibody responses. 
3.3.2.2 Antibody response results obtained from the vaccine trials conducted on the Schoeman farm 
The average titre values representing the antibody response elicited in the ostriches on the Schoeman farm 
following immunization with the poultry mycoplasma vaccines against MS and MG as obtained from the 
MS Antibody Test kit plates are shown in Figure 3.3. 
The MS vaccine elicited an immune response in ostriches in group A, while no antibodies could be 
detected in serum samples from ostriches in group B, immunized with the MG vaccine when testing with 
the MS Antibody Test kit plates.  From the available data points, a clear primary and secondary antibody 
response cannot be distinguished, in all likelihood because the serum samples were not collected at the 
peak of the primary immune response. 
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Figure 3.3 Antibody responses, as determined with MS Antibody Test kit plates, elicited in ostriches from the 
Schoeman farm after immunization with poultry mycoplasma vaccines.  Groups A and B were vaccinated with 1 ml 
oil-free MS-Bac and MG-Bac respectively, and the control group received no vaccine.  The days on which the initial 
(day 0) and second (day 27) immunizations took place, are indicated with arrows.  The LSD value for this trial was 
0.020 
Ostriches in group A reached their peak of serum antibody production after the second immunization 
when 58% of birds in group A responded with a titre value higher that 0.2 (see Table 3.3, day 53).  The 
responses of group B and the control group did not differ significantly from each other, but did differ 
significantly from group A.  Although serum antibody levels dropped after 84 days, ostriches in group A 
still showed high levels of circulating antibody with 26% of birds maintaining a positive antibody 
response (see Table 3.3, day 83).  No immune response was detected in ostriches in the control group and 
group B, immunized with MG vaccine. 
Table 3.3 Antibody responses detected in serum samples of ostriches from the Schmoeman farm as detected with 
the MS Antibody Test kit plates.  Positive responses (0.2 ≤ titre) are indicated as fractions and percentages for group 
A immunized with MS-Bac, group G immunized with MG-Bac, and the control group which received no vaccine. 
Group A Group B Control group Day 
Fraction % Fraction % Fraction % 
0 0/29 0 0/30 0 0/18 0 
7 0/27 0 0/28 0 0/18 0 
27 0/27 0 0/25 0 0/17 0 
34 5/28 18 1/26 3.8 0/15 0 
45 14/26 54 0/26 0 0/16 0 
53 15/26 58 1/26 3.8 0/14 0 
83 6/23 26 0/25 0 0/14 0 
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The average titre values representing the antibody response elicited in the ostriches on the Schoeman 
farm following immunization with the poultry mycoplasma vaccines against MS and MG as obtained 
from the MG Antibody Test kit plates are shown in Figure 3.4. 
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Figure 3.4 Antibody responses, as determined with MG Antibody Test kit plates, elicited in ostriches from the 
Schoeman farm after immunization with poultry mycoplasma vaccines.  Groups A and B were vaccinated with 1 ml 
oil-free MS-Bac and MG-Bac respectively, and the control group received no vaccine.  The days on which the initial 
(day 0) and second (day 27) immunizations took place, are indicated with arrows.  The LSD value for this trial was 
0.043. 
The MG vaccine elicited an immune response in ostriches in group B, while no antibodies could be 
detected in serum samples from ostriches in group A, immunized with the MS vaccine when testing with 
the MG Antibody Test kit plates.  As before, the available data points made it difficult to distinguish a 
clear primary and secondary antibody response, in all likelihood because the serum samples were not 
collected at the peak of the immune response.  Ostriches in group B reached their peak of serum antibody 
production after the second vaccination (day 27) when 96% of birds responded with a titre higher that 0.2 
(see Table 3.4, day 53).  Although serum antibody levels dropped after 83 days, ostriches in group B still 
showed high levels of circulating antibody with 92% of birds maintaining a positive antibody response 
(see Table 3.4, day 83).  No immune response was detected in ostriches in the control group and group A, 
immunized with MS vaccine. 
Once again both vaccines elicited antibody responses in the immunized ostriches.  Similarly as before, a 
comparison between the antibody responses of ostriches immunized with the MS and MG vaccine and 
measured with ELISAs against MS and MG respectively (comparison of group A in Figure 3.3 with 
group B in Figure 3.4) was not statistically comparable due to the fact that two different ELISAs were 
used for the detection of these antibody responses. 
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Table 3.4 Antibody responses detected in serum samples of ostriches from the Schmoeman farm as detected with 
the MG Antibody Test kit plates.  Positive responses (0.2 ≤ titre) are indicated as fractions and percentages for 
group A immunized with MS-Bac, group G immunized with MG-Bac, and the control group which received no 
vaccine. 
Group A Group B Control group Day 
Fraction % Fraction % Fraction % 
0 0/29 0 0/30 0 0/18 0 
7 0/27 0 0/28 0 0/18 0 
27 0/27 0 22/25 88 0/17 0 
34 0/28 0 23/26 89 0/15 0 
45 0/26 0 24/26 92 0/16 0 
53 1/26 3.8 25/26 96 2/14 14.3 
83 1/23 4.3 23/25 92 3/14 21.4 
 
3.3.2 Field challenge 
Although there was generally a lower incidence of mycoplasma infections in ostriches during the autumn 
of 2008, symptoms associated with mycoplasma infections were still observed in the immunized birds 
once exposed to Ms01, Ms02 and Ms03 by field challenge.  Immunized birds on the Schoeman farm 
showed a high incidence of symptoms associated with mycoplasma infection such as the appearance of 
mucus exudates from the nasal cavities and foaming eyes, and had notably poor growth rates.  Birds from 
the Kwessie farm sporadically showed signs of mycoplasma infection, such as mucus exudates from the 
nasal cavities and foaming eyes, before the second immunization was administered.  However, there was 
not such a large effect on the growth rate of the birds from the Kwessie farm.  Unfortunately none of the 
findings of the visual inspections were properly documented due to the unmanageable large flock sizes on 
the respective farms. 
3.4 Discussion 
In chickens and turkeys, MS vaccines provide protection against MS infections and MG vaccines provide 
protection against MG infections.  The fact that two separate vaccines have been developed for protection 
against these mycoplasmas indicates that the respective vaccines do not give sufficient cross protection 
against both MS and MG infections, and that a separate vaccine is required in order to elicit antibody 
responses against each of these mycoplasmas. 
From the results obtained in this study, it can be concluded that poultry mycoplasma vaccines can also 
elicit strong primary antibody responses in ostriches, and even more rapid and greater secondary antibody 
responses, indicative of acquired memory.  It was further found that the produced anti-MS and anti-MG 
antibodies were specific for MS and MG antigen respectively, and that cross-reactivity between the 
immunity raised against them is low.  It is therefore unlikely that one of the two would provide protection 
against infections with both mycoplasmas.  Furthermore, the antibody responses elicited against MS and 
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MG in ostriches did not provide protection against the ostrich-specific mycoplasmas Ms01, Ms02 and 
Ms03 as observed from the high infection rate of the ostriches with the ostrich-specific mycoplasmas 
Ms01, Ms02 or Ms03 after vaccination with MS or MG.  Due to the distant phylogenetic relationship of 
MG to the ostrich-specific mycoplasmas Ms01, Ms02 and Ms03 it was not unexpected that MG vaccines 
do not give protection against these ostrich-specific mycoplasmas.  However, MS is phylogenetically 
more closely related to the ostrich-specific mycoplasmas Ms02 and Ms03, yet it would appear that MS 
vaccines also do not give protection against ostrich-specific mycoplasmas.  However, it must be 
considered that it was not established which of the ostrich-specific mycoplamas, Ms01, Ms02 or Ms03 
was the causative organism that was responsible for the mycoplasma infection symptoms that these 
ostriches showed.  Therefore, the lack of protection could also be attributed to the phylogenetic distance 
between MS and the ostrich-specific mycoplasma Ms01, with the result that even if MS vaccines could 
provide protection against its two closely related ostrich-specific mycoplasmas (Ms02 and Ms03), Ms01 
could have been responsible for the observed mycoplasma infections. 
A second possible explanation for lack of protection provided by MS could be the highly divergent 
antigenic properties of Ms01, Ms02 and Ms03.  Ostrich mycoplasma serological cross-reactivity tests 
were conducted at Onderstepoort to determine the incidence of cross-reactivity between the different 
strains of ostrich mycoplasmas and these results, which are unpublished (Gouws, personal 
communication) are shown in Table 4.3. 
 
Table 4.3 Antibody titres obtained from serological cross-reactivity tests with the ostrich-specific mycoplasmas 
Ms01, Ms02 and Ms03. 
 Antibody
  Ms01 Ms02 Ms03 
Ms01 1280 - - 
Ms02 - 320 - 
Antigen 
Ms03 - 80 2560 
 
This revealed that antibodies to Ms01 did not recognize Ms02 or Ms03 and antibodies to Ms03 did not 
recognize Ms01 or Ms02.  Antibodies to Ms02 did not recognize Ms01, but did partially cross-react with 
Ms03.  This further illustrates that the cross-reactivity between mycoplasmas appears to be low in general.  
Ms02 and Ms03 are phylogenetically more closely related to each other than they are to MS, yet they 
show little cross-reactivity toward each other.  Therefore it is not surprising that MS vaccines do not give 
protection against any of the ostrich-specific mycoplasmas. 
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A third possible explanation could be the result of insufficient mucosal immunity elicited by the 
poultry vaccines in ostriches.  In chickens, live vaccines administered by eye drop or orally have been 
found to induce protective mucosal immunity mediated by IgA antibodies, while injected inactivate 
vaccines lead to the production of high levels of serum antibodies (Blignaut, 1998).  As ostrich 
mycoplasmas are pathogens of the respiratory tract of ostriches, the production of serum antibodies may 
be insufficient to provide protection against these pathogens of the respiratory tract. 
An alternative to employing poultry mycoplasma vaccines, such as MS and MG vaccines, to control 
Ms01, Ms02 and Ms03 infections, is to develop specific vaccines against each of the ostrich-specific 
mycoplasmas separately.  The possibility of developing a conventional vaccine such as a whole killed 
organism or live attenuated organism vaccine has to date been hindered by the poor in vitro cultivation 
properties of these mycoplasmas.  The development of a DNA vaccine may therefore be an attractive 
alternative since this strategy does not require the large scale in vitro cultivation of ostrich mycoplasmas. 
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Chapter 4 – Identification, isolation, and site-directed mutagenesis of the 
P100 vaccine candidate gene in the ostrich mycoplasma Ms01 
4.1 Introduction 
Mycoplasmas are members of the class Mollicutes (mollis, soft; cutes, skin) and are described to be the 
smallest known organisms capable of self-reproduction (Razin, 1985; Weisburg et al., 1989).  They 
originated by degenerate evolution from low G+C content Gram-positive bacteria by losing many non-
essential genes, such as genes encoding proteins involved in several biosynthetic pathways, as well as cell 
wall synthesis.  This degenerate mode of mycoplasma evolution ultimately resulted in their two most 
prominent features being (i) the complete lack of a cell wall, and (ii) their unusually small genome (580 - 
1350 kb) with a G+C content of 23-41 mol%.  The AT-richness of the mycoplasma genome has resulted 
in their use of an alternative genetic code, where the universal termination codon TGA, encodes 
tryptophan instead (Dubvig and Voelker, 1996; Razin et al., 1998; Söll and RajBhandary, 2006). 
Mycoplasmas are parasites of a wide range of animal hosts.  Their restricted anabolic abilities render 
them completely reliant on their hosts for their nutrient requirements.  Accordingly, the mycoplasma 
genome encodes a large number of transport proteins, the majority of which are ABC transporters, 
responsible for uptake of essential nutrients such as sterols, fatty acids, vitamins, amino acids, purines, 
pyrimidines from their host (Heinrich et al., 1999; Prescott et al., 2002).  Although in many cases 
mycoplasmas form part of the normal flora of their hosts, a number of species have been shown to be 
pathogenic (Razin, 1985).  Attachment of mycoplasmas to the cells of their host plays a key role in their 
pathogenesis and is, in fact, a prerequisite for mycoplasma infection to occur.  In some species a 
specialized organelle or tip structure has been identified to mediate mycoplasma attachment to their host 
(Henrich et al., 1993; Lockaby et al., 1998).  In mammals and birds, mycoplasmas often reside in the 
mucosal surfaces and are associated with diseases of the respiratory and urogenital tracts (Prescott et al., 
2002).  Recently, three unique mycoplasmas were identified to infect ostriches in South Africa.  These 
ostrich-specific pathogens, provisionally named Ms01, Ms02 and Ms03 are associated with respiratory 
disease in ostriches, ultimately resulting in large production losses and therefore posing a threat to the 
ostrich industry (Botes et al., 2005). 
Even though mycoplasma infections in ostriches can be controlled by following a certain set of bio-
security guidelines to try and maintain infection free flocks, as well as by treatment with a narrow range 
of antibiotics (Kleven, 2008), there is currently no registered vaccine available to prevent mycoplasma 
infections in ostriches.  Conventional approaches to mycoplasma vaccine development are hindered by 
their weak cultivation properties, and to date, attempts at developing a vaccine against ostrich-specific 
mycoplasmas have been unsuccessful.  We have also found that vaccines against the poultry 
mycoplasmas, M. gallisepticum and M. synoviae, do not provide protection against any of the ostrich-
specific mycoplasmas.  These vaccines are therefore ruled out as an alternative to vaccine development 
Stellenbosch University  https://scholar.sun.ac.za
  
43
 
(unpublished results).  The approach of DNA vaccine development is an attractive alternative as it 
obviates the requirement for large quantitiy in vitro cultivation of the pathogens (Gurunathan et al., 
2000).  As a first step to DNA vaccine development, a vaccine candidate gene needs to be identified.  
Genes encoding membrane proteins, such as proteins involved in transport of nutrients across the plasma 
membrane, as well as proteins mediating attachment to host cells, have been shown to possess strong 
antigenic properties, and have therefore been proposed as good vaccine candidate genes (Garmory and 
Titball, 2007). 
In order to identify suitable vaccine candidate genes, the whole genome of Ms01 was sequenced using 
GS20 sequencing.  To this end, Ms01 gDNA was isolated by means of four different extraction methods.  
One gDNA preparation was subsequently used for whole-genome GS20 sequencing followed by 
assembly of the resulting contiguous sequences.  A search was launched for suitable vaccine candidate 
genes in these contigs.  The P100 gene was identified in the genome of Ms01, cloned, and modified by 
changing the mycoplasma codon for tryptophan (TGA), to the universal codon for tryptophan (TGG), to 
prepare the gene for insertion into a suitable DNA vaccine vector. 
4.2 Materials and Methods 
4.2.1 Isolation of genomic DNA 
Ms01 was cultivated on modified Chanock’s medium in candle jars incubated at 37˚C for approximately 
15 days (cultivation was performed by Mr Johan Gouws, Onderstepoort Veterinary Institute, Pretoria).  
Colonies were usually visible 72 hours after inoculation of the plates, although this was found to vary.  
The mycoplasmas tended to penetrate the surface of the solid medium, resulting in a central nucleus that 
remained embedded in the medium, while the rest of the colony (peripheral zone) was removed by gentle 
scraping of the agar.  The colonies of 50 plates were suspended in 100 ml of phosphate buffered saline 
(PBS).  The gDNA was subsequently isolated from the above suspension.  The modified Hempstead 
method, a modified phenol:chloroform method, and two DNA isolation kits were employed in an attempt 
to achieve optimum yields of gDNA for subsequent whole-genome GS20 sequencing. 
4.2.1.1 Modified Hempstead method 
The protocol for gDNA isolation as described by Hempstead (1990) was modified and adapted to 
optimize yield.  Briefly, 20 ml Ms01 culture was placed in a sterilized screw cap JA-20 tube followed by 
centrifugation at 27 200 x g for 50 min at 4˚C (Beckman Model J2-21 Centrifuge, JA-20 rotor).  The 
supernatant was decanted and the pellet resuspended in 10 ml concentrated TE buffer (50 mM Tris-HCl, 
10 mM EDTA, pH 8.0) followed by centrifugation at 12 100 x g for 40 min at 4˚C.  The supernatant was 
again decanted and the pellet resuspended in 1 ml concentrated TE buffer.  The suspension was 
transferred to a 1.5 ml microcentrifuge tube and centrifuged at 16 000 x g for 40 min at 4˚C (Biofuge 
Fresco, Heraeus).  Following centrifugation, the supernatant was decanted and the pellet resuspended in 
100 μl concentrated TE buffer and the sample kept at -20˚C overnight.  A volume of 1 ml concentrated 
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TE buffer containing 1% (v/v) SDS, and 11 μl proteinase K (20 mg/ml, Roche) was added to lysed 
cells, followed by 15-30 min incubation at 55˚C.  To the clear suspension, 100 μl of 5 M potassium 
acetate solution was added, and the mixture kept on ice for 30 min.  This was followed by centrifugation 
at 16 000 x g for 10 min at 4˚C, after which the upper phase was removed and divided into two clean 2 ml 
microcentrifuge tubes.  An equal volume of chloroform:isoamylalcohol (24:1) was added to each tube and 
mixed by inverting the tubes for 15 min, followed by centrifugation at 16 000 x g for 2 min at 4˚C.  This 
was repeated three times.  Subsequently the upper phase was transferred to a clean 1.5 ml microcentrifuge 
tube, to which 1/10 volume sodium acetate (3 M, pH 4.8), as well as 2 volumes 95% (v/v) ethanol was 
added.  DNA was allowed to precipitate overnight at -20˚C.  Subsequently the mixtures were centrifuged 
at 16 000 x g for 10 min at 4˚C, after which the supernatants were decanted and the pellets washed in 
70% (v/v) ethanol for 30 min at room temperature.  The ethanol was decanted and the remaining pellets 
air-dried for 30 min at 37˚C, after which the DNA was redissolved overnight in 50 μl TE buffer. 
4.2.1.2 Modified phenol:chloroform isolation method 
The commonly used phenol:chloroform DNA extraction method was also employed for the isolation of 
gDNA, with certain adjustments to the protocol to optimize yield.  In this case, 25 ml Ms01 culture was 
measured into a sterilized screw cap JA-20 tube followed by centrifugation at 12 100 x g for 60 min at 
4˚C (Beckman Model J2-21 Centrifuge, JA-20 rotor).  The supernatant was decanted and the remaining 
pellet washed in an equal volume (25 ml) PBS (pH 7.2), followed by centrifugation at 12 100 x g for 60 
min at 4˚C.  The supernatant was subsequently decanted and the pellet resuspended in 6 ml TE buffer.  A 
volume of 385 μl of a 10% (v/v) SDS solution, and 240 μl proteinase K (20 mg/ml) was added to the 
suspension, mixed, and incubated for 60 min at 55˚C.  Following incubation, an equal volume of 
phenol:chloroform (1:1) was added, and the suspension mixed by inverting the tube for 10 min, followed 
by centrifugation at 7000 x g for 5 min at room temperature.  The upper phase was removed and 
transferred to a fresh sterilized screw cap JA-20 tube.  An equal volume of phenol:chloroform was added 
and the suspension mixed, followed by to centrifugation at 7000 x g for 5 min at room temperature.  The 
upper phase was again removed and this time transferred to a clean 2 ml microcentrifuge tube to which 
1/10 volume sodium acetate (3 M, pH 5.2), as well as 0.6 volume isopropanol (-20˚C) was added.  After 
thorough mixing, the sample was left overnight at room temperature to allow the DNA to precipitate.  
Subsequently the sample was centrifuged at 13 000 x g for 10 minutes at 4˚C (Biofuge Fresco, Heraeus), 
after which the supernatant was decanted, and the pellet washed twice in 30 ml 70% (v/v) ethanol for 20 
min at room temperature.  The ethanol was decanted and the remaining pellets air-dried for 30 min at 
37˚C, after which the DNA was dissolved overnight in 50 μl TE buffer. 
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4.2.1.3 DNA isolations with commercial kits 
Genomic DNA was isolated form Ms01 cultures using the protocol for the isolation of gDNA from Gram 
negative bacteria as described by the Wizard® Genomic DNA Purification Kit (Promega), as well as the 
ZR Fungal/Bacterial DNA Kit™ (ZYMO Research) according to manufacturers’ instructions. 
4.2.1.4 Quantity and quality determination 
After the isolation of gDNA from Ms01 cultures by means of the four different extraction methods, the 
resulting gDNA preparations were analysed spectrophotometrically (NanoDrop, ND-1000) and their 
concentration (ng/μl) and purity (A260/A230 and A260/A280 ratios) determined in order to establish which 
extraction method produced gDNA most suitable for subsequent whole-genome GS20 sequencing. 
4.2.1.5 Confirmation of Ms01 identity 
In order to confirm that the gDNA preparations isolated from the cultures received from Onderstepoort 
were indeed of Ms01 origin, and were not contaminated by Ms02 or Ms03, a standardized mycoplasma 
polymerase chain reaction (PCR) was carried out using the species specific primer pair with the forward 
primer (F) GPO3F and reverse primer (R) MYC 16R1541 (R) based on the 16S rRNA gene sequence of 
Ms01 (Table 3.1) and this product was sequenced (Botes et al., 2005). 
 
Table 4.1 Nucleotide sequences of the species specific primer pair used to verify Ms01 identity of gDNA 
preparation isolated from cultures prepared at and received from Onderstepoort. 
Primer name Primer sequence (5’→3’) bp-position Tm (˚C) 
GPO3F (F) 5’-TGGGGAGCAAACAGGATTAGATACC-3’ 745 78 
MYC 16R1541 (R) 5’-TGCACCATCTGTCACTCTGTTAACCTC-3’ 1017 79 
 
Amplification reactions using the primer pair GPO3F and MYC 16R1514 (Table 3.1) were carried out in 
50 μl volumes.  Each reaction mixture contained 25 μl of 2 x Ready Mix reaction buffer (Kapa), 1.0 μl of 
each primer (20 pmol/μl), 2.5 μl gDNA (544 ng/μl), and 20.5 μl Milli-Q® water.  Amplifications were 
performed in a Hybaid Px2 Thermal Cycler programmed to perform 35 cycles of 94˚C (45 s), 55˚C (45 s) 
and 72˚C (1 min 30 s), followed by a final extension reaction for 6 min at 72˚C.  Amplified DNA was 
subsequently analyzed by gel electrophoresis.  Ten microliters of the PCR product, mixed with 0.1 
volume of gel loading buffer [50% (v/v) glycerol; 0.1% (v/v) bromophenol blue; 50 mM EDTA; 100 mM 
Tris-base, pH 8.0] were electrophoresed (100 V, ~60 min) on a 2% (w/v) agarose gel (Molecular Grade 
Agarose D1-LE, Whitehead Scientific) in 1 x TAE buffer (0.04 M Tris-acetate; 0.002 M EDTA, pH 8.0).  
Ethidium bromide (0.175 μg/ml) was included in the gel for ultraviolet (UV) visualization of the DNA. 
Following visualization, the PCR product obtained from the respective DNA preparations with the primer 
pair GPO3F and MYC 16R1541 were purified as template for sequencing reactions.  To this end, the 
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remaining PCR product was electrophoresed (150 V, 2-3 hours) on a 0.5% (w/v) agarose gel in 1 x 
TAE buffer containing ethidium bromide (0.15 μg/ml) as previously described.  Single DNA containing 
bands corresponding to a size of 750 bp were excised under UV light and purified using the GFX™ PCR 
DNA and Gel Band Purification Kit (GE Healthcare) according to the manufacturers’ instructions.  The 
purified DNA samples were each concentrated by centrifugal evaporation to 20 μl on a Savant Speedvac, 
after which 2 μl of the purified and concentrated product was analyzed by gel electrophoresis as 
previously described. 
Sequencing reactions on the purified DNA templates were subsequently prepared using the BigDye® 
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems).  Each 10 μl sequencing reaction consisted 
of 5 μl of 5x Sequencing buffer, 2 μl Terminator mix, 1 μl primer (GPO3F, 0.8 pmol/ μl), 0.5 μl purified 
and concentrated DNA, and 1.5 μl Milli-Q® water.  Amplifications were performed in a Hybaid Px2 
Thermal Cycler programmed to perform 35 cycles of 96˚C (10 s), 52˚C (30 s) and 60˚C (4min), followed 
by a final extension reaction of 10 min at 60˚C. 
Sequencing PCR reaction products were analyzed with an ABI® 3100 Genetic Analyser (Applied 
Biosystems) at the DNA sequencing facility of the University of Stellenbosch.  Resulting chromatograms 
were edited using Chromas (v 2.23, Technelysium, Pty., Ltd.) and the nucleotide sequences manually 
aligned with the known 16S rRNA gene sequence of Ms01 in BioEdit (v 7.0.5.2, Hall). 
4.2.2 Whole-genome GS20 sequencing of Ms01 
Following the successful isolation of uncontaminated gDNA from Ms01 cultures, the entire genome of 
Ms01 was sequenced using the Roche 454 Sequencing System based on GS20 sequencing technology at 
InqabaBiotec in Pretoria (see section 2.12.1.1).  Two 20 Mb runs of this sequencing were performed. 
Short sequences of an average length of 100 bp were generated, which were assembled into larger 
contiguous sequences based on the overlap between the reads.  This was done with a de novo shotgun 
sequence assembler program which also gave an estimate of the size and G+C content of the Ms01 
genome. 
4.2.3 Identification of a vaccine candidate gene in Ms01 by bioinformatic analysis of the whole-
genome GS20 sequencing data 
In order to identify a gene encoding a membrane protein in Ms01 to serve as a possible DNA vaccine 
candidate gene, the data obtained from the whole-genome GS20 sequencing of Ms01 were subjected to 
bioinformatic analysis. 
4.2.3.1 Similarity searches in the National Center for Biotechnology Information (NCBI) database 
Firstly, similarity searches were performed on the individual contiguous sequences (contigs) spanning the 
entire Ms01 genome using the Basic Local Alignment Search Tool (BLAST) engine available online on 
the NCBI website (http://www/ncbi.nlm.nih.gov/blast).  Several BLAST search programs, each with a 
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different search strategy, are available.  For this study, blastn, which compares a nucleotide query 
sequence with a nucleotide sequence database, as well as tblastx, which compares a translated nucleotide 
query sequence with a translated nucleotide sequence database, was used. 
Each individual contig obtained from the whole-genome sequencing of Ms01, was analysed for similarity 
at nucleotide level using blastn with a specified wordsize of 15 bases.  The significance of identified 
sequence similarities, also referred to as blast hits, was determined by the Expect (E)-value, as well as the 
bit score of the match.  The E-value indicates the statistical significance of an alignment between the 
query sequence and a sequence in a database; the lower the E-value, the more likely it is that the 
alignment did not occur randomly, and therefore reflects a true sequence similarity.  On the other hand, a 
bit score reflects the length of the alignment between a query sequence and a sequence in a database.  In 
general, as in this study, hits with E-values higher than 0.1, and bit scores lower than 50, are not regarded 
to reflect statistically significant sequence similarity. 
The results obtained from blastn searches with the individual contigs were screened for hits with genes 
encoding membrane proteins involved in membrane transport and/or host attachment.  Contigs in which 
such genes were identified were further analysed for similarity at amino acid level using tblastx 
employing the specified mold mitochondrial genetic code. 
4.2.3.2 Open reading frame identification using CLC Combined Workbench software 
Following identification of contigs showing significant similarity with a suitable membrane protein 
within the NCBI database, these contigs were subjected to open reading frame (ORF) analysis in CLC 
Combined Workbench (v 4.0.1).  For the purpose of our search, an ORF was assigned the initiation and 
termination codon ATG and TAA respectively (see section 2.5.6.2), with a minimum length of 100 
codons.  Resulting ORFs were confirmed by alignment and comparison to the ORFs of the identified 
homologous genes within the NCBI database. 
4.2.3.3 Linkage of contiguous sequences by PCR 
Following identification of two separate contigs; contig number 835 (1645 bp) and contig number 9312 
(53326 bp), each containing a part of the same vaccine candidate gene in Ms01, the contigs were linked 
together by PCR. 
For this, two primers were designed using Primer Designer (v 1.01); the forward primer on the 3’ end of 
contig 835, and the reverse primer on the 5’ end of contig 9312 (Figure 4.1). 
Figure 4.1 Schematic illustration of the primer position on contig 835 (1645 bp) and contig 9312 (53 326 bp) for 
subsequent linkage PCR. 
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The nucleotide sequences of the primers that were subsequently synthesized by the DNA Synthesis 
Laboratory, Department of Molecular and Cellular Biology, University of Cape Town, are shown in 
Table 4.2. 
 
Table 4.2 Nucleotide sequences of the primers used for the linkage of contig 835 and contig 9312, each identified to 
contain part of a gene encoding a membrane protein in Ms01. 
Primer name Primer sequence (5’→3’) bp-position Tm (˚C) 
LinkP100F 5’-GATCAATTAATGCATGACTATACATTCT-3’ 1511-1539 71 
LinkP100R 5’-CACCATATCAGTAAACACCTAATTTAGC-3’ 29-57 73 
 
Amplification reactions using the primer pair LinkP100F and LinkP100R (Table 4.2) were carried out in 
50 μl volumes.  Each reaction mixture contained 5 μl of 10 x Taq reaction buffer, 2 μl of 5 mM of each 
deoxynucleotide (dATP, dCTP, dGTP and dTTP) (Bioline), 2.5 μl of each primer (20 pmol/μl), 3 μl of 25 
mM MgCl2, 0.5 μl of 5 U/μl Super-Therm Taq DNA polymerase (Southern Cross Biotechnology), 5 μl of 
1:10 diluted purified DNA, and 29.5 μl Milli-Q®.  Amplifications were performed in a Hybaid Px2 
Thermal Cycler, programmed to perform 35 cycles of 94˚C (45 s), 55˚C (45 s) and 72˚C (1 min 30 s), 
followed by a final extension reaction for 6 min at 72˚C. 
Amplified DNA was subsequently analyzed by gel electrophoresis and the remaining product purified as 
template for sequencing reactions as previously described.  Following purification and centrifugal 
evaporation, the concentration of the PCR product was determined spectrophotometrically (NanoDrop, 
ND-1000). 
Sequencing reactions on the purified DNA templates were prepared using the BigDye® Terminator v3.1 
Cycle Sequencing kit (Applied Biosystems).  Each sequencing reaction consisted of 5 μl of 5x 
Sequencing buffer, 2 μl Terminator mix, 1 μl of either of the primers (LinkP100F or LinkP100R, 0.8 
pmol/μl), 3 ng purified and concentrated DNA, and Milli-Q® water to a final volume of 10 μl.  
Amplifications were performed in a Hybaid Px2 Thermal Cycler, programmed to perform 35 cycles of 
96˚C (10 s), 52˚C (30 s) and 60˚C (4 min), followed by a final extension reaction of 10 min at 60˚C.  
Sequencing PCR reaction products were analyzed with an ABI® 3100 Genetic Analyser as previously 
described, and resulting chromatograms were edited using Chromas and the nucleotide sequences aligned 
with the 3’ end of contig 835 and the 5’ end of contig 9312 in BioEdit. 
4.2.3.4 Revision on open reading frames in CLC Combined Workbench 
Once contig 835 and contig 9312 were successfully linked together in one contig (54 973 bp), previously 
identified ORFs on the separate contigs were revised to confirm assigned ORF positions in CLC 
Combined Workbench as previously described. 
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4.2.3.5 Comparative genomics 
Consensus promoter areas upstream of the predicted initiation codon, and conserved motifs related to the 
function of the proteins encoded by the opp genes were identified by manual alignment to the gene 
homologs of M. hominis and published ABC transporter consensus motifs (Henrich et al., 1999; Weiner 
et al., 2000; Garmory and Titball, 2004; Hopfe and Henrich, 2004; Davidson and Maloney, 2007). 
4.2.4 Isolation of the P100 gene of Ms01 by PCR 
Once the complete nucleotide sequence of the P100 vaccine candidate gene was determined, the gene was 
isolated from the gDNA of Ms01 by PCR for subsequent cloning.  Primers for the isolation of the P100 
gene were designed using Primer Designer (v 1.01).  Endonuclease restriction sites were incorporated at 
the 5’ end of each primer for later insertion of the gene into the vaccine expression vector pCI-neo (see 
Figure 2.2 section 2.11.2.1).  Accordingly the choice of restriction sites was limited to endonucleases that 
recognize restriction sites within both the cloning vectors pGEM®-T Easy and pCI-neo, but with no 
restriction sites in the P100 gene prior to or following modification.  The primers, of which the sequences 
are shown in Table 4.3, were synthesized by Integrated DNA Technologies (IDT). 
Table 4.3 Nucleotide sequences of the primers used for the isolation of the P100 gene from the gDNA of Ms01.  
The endonuclease recognition sequences incorporated for ultimate cloning in pCI-neo are underlined, with the 
arrows indicating the respective restriction sites.  The initiation codon (ATG) and the termination codon (TAA) of 
P100 gene are indicated in bold. 
Primer name Primer sequence (5’→3’) bp-position Tm (˚C) Endonuclease 
P100_ampF 5’-ACGCGTATGAAAAAAAGCGCAAGACT-3’ 1-20 68 MluI 
P100_ampR 5’-GTCGACTTATTTATTGATTCTTCAATCAAC-3’ 2802-2829 64 AccI 
 
Amplification reactions using the primer pair P100_ampF and P100_ampR (Table 4.3) were carried out in 
50 μl volumes.  Each reaction mixture contained 10 μl of 5x reaction buffer, 1.5 μl of 10 mM of each 
deoxynucleotide (dATP, dCTP, dGTP and dTTP) (KapaBiosystems), 1.5 μl of each primer (20 pmol/μl), 
0.5 μl of 25 mM MgCl2, 1 μl of 1 U/μl High Fidelity proofreading Taq DNA polymerase 
(KapaBiosystems), 200 ng purified DNA, and Milli-Q® water to a final volume of 50 μl.  Amplifications 
were carried out in a Hybaid Px2 Thermal Cycler programmed to perform an initial denaturation step at 
95˚C (2 min), 25 cycles of 98˚C (20 s), 50˚C (15 s) and 68˚C (1 min 30 s), followed by a final extension 
step for 5 min at 68˚C.  Ten microliters of amplified DNA was analyzed by gel electrophoresis as 
previously described.  The remaining PCR product was purified for subsequent cloning using the GFX™ 
PCR DNA and Gel Band Purification kit (GE Healthcare) according to the manufacturer’s instructions 
and the concentration of the purified DNA determined spectrophotometrically (NanoDrop). 
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4.2.5 Cloning of the P100 gene into the pGEM®-T Easy plasmid 
The purified P100 gene was cloned into the pGEM®-T Easy plasmid.  Prior to cloning the blunt-ended 
PCR product produced by the exonuclease activity (proofreading) DNA polymerase was modified, 
creating adenosine overhangs to allow sticky-end cloning of the P100 gene into the pGEM®-T Easy 
plasmid. 
4.2.5.1 A-Tailing of blunt-ended PCR product for subsequent ligation with the pGEM®-T Easy cloning 
vector 
The purified PCR product of the primer pair P100_ampF and P100_ampR (Table 4.3) was used as 
template for A-Tailing.  A-Tailing was performed according to the protocol described in the pGEM®-T 
and pGEM®-T Easy Vector System kit (Promega).  In short, the 10 μl reaction mixture contained 1 μl of 
10x reaction buffer, 0.4 μl of 0.2 mM dATP (Bioline), 0.8 μl of 25 mM MgCl2, 1 μl of 5 U/μl Taq DNA 
polymerase (Super-Therm), 6 μl purified blunt-ended PCR product, and 0.8 μl Milli-Q® water.  The 
reaction was incubated at 70˚C for 25 min, after which the DNA was purified by using the DNA Clean & 
Concentrator™-5 Kit (ZYMO Research) according to the manufacturer’s instructions. 
4.2.5.2 Transformation of JM-109 cells with recombinant pGEM®-T Easy plasmids 
The purified DNA obtained after A-Tailing was subsequently cloned into the pGEM®-T Easy vectors 
using the pGEM®-T Easy Vector System Kit according to the manufacturer’s instructions.  Briefly, 2 μl 
purified DNA was used in a ligation reaction with 50 ng pGEM®-T Easy vector, in a reaction also 
containing 5 μl 2x Rapid Ligation buffer, 1 μl T4 DNA ligase, and Milli-Q® water amounting to 10 μl.  A 
positive control ligation reaction containing control insert supplied with the kit, and a background ligation 
reaction containing no insert, were also included as suggested by the manufacturer.  The ligation reactions 
were kept at 4˚C for 16 hours before being used in transformation reactions.  Two microliters of each 
recombinant plasmid construct were introduced to 50 μl competent Escherichia coli (JM-109, 1 x 107 
cfu/μg DNA, Promega).  The cells were kept on ice for 20 min, followed by heat shock in a water bath at 
42˚C for 45 s, after which the cells were put on ice for a further 2 min.  Subsequently, 950 μl LB-medium 
was added to the cells, and the cells were allowed to grow at 37˚C for 1 hour 30 min on an IKA® KS 260 
Basic orbital shaker at 150 rpm.  Transformed cultures were then plated out in duplicate (50 μl and 150 
μl) on LB/agar plates (15 g/ml) containing ampicillin at100 μg/ml (Sigma), 0.1 M IPTG at 160 μl/100 ml) 
(Bioline) and 50 mg/ml X-Gal at 80 μl/100 ml (Bioline) and were examined for colony development after 
16 hours of incubation at 37˚C. 
4.2.5.3 Confirmation of insert by diagnostic PCR 
The blue/white screening system was used to identify positive clones containing the recombinant 
pGEM®-T Easy vector.  Positive transformants were subsequently subjected to diagnostic PCR with T7 
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(5’-TAATACGACTCACTATAGGG-3’) and SP6 (5’-ATTTAGGTGACACTATAGAA-3’) primers to 
verify the presence of insert in the white colonies.  Each PCR reaction contained 1 μl of 10 x reaction 
buffer, 0.6 μl of 25 mM MgCl2, 0.5 μl of each primer (20 pmol/μl), 0.4 μl of 5 mM of each 
deoxynucleotide (dATP, dCTP, dGTP and dTTP) (Bioline), 0.1 μl Taq DNA polymerase (Super-Therm), 
and 6.9 μl Milli-Q® water.  A sterilized toothpick was pricked into a colony of interest, and the tip of the 
toothpick was then placed into the PCR mixture and flicked 5 times to release some of the bacteria from 
the colony.  The DNA contained in the colony therefore served as DNA source for the PCR.  Two 
positive control samples of previously purified plasmid DNA samples containing 800 bp inserts were also 
included adding 1 μl of 1:1000 diluted plasmid DNA (100 ng/μl) to the PCR mix.  Amplifications were 
carried out in a Hybaid Px2 Thermal Cycler programmed to perform an initial denaturation step at 94˚C 
(5 min), 25 cycles of 94˚C (30 s), 55˚C (30 s) and 72˚C (30 s), followed by a final extension step at 72˚C 
for 7 min.  Subsequently the entire 10 μl product of each reaction was electrophoresed on a 1% (w/v) 
agarose gel for detection as previously described. 
4.2.5.4 Isolation of pGEM T-easy constructs 
The confirmed positive colonies were inoculated in 14 ml Falcon tubes in 5 ml of LB-medium containing 
ampicillin (100 μg/ml) (Sigma) and incubated at 37˚C for 16 hours on an orbital shaker set at 200 rpm.  A 
volume of 2 ml of each inoculant was used for subsequent plasmid isolations using a Plasmix Miniprep 
kit (Talent) according to the manufacture’s instructions, while 500 μl of each inoculant was stored in an 
equal volume 80% (v/v) glycerol at -80˚C for future use.  Following plasmid isolation, 2 μl of each 50 μl 
product was electrophoresed on a 1% (w/v) agarose gel for detection as previously described, and the 
concentration of each sample determined spectrophotometrically (NanoDrop). 
4.2.5.5 Sequencing of plasmid inserts 
The insert in the purified plasmid DNA was amplified during sequencing PCR.  For this, six overlapping 
primers were designed using Primer Designer (v 1.01) (Figure 4.2). 
These primers (Table 4.4) were used in conjunction with T7 (5’-TAATACGACTCACTATAGGG-3’) 
and SP6 (5’-ATTTAGGTGACACTATAGAA-3’) in order to sequence the entire 2829 bp insert in eight 
separate sequencing reactions.  Sequencing was performed using the BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems).  Each sequencing reaction contained 4 μl Terminator mix, 3 μl 
primer (3.3 pmol/μl), and 3 μl plasmid DNA (92.5 ng/μl).  Amplifications were carried out in a Hybaid 
Px2 Thermal Cycler programmed to perform 35 cycles of 96˚C (10 s), 52˚C (30 s), 60˚C (4 min), 
followed by a final extension step at 60˚C for 10 min.  Sequencing PCR reaction products were analyzed 
with an ABI® 3100 Genetic Analyser at the DNA sequencing facility of the University of Stellenbosch.  
Resulting chromatograms were edited using Chromas and the nucleotide sequences manually aligned in 
BioEdit. 
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Figure 4.2 Schematic illustration of the P100 gene (2829 bp) cloned into pGEM®-T Easy vector (3015 bp) to 
indicate the positions of the primers in the recombinant vector for subsequent sequencing of the P100 gene. 
 
4.2.6. Modification of the P100 gene by site-directed mutagenesis 
Following the successful cloning of the P100 gene into the pGEM®-T Easy plasmid, the gene was 
modified by changing all the mycoplama tryptophan codons (TGA) to universal tryptophan codons 
(TGG) by site-directed mutagenesis (SDM). 
4.2.6.1 Primer design 
Primers for the insertion of ten point mutations at specific sites within the P100 gene (Figure 4.3) were 
designed using Primer Designer (v 1.01). 
 
 
Figure 4.3 Schematic illustration of the position of the ten sites in the P100 gene for which site-directed 
mutagenesis primers were designed. 
 
The nucleotide sequences of the primers that were subsequently synthesized by IDT are shown in Table 
4.5. 
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Table 4.5 Nucleotide sequences of the primers used for side-directed mutagenesis in the P100 gene inserted in 
the pGEM®-T Easy plasmid.  The underlined base in each primer represents the incorporated mutation; in the 
forward primers – TGA becomes TGG, and in the reverse primers – TCA becomes CCA.  In the primer pair SDM 
P10F/R the termination codon is indicated in bold, and the AccI recognition sequence is underlined with the arrows 
indicating the restriction cut site. 
Primer name Primer sequence (5’→3’) bp-position Tm (˚C) 
SDM P1F 5’-CTTAAAGACAATTTAAAATGGGTAAATTCAAAAGGTGAAG-3’ 580-619 57.8 
SDM P1R 5’-CTTCACCTTTTGAATTTACCCATTTTAAATTGTCTTTAAG-3’   
SDM P2F 5’-CTAAAGATTTCTATTATTCATGGCTAAGAACAAATCAAACAATTG-3’ 641-685 58.7 
SDM P2R 5’-CAATTGTTTGATTTGTTCTTAGCCATGAATAATAGAAATCTTTAG-3’   
SDM P3F 5’-GCTAAATTAGGTGTTTACTGGTATGGTGTAACAGCAAATAC-3’ 1132-1172 61 
SDM P3R 5’-CTATTTGCTGTTACACCATACCAGTAAACACCTAATTTAGC-3’   
SDM P4F 5’-CTTTATTACAAGCTGCAATTAACTGGAATACAGTAGCAGATGTAAGAAC-3’ 1652-1700 62.4 
SDM P4R 5’-GTTCTTACATCTGCTACTGTATTCCAGTTAATTGCAGCTTGTAATAAAG-3’   
SDM P5F 5’-CAAACGGTGTTTCAGAAGCTTGGTTGGCGAAATTAGCCGATGGTG-3’ 1700-1744 68.2 
SDM P5R 5’-CACCATCGGCTAATTTCGCCAACCAAGCTTCTGAAACACCGTTTG-3’   
SDM P6F 5’-GGAACAAGAAACGTTGGTTGGAGTTATGACTATAACTCAATAG-3’ 2209-2251 61.6 
SDM P6R 5’-CTATTGAGTTATAGTCATAACTCCAACCAACGTTTCTTGTTCC-3’   
SDM P7&8F 5’-GTTATGATGGTTTATCATGGAATTGGCCATTATTCCCAACTC-3’ 2258-2299 62.4 
SDM P7&8R 5’-GAGTTGGGAATAATGGCCAATTCCATGATAAACCATCATAAC-3’   
SDM P9F 5’-CAATACTCAGCGGTTTTCTGGAACCAATACGTAGCAGAC-3’ 2602-2640 64.3 
SDM P9R 5’-GTCTGCTACGTATTGGTTCCAGAAAACCGCTGAGTATTG-3’   
SDM P10F 5’-GACATGTATGTTGATTGGAGAATCAATAAATAAGTCGAC-3’ 2797-2835 60.1 
SDM P10R 5’-GTCGACTTATTTATTGATTCTCCAATCAACATACATGTC-3’   
 
4.2.6.2 PCR based site-directed mutagenesis 
PCR-based SDM reactions were carried out in accordance to the KAPAHiFi PCR protocol.  Each 
reaction contained 10 μl of 5x reaction buffer, 1.5 μl of 10 mM of each deoxynucleotide (dATP, dCTP, 
dGTP and dTTP) (KapaBiosystems), 1.5 μl of each complimentary mutagenic primer (10 pmol/μl), 0.5 μl 
of 25 mM MgCl2, 1 μl of 1 U/μl High Fidelity Taq DNA polymerase (KapaBiosystems), 10 ng purified 
template DNA, and Milli-Q® water to a final volume of 50 μl.  Amplifications were carried out in a 
Hybaid Px2 Thermal Cycler programmed to perform an initial denaturation step at 95˚C (2 min), 15 
cycles of 98˚C (20 s), annealing at (Tm + 3˚C) for 15 s and 68˚C (1 min 30 s), followed by a final 
extension step for 5 min at 68˚C. 
In cases where the melting temperature of two mutagenic primer pairs did not differ by more than 4˚C, 
and primers were not situated too close to one another, two primer pairs were used together in a SDM 
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PCR (SDM-PCR), thus allowing simultaneous modification of their respective sites.  In cases where 
the melting temperature differed, the melting temperature that was used in the PCR was that of the primer 
pair possessing the lower melting temperature.  Where two primer pairs were used, the PCR mix 
remained the same, with the only adjustment being the amount of Milli-Q® water added.  The sequence in 
which the primer pairs or combinations of primer pairs were used were as follows:  SDM P1 (F & R, Tm = 
57.8˚C); SDM P4 (F & R, Tm = 62.4˚C) together with SDM P4 (F & R, Tm = 62.4˚C) and SDM P7&8 (F 
& R, Tm = 62.4˚C); SDM P3 (F & R, Tm = 61˚C) together with SDM P3 (F & R, Tm = 61˚C) and SDM P6 
(F & R, Tm = 61.6˚C); SDM P2 (F & R, Tm = 58.7˚C) together with SDM P3 (F & R, Tm = 61˚C) and 
SDM P10 (F & R, Tm = 60.1˚C); and finally SDM P5 (F & R, Tm = 68.2˚C) together with SDM P5 (F & 
R, Tm = 68.2˚C) and SDM P9 (F & R, Tm = 64.3˚C). 
4.2.6.3 DpnI treatment of PCR product 
The SDM-PCR product was subsequently treated with DpnI to digest methylated wild-type DNA.  The 50 
μl reaction mixture contained 5 μl of 10x reaction buffer, 10 μl DNA (PCR product), 0.1 μl of 10 U/μl 
Dpn I (Fermentas) and 34.9 μl Milli-Q® water.  Digestion was carried out at 37˚C for 2 hours, after which 
the enzyme was inactivated at 80˚C for 20 min. 
4.2.6.4 Agarose gel analysis 
To assess the success of the SDM-PCR and digestion of methylated wild-type DNA, 2 μl supercoiled 
plasmid DNA (pre-PCR), 10 μl SDM-PCR product (post-PCR), and 18 μl DpnI treated SDM-PCR 
product (post-DpnI) respectively was electrophoresed on a 1% (w/v) agarose gel for visualization as 
previously described. 
4.2.6.5 Isolation of modified recombinant pGEM T-easy constructs 
The DpnI digestion products was subsequently purified by using the DNA Clean & Concentrator™-5 kit 
(ZYMO Research) according to manufacturers’ instruction, and the vector constructs used directly in the 
transformation of competent JM109 cells as previously described. 
Once again the blue/white screening system was used to identify positive clones containing the 
recombinant pGEM®-T Easy vector, and the positive transformants subjected to diagnostic PCR with T7 
(5’-TAATACGACTCACTATAGGG-3’) and SP6 (5’-ATTTAGGTGACACTATAGAA-3’) primers to 
verify the presence of insert as previously described.  Confirmed positive clones were cultivated for 
subsequent plasmid isolations as previously described. 
4.2.6.8 Sequencing of modified plasmid insert 
In order to verify that a specific base was successfully modified, the insertion of the purified recombinant 
plasmid DNA was sequenced using the six overlapping primers described in Table 4.4, as well as T7 (5’-
TAATACGACTCACTATAGGG-3’) and SP6 (5’-ATTTAGGTGACACTATAGAA-3’) in order to 
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sequence the entire 2829 bp insert in eight separate sequencing reactions as previously described.  
Sequencing was performed using the BigDye® Terminator v3.1 Cycle Sequencing Kit, and the products 
analyzed with an ABI® 3100 Genetic Analyser as previously described, and resulting chromatograms 
edited using Chromas and the nucleotide sequences manually aligned in BioEdit. 
4.3 Results 
4.3.1 Isolation of genomic DNA 
4.3.1.1 Comparison of gDNA extraction methods 
Genomic DNA was isolated successfully from Ms01 cultures by the four different extraction methods.  
The concentration (ng/μl) and purity (A260/A230 and A260/A280 ratios) of the gDNA preparations obtained 
by means of the respective extraction methods are shown in Table 4.6. 
Table 4.6 Comparison of the average gDNA yield obtained from the respective extraction methods determined by 
spectrophotometric analysis (NanoDrop, ND-1000). 
Isolation method Concentration (ng/μl) μg  A260/A280 A260/A230 
Hempstead 524.32 26.22 1.93 1.80 
Phenol:chloroform 753.58 37.68 1.96 2.06 
Wizard Genomic DNA Purification kit (Promega) 53.64 5.36 1.55 0.60 
ZR Fungal/Bacterial DNA (ZYMO Research) 2.62 0.26 0.89 1.36 
 
The phenol:chloroform extraction method yielded the highest concentration of DNA, with the Hempstead 
method giving a slightly lower yield, while the Wizard Genomic DNA Purification kit (Promega) yielded 
a low but adequate amount of DNA, and the ZR Fungal/Bacterial DNA kit (ZYMO Research) gave a less 
than satisfactory yield.  The same trend was apparent when comparing the A260/A280 and A260/A230 ratios 
of the phenol:chloroform and Hempstead extractions methods.  The Wizard Genomic DNA Purification 
kit gave lower A260/A280 and A260/A230 ratios, indicative of protein and organic solvent contamination 
respectively.  Over and above its extremely low yield, the ZR Fungal/Bacterial DNA kit also gave a very 
low A260/A280 ratio, indicative of major protein contamination, and a lower A260/A230 ratio showing high 
organic solvent contamination. 
4.3.1.2 Confirmation of Ms01 identity 
The identity of the mycoplasma from which gDNA was isolated was confirmed to be Ms01 by the 
successful production of an amplification product of 750 bp, sequencing and subsequent alignment of the 
750 bp product with the known 16S rRNA gene sequence of Ms01. 
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4.3.2 Whole-genome GS20 sequencing of Ms01 
Using gDNA isolated by means of the Hempstead method, the entire genome of Ms01 was successfully 
sequenced with 99.7% accuracy.  De novo shotgun sequence assembly resulted in 64 large contiguous 
sequences (contigs) amounting to the estimated 700 kbp (693513 bp) genome size of Ms01 with a G+C 
content of 27%.  The contigs ranged in size from 491-86684 bp and are listed from smallest to largest in 
no fixed orientation in Table 4.7. 
Stellenbosch University  https://scholar.sun.ac.za
  
57
 
Table 4.7 Summary of the 64 large contigs obtained from whole-genome GS20 sequencing of Ms01 using the 
Roche 454 Sequencing System. 
500-1000 bp (29 contigs)  1000-10 000 bp (18 contigs)  >10 000 (17 contigs) 
Contig ID 
number 
Contig 
length 
Number of 
reads 
 Contig ID 
number 
Contig 
length (bp) 
Number of 
reads 
Contig ID 
number 
Contig 
length 
Number of 
reads 
9732 491 24  9330 1499 101 9373 11511 4159 
9340 503 28  9390 1578 198 9372 13994 5105 
9924 505 38  9405 1606 1107 9355 16063 5792 
10610 520 28  835 1645 561 9391 16788 6195 
9385 527 21  9337 1702 1256 4709 17166 6536 
10199 529 25  9381 1989 687 4259 18387 6534 
9656 535 22  9339 2145 749 9383 18643 7064 
8968 542 31  9309 2263 834 9420 21331 7395 
9913 548 23  9333 2263 858 9343 21528 7847 
6122 550 25  9 3243 471 9423 29944 10868 
9824 550 25  9409 5557 1977 9371 30066 10619 
6749 557 19  9358 5874 1940 9310 32759 12524 
9379 568 44  9360 7195 2578 9394 44778 15603 
6767 605 22  1863 7364 2494 10065 49240 17434 
10003 642 34  7839 7365 2661 9312 53326 17519 
9336 657 36  9316 7607 2785 10066 68032 22897 
3878 664 27  9387 8040 2898 9398 86684 29349 
10592 665 28  6 9828 3325  
9318 701 231   
9542 707 32   
9885 726 39   
9406 767 40   
7865 791 41   
9914 793 38   
9317 820 213   
9401 848 262   
9319 874 575   
9356 887 634   
1224 888 36   
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4.3.3 Identification of a vaccine candidate gene in Ms01 by bioinformatic analysis of whole-
genome GS20 sequencing data 
4.3.3.1 Identification of contigs in the genome of Ms01 
Similarity searches using blastn with individual contigs in the NCBI database, led to the identification of 
two contigs in the Ms01 genome, contig 835 (1645 bp) and contig 9312 (53 326 bp), which contained a 
number of genes encoding membrane proteins involved in membrane transport and/or host attachment.  
Similarity searches in contig 9312 using blastn and tblastx resulted in 1288 and 8095 hits respectively, 
while similar searches in contig 835 yielded 163 and 154 hits, respectively.  Of these, the 5 most 
significant hits are indicated in Table 4.8.  In particular, the well-documented oligopeptide permease 
system, the Opp operon, was further analyzed since the oppA/P100 gene encodes a surface exposed 
substrate-binding protein in M. hominis and is predicted to show strong immunogenic properties when 
recognized by the host’s immune system (Henrich et al., 1993; Garmory and Titball, 2004; Nicolás et al., 
2007).  Alignment of the contigs and their M. hominis Opp operon counterpart revealed that the Ms01 
P100 gene analogue was situated on the 5’ end of contig 9312, and on the 3’ end of contig 835. 
4.3.3.2 ORF analysis using CLC Combined Workbench software 
ORF searches in contig 9312 resulted in a total of 49 ORFs of a minimum length of 100 codons of which 
22 ORFs were in the positive direction, and 27 ORFs in the negative direction.  In contig 835, an 
initiation codon was recognized at base position 545, but no corresponding termination codon could be 
identified; therefore no ORFs of a minimum length of 100 codons were identified.  Since our interest lay 
in the 5’ end of contig 9312, the first five 5’ ORFs identified in contig 9312 are summarized in Table 4.9.  
Downstream of the P100 gene, four ORFs with the highest similarity to genes encoding the core domains 
of the M. hominis oligopeptide permease (Opp) system were found.  The second ORF started 17 bp 
downstream of the P100 gene and encoded a putative protein with homologies to the integral membrane 
domain, OppB, of M. hominis.  The third ORF followed 5 bp downstream of the oppB gene and encoded 
a putative protein with homologies to the integral membrane domain, OppC, of M. hominis.  The fourth 
ORF started directly downstream of the oppC gene, with a single base overlap between the termination 
codon of the oppC gene and the initiation codon of the next ORF encoding a protein with homologies to 
the ATP-binding domain OppD.  The fifth and final ORF showed an overlap of 14 bp at the 3’ end of the 
oppD gene and showed homologies to the ATP-binding domain OppF.  When comparing the length of the 
five ORFs identified at the 5’ end of contig 9312 with those of the ORFs encoding the respective genes of 
the Opp operon in M. hominis, it was found that the lengths were very similar to the oppBCDF genes.  
However, the ORF encoding the P100 gene in Ms01 (1166 bp), was notably shorter than that of M. 
hominis (2885 bp), possibly indicating that the full gene had not been identified and that part of the Ms01 
P100 gene was contained in contig 835. 
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Table 4.8 The five most significant hits obtained from BLAST searches on contig 9312 and 835 in the NCBI 
database; blastn; with a wordsize of 15, and tblastx employing the mold mitochondrial genetic code. 
Query 
sequence 
Search 
type 
Accession number Description Bit 
score 
E-value 
Contig 
9312 
blastn X99740.1 M. hominis P100, oppB, oppC, oppD, oppF genes (oligopeptide 
permease system) 
1833 0 
  CP001047.1 M. arthritidis 158L3-1, complete genome (peptide chain release 
factor 1; protoporphyrinogen oxidase) 
1142 0 
  CU179680.1 
M. agalactiae PG2 chromosome, complete sequence (oligopeptide 
ABC transporter permease protein oppC and ATP-binding protein 
oppD) 
711 0 
  AE017245.1 M. synoviae 53, complete genome (oligopeptide ABC transporter 
ATP-binding protein) 
587 2e-162 
  AE017308.1 M. mobile 163K complete genome (protoporphyrinogen oxidase; 
peptide chain release factor 1) 
580 3e-160 
 tblastx gb|CP001047.1| M. arthritidis 158L3-1, complete genome (peptide chain release 
factor 1; protoporphyrinogen oxidase) 
888 0 
  emb|X99740.1|MHX99740 M. hominis P100, oppB, oppC, oppD, oppF genes (oligopeptide 
permease system) 
719 0 
  emb|CU179680.1| 
M. agalactiae PG2 chromosome, complete genome (oligopeptide 
ABC transporter permease protein oppC and ATP-binding protein 
oppD) 
570 0 
  gb|AE017245.1| M. synoviae 53, complete genome (oligopeptide ABC transporter 
ATP-binding protein) 
519 0 
  gb|AE017243.1| M. hyopneumoniae J, complete genome (putative lipoprotein) 279 0 
Contig 
835 
blastn X99740.1 M. hominis P100, oppB, oppC, oppD, oppF genes (oligopeptide 
permease system) 
62.6 6e-06 
  CP000123.1 M. capricolum subsp. capricolum ATCC 27343, complete genome 
(thioredoxin reductase) 
44.6 0.001 
  CP001047.1 M. arthritidis 158L3-1, complete genome 
(methylenetetrahydrofolate dehydrogenase) 
41.0 0.013 
  AL445563.1 M. pulmonis (strain UAB CTIP) complete genome; segment (ABC 
transporter ATP-binding protein) 
41.0 0.013 
  CU179680.1 M. agalactiae PG2 chromosome, complete sequence (putative 
transmembrane protein)
39.2 0.046 
 tblastx emb|CU179680.1| M. agalactiae PG2 chromosome, complete genome (conserved 
hypothetical protein; predicted lipoprotein) 
99.6 1e-29 
  emb|X99740.1|MHX99740 M. hominis P100, oppB, oppC, oppD, oppF genes (oligopeptide 
permease system) 
77.1 1e-29 
  gb|CP001047.1| M. arthritidis 158L3-1, complete genome (hypothetical 
lipoprotein)
79.9 2e-22 
  gb|AE017244.1| M. hyopneumoniae 7448, complete genome (lipoprotein) 64.3 8e-20 
  gb|AE017243.1| M. hyopneumoniae J, complete genome (putative lipoprotein) 64.3 8e-20 
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Table 4.9 The first five ORF identified 5’ in contig 9312. 
Contig No. Start position End position Length Assigned gene analogue 
9312 8 1726 1719 P100 
 1744 2877 1134 oppB 
 2883 4193 1311 oppC 
 4193 5332 1140 oppD 
 5319 7826 2508 oppF 
 
4.3.3.3 Analysis of contiguous sequences by PCR 
PCR amplification with the primer pair LinkP100F/R generated a 200 bp product, which upon sequencing 
and alignment with contig 835 and contig 9312 revealed firstly that the position of contig 835 was 
immediately upstream of contig 9312, and secondly that the two contigs were separated by two 
nucleotides only.  Contigs 835 and 9312 could therefore be combined in a new contig of 54 971 bp in 
length (Figure 4.4). 
 
Figure 4.4 Schematic illustration of the combined contig following linkage of contig 9312 (53 326 bp) and contig 
835 (1645 bp) by PCR with the primer pair LinkP100F and LinkP100R. 
When ORF searches were repeated on the combined 54 973 bp contig, all the ORF identified in Table 4.9 
remained the same, with the exception of the first ORF encoding the putative P100 gene.  Initial ORF 
analysis on the separate contigs indicated the first ORF to start at base position 8 on contig 9312.  
However, revision of this ORF revealed a new initiation codon at base position 545 in contig 835, 
resulting in an increase in the size of the first ORF assigned to the P100 gene from 1719 bp to 2829 bp, 
corresponding in size with that of the ORF encoding the P100 gene in M. hominis (2885 bp).  No further 
ORFs were identified upstream of the P100 gene and within 72 bp downstream of the oppF gene. 
4.3.3.5 Identification of functional domains by comparative genomics 
Analysis by comparative genomics revealed a putative ribosomal binding site (Shine-Dalgarno sequence) 
and two consensus promoter binding sites, designated the -35 and -10 box, 42 bp, 21 bp and 5 bp 
upstream of the translation initiation codon ATG of the P100 gene in the combined 54 971 bp contig 
respectively (Figure 4.5 (A)).  The length of the genes of the Opp operon of Ms01 and M. hominis were 
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compared (Figure 4.5 (B)), and functionally important conserved motifs of the respective Opp domains 
were identified (Figure 4.5 (C-F)).  At the N-terminal of the translated P100 polypeptide chain, a signal 
peptide II recognition site [(-4)-VAASC-(+1)] with a lipoprotein cysteine attachment site 
(22LVAAACNSKSA32) was identified.  A characteristic oligopeptide-binding domain 
(192YVLKDNLKW200) was also identified on the translated P100 polypeptide chain confirming the 
substrate-binding function of the P100 protein.  Furthermore, the highly conserved ATP-binding Walker 
A motif (752GSGYDGLS759), as well as the less conserved Walker B motif 
(732INQGANGTRNVGWSYD747), was identified on the translated P100 polypeptide chain, lending to the 
substrate-binding domain its unusual ecto-ATPase activity as first described for the OppA domain of M. 
hominis (Figure 4.5 (C)).  A characteristic conserved membrane spanning domain was identified in each 
of the integral pore forming domains, OppB (241IAKTKGLSSTQIFFKYVLR259) and OppC 
(325TAAKAIGASTKRQVFVHALP344) (Figure 4.5 (D)).  In each of the two ATP-binding domains, OppD 
and OppF, the highly conserved Walker A motif (72GESGSGKS78 and 53GESGSGKT60), the less 
conserved Walker B motif (208VIIADEPTTALD219 and 695IIVADEPIASLD706), as well as a highly 
conserved consensus signature sequence known as the C-motif (188LSGGM192 and 675FSGGQ679) were 
identified (Figure 4.5 (E-F)). 
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Figure 4.5 (A) Identification of a putative ribosomal binding site (Shine-Dalgarno sequence) and two consensus 
promoter binding sites (-10 and -35 box) upstream of translation initiation codon ATG of the P100 gene.  (B) Size 
(bp) comparison of the genes within the Ms01 Opp operon and M. hominis Opp operon.  (C) Identification of 
functionally important conserved motifs within the P100/oppA domain of Ms01. 
A.
C.
B.
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Figure 4.5 (continued) (D) Identification of functionally important conserved motifs within the integral membrane 
domains OppB and OppC of Ms01.  (E and F) Identification of functionally important conserved motifs within the 
ATP-binding domains OppD and OppF of Ms01 respectively. 
D.
F.
E.
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4.3.4 Analysis of PCR amplification of the P100 gene 
The P100 gene of Ms01 was successfully isolated from gDNA by PCR using the primer pair P100_ampF 
and P100_ampR yielding a 2841 bp amplification product (2829 bp P100 gene + 2 x 6 bp representing 
restriction enzyme cut sites) (Figure 4.6). 
 
Figure 4.6 Image of the PCR product obtained with the primer pair P100_ampF and P100_ampR electrophoresed 
on a 2% (w/v) agarose gel.  The gel contained ethidium bromide (0.175 μg/ml) for UV visualization of the DNA.  
Lane 1-8: 10 μl PCR product.  Amplifications were performed and analyzed in duplicate and with an annealing 
temperature gradient (50˚C -65˚C).  Lane 9: 5 μl DNA ladder mix (Fermentas).  The bands in lanes 1 to 6 did not 
migrate as expected due to a reduced mobility on this gel (gel smiling). 
A high-quality amplification product was obtained with annealing temperatures at 50˚C and 55˚C.  An 
annealing temperature of 60˚C yielded inadequate amplification product, while no amplification occurred 
at 65˚C.  Subsequently it was decided that an annealing temperature of 55˚C was most suitable for 
amplifications with the primer pair P100_ampF and P100_ampR. 
4.3 5 Cloning of P100 gene into the pGEM®-T Easy plasmid 
The P100 gene of Ms01 was successfully cloned into the pGEM®-T Easy plasmid using the pGEM®-T 
Easy cloning kit (Promega) resulting in ample white colonies.  The presence of insert in white colonies 
was confirmed by use of diagnostic PCR with the primers T7 and SP6 resulting in a 2969 bp 
amplification product (2829 bp P100 gene + 2 x 6 bp representing restriction enzyme cut sites + 128 bp 
plasmid DNA) (Figure 4.7). 
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Figure 4.7 Image of the product obtained after diagnostic PCR with the primer pair T7 and SP6 electrophoresed on 
a 2% (w/v) agarose gel.  The gel contained ethidium bromide (0.175 μg/ml) for UV visualization of the DNA.  Lane 
1-7: 10 μl PCR product using white colonies as template DNA.  Lane 8-9: 10 μl PCR product (positive control).  
Lane 10-11: 10 μl PCR product using blue colonies as template DNA (negative control).  Lane 12: 5 μl DNA ladder 
mix (Fermentas). 
Plasmids containing the P100 gene were successfully isolated from the bacteria, followed by sequencing 
to examine the inserted P100 gene for point mutations (deletions, substitutions, insertions) that may have 
occurred during amplification.  An inspection of the sequences of the P100 gene of 8 clones in which the 
P100 gene had been amplified with the non-proofreading DNA polymerase (Super-Therm), revealed that 
between 1 and 5 errors occurred per clone during amplification (0% error-free clones).  Consequently, a 
proofreading DNA polymerase was used for amplification prior to cloning, where 8 clones containing the 
P100 gene revealed that although errors did still occur in some clones, at least one point mutation-free 
clone could be identified (minimum of 12.5% error-free clones). A plasmid containing the error-free 
P100 gene insert was selected for subsequent modification by site-directed mutagenesis of the P100 gene. 
4.3.6. Analysis of the P100 gene after modification by site-directed mutagenesis 
The progress of the PCR-based SDM and subsequent DpnI treatments was monitored by agarose gel 
electrophoresis.  A typical result, in this instance the SDM of sites 5 and 9, is illustrated in Figure 4.8.  
Isolated recombinant plasmid, pGEM®-T Easy-P100 gene construct was used as a supercoiled pre-SDM-
PCR reference in lane 1.  The SDM-PCR with one SDM primer pair produced a full plasmid copy (in 
which site 5 was corrected) which was unmethylated and not supercoiled, and therefore showed a lower 
mobility (lanes 2 and 3). In this instance, the supercoiled plasmid template is not visible in lanes 2 and 3 
due to its low concentration.  The SDM-PCR with two SDM primer pairs produced a full plasmid copy 
(in which sites 5 and 9 were corrected) and also a large and a small truncated PCR product (the product of 
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primers SDM P5R and SDM P9F, and primers SDM P5F and SDM P9R, respectively). The large and 
the small truncated PCR products are linear, blunt-ended and therefore not functional plasmids. The full 
plasmid copy is unmethylated and not supercoiled, and therefore showed a lower mobility (the faint bands 
in lanes 4 and 5 of an approximate size of 6000 bp).  By contrast, the methylated template was 
supercoiled (which is not visible in lanes 4 and 5 due to its low concentration).  The methylated 
supercoiled plasmid template was removed prior to transformation by DpnI treatment as the methylated 
plasmid template would be preferentially transformed over unmethylated SDM-PCR product. The SDM 
products after DpnI treatment are shown in lanes 6 to 9 respectively. The intensities of the bands are 
reduced due to the 5 fold dilution brought about by the DpnI treatment. 
 
Figure 4.8 An image of a 1% (w/v) agarose gel showing the analysis of product following every step during site-
directed mutagenesis of P100 gene.  Reactions were preformed in duplicate.  Lane 1: 2 μl of a 100 ng/μl solution of 
plasmid containing P100 gene insert (supercoiled) (pre-SDM PCR), lane 2-3:  10 μl post-SDM PCR product with 
primer pair SDM P5F/R, lane 4-5:  10 μl post-SDM PCR product with primer pairs SDM P5F/R (position 1722; Tm 
= 68.2˚C) and SDM P9F/R (position 2622; Tm = 64.3˚C), lane 6-7:  18 μl of SDM PCR product (SDM P5F/R) 
post-DpnI-treatment, lane 8-9:  18 μl of SDM PCR product (SDM P5F/R and SDM P9F/R) post-DpnI-treatment, 
lane 10:  5 μl DNA ladder mix. 
By employing SDM, the ten mycoplasmal codons for tryptophan (TGA) were modified to the universal 
codon for tryptophan (TGG), and the modifications confirmed by sequencing and subsequent alignment 
in BioEdit (Addendum C). 
4.4 Discussion 
The isolation of gDNA from Ms01 cultures by means of the four different extraction methods yielded 
DNA with different degrees of purity.  The phenol:chloroform extraction method yielded gDNA with the 
highest concentration and quality.  However, in view of the fact that phenol contamination in the gDNA 
preparations may be problematic in GS20 sequencing, it was decided to use the gDNA isolated by means 
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of the Hempstead method for subsequent whole-genome GS20 sequencing, since it yielded gDNA of 
similar concentration and quality. 
The entire genome of Ms01 was sequenced successfully with 99.7% accuracy using GS20 sequencing 
technology.  The estimated 700 kbp genome size of Ms01 with a G+C content of 27 mol% is in 
agreement with the small size of mycoplasmal genomes ranging in size from 580 kbp (M. genitalium) to 
1360 kbp (M. penetrans) and their characteristically low G+C content (23-41 mol%) (Nicolás et al., 
2007).  It can be deduced that assembly of the contigs was largely successful as a high proportion of the 
contigs were of a size larger than 1000 bp.  However, the undesirably large number of contigs generated 
may be attributed to the abundance of A and T-runs contained in the Ms01 genome, as the assembler has 
difficulty in finding overlaps in the presence of poly-base runs exceeding a length of 8 bases, as well as 
when dealing with highly repetitive genomes (Leamon et al., 2007). 
During the search for a vaccine candidate gene in the Ms01 genome data, no gene analogue encoding 
membrane proteins such as P1 in M. pneumoniae, MgPa in M. genitalium, or GapA in M. gallisepticum, 
could be identified. However, an analogue of the gene encoding the membrane protein P100 was 
identified.  The P100 gene forms part of the Opp operon encoding the well-documented oligopeptide 
permease (Opp) system.  The identified P100 gene analogue of Ms01 was found to be contained partly on 
contig 835 (1645 bp) and contig 9312 (53 326 bp) respectively, and showed the highest sequence 
similarity to that of M. hominis.  The Opp system of M. hominis contains a multifunctional P100 protein, 
which not only represents the substrate-binding OppA domain of the system, but is also involved in 
mycoplasma attachment to host cells (Henrich et al., 1993, 1999; Hopfe and Henrich, 2004), therefore 
making the P100 gene of Ms01 a prime candidate for the development of a DNA vaccine. 
Open reading frame searches on the two contigs, revealed that contig 9312 contained the major part of the 
P100 gene on its 5’ end, and that the rest of the gene was contained on the 3’ end of 835.  Consequently, a 
PCR strategy was followed to link these two contigs, followed by revision of identified open reading 
frames, which ultimately resulted in the identification of the entire P100 gene, as well as the rest of the 
opp genes (oppB, oppC, oppD and oppF) of Ms01.  Comparative genomics of the area upstream of the 
ATG translation initiation codon of the P100 gene, led to the identification of the -10 and -35 consensus 
promoter binding sites, as well as a Shine-Dalgarno-like sequence, further confirming the assigned ORF 
of the P100 protein.  Comparison of the Opp operon of M. hominis and the Opp operon of Ms01, revealed 
a clear correlation in gene length between the two species.  The overlapping nature of the opp genes in the 
Ms01 Opp operon is a common feature of many prokaryotes, bacteriophages, animal virus and 
mitochondrial genomes (Fukuda et al., 1999).  Although overlapping genes were initially thought to have 
emerged due to evolutionary pressure to minimize genome size, comparative genomics of the two 
mycoplasmas M. pneumoniae and M. genitalium reveal that overlapping genes, in many cases, arise due 
to the loss of a stop codon in either gene, resulting in elongation of the 3’ of the genes’ coding region.  
Furthermore, the overlapping genes of the Ms01 Opp operon were found to be uni-directional, which is in 
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agreement with the majority of overlapping genes identified in the M. pneumoniae and M. genitalium 
genomes (Fukuda et al., 1999). 
Alignment of crucial conserved amino acid motifs of the M. hominis Opp operon and that of the Ms01 
Opp operon, revealed characteristic motifs related to the function of the individual opp genes, but also 
characteristic of ABC-transporters.  The OppB and OppC domains contain motifs characteristic of 
integral membrane-spanning domains, while the OppD and OppF domains possess the typical highly 
conserved ATP-binding Walker A and Walker B motifs, as well as the highly conserved C-motif/linker 
peptide specific to the ABC superfamily.  Together these motifs form the structure for ATP binding, 
lending to the ATPase domain the ability to bind and hydrolyse ATP to provide the energy for the 
transport of oligopeptides into the cell.  The N-terminus of the P100 polypeptide chain contains a highly 
hydrophobic signal peptide II leader sequence which directs the translocation of the P100 protein from the 
cytoplasma to the plasma membrane.  Within this sequence, a crucial cysteine residue was found, of 
which the SH-group is reportedly used to covalently link the P100 protein to an outermembrane 
lipoprotein, thereby ensuring that the P100 protein remains attached to the membrane of the mycoplasma 
after translocation (Henrich et al., 1999).  Furthermore, the P100 polypeptide chain contains a 
characteristic oligopeptide-binding domain which putatively binds oligopeptide substrates on the outside 
of the mycoplasma cell, and delivers them to the OppBC pore-forming complex of the permease system.  
An interesting finding is that the P100 polypeptide chain also possesses the highly conserved Walker A 
and Walker B motifs normally only found in the ATP-binding domains OppD and OppF.  This was first 
described for the substrate-binding domain, OppA of M. hominis, where several functions for this ecto-
ATPase activity of the substrate-binding domain were postulated; (i) protection from the cytolytic effect 
of extracellular ATP released by the colonized host cells, (ii) regulation of ecto-kinase substrate 
concentration, (iii) involvement in signal transduction, as well as (iv) possible involvement in cellular 
adhesion (Hopfe and Henrich, 2004).  To our knowledge, this is only the second time that a mycoplasma 
substrate-binding domain has been identified to possess the highly conserved Walker A and Walker B 
motifs, shown to lend ecto-ATPase activity to the P100 of M. hominis. 
The P100 gene of Ms01 was isolated from gDNA by PCR, exploring the use of proofreading and non-
proofreading DNA polymerases.  After successful cloning and sequencing of the P100 gene in the 
pGEM®-T Easy plasmid, it was found that an abundance of point mutations was generated during 
amplification with non-proofreading enzyme.  This indicated that the use of a proofreading DNA 
polymerase was a necessity during the isolation of the P100 gene, as it resulted in notably less point 
mutations. 
As the isolated and cloned P100 gene of Ms01 is to be used in a DNA vaccine, the ten mycoplasma 
tryptophan codons (TGA), encoding stop codons in the universal genetic code, were modified 
successfully by means of SDM to universal tryptophan codons (TGG) for expression in eukaryotes.  The 
modified P100 gene may now be cloned into a suitable eukaryotic expression vector such as pCI-neo, 
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after which vaccine trials in ostriches may be conducted to assess the efficacy of this gene in the 
successful application of a the DNA vaccine in combating mycoplasmas in ostriches.  In addition, 
assembly of all the contigs and subsequent annotation of the entire genome of Ms01, will facilitate future 
identification of further vaccine candidate genes. 
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Chapter 5 – Conclusions and future perspectives  
Three ostrich-specific mycoplasmas, Ms01, Ms02 and Ms03, have been implicated in upper respiratory 
infection in feedlot ostriches.  These infections place a considerable strain on production in the South 
African ostrich industry. Since there is currently no registered mycoplasma vaccine available for use in 
ostriches, the use of existing poultry mycoplasma vaccines to prevent mycoplasma infections in ostriches 
were suggested.  From the results of the vaccine trials with MS and MG vaccines in ostriches conducted 
in this study, it is concluded that these poultry mycoplasma vaccines do not provide protection against 
ostrich-specific mycoplasma infecting ostriches in South Africa.  Therefore, the approach of using poultry 
mycoplasma vaccines to prevent mycoplasma infections in ostriches is ineffective due to the lack of 
immunological cross-reactivity.  This therefore emphasizes the importance of the development of a 
species specific vaccine against each of the ostrich-specific mycoplasmas Ms01, Ms02 and Ms03. 
However, conventional approaches to vaccine development against mycoplasmas are hindered by the 
weak cultivation properties of these ostrich mycoplasmas.  Accordingly the DNA vaccine route was 
chosen for the development of a vaccine against the ostrich-specific mycoplasma Ms01.  In order to 
identify a vaccine candidate gene in Ms01, the entire genome of Ms01 was sequenced using the 454 
Sequencing System based on GS20 sequencing technology.  The resulting whole-genome sequencing data 
was subjected to bioinformatic analysis which resulted in the identification of the P100 gene of Ms01.  
This gene was chosen as vaccine candidate as it was found to be an analogue of the M. hominis gene 
encoding the multifunctional substrate-binding and cytadherence associated P100 protein.  After the 
successful isolation and site-directed mutational modification of the P100 gene of Ms01, the modified 
gene may be inserted into an appropriate DNA vaccine vector such as pCI-neo for subsequent use as a 
DNA vaccine in ostriches. 
Vaccination trials with the resulting DNA vaccine, followed by field challenge with ostrich-specific 
mycoplasmas, will have to be conducted in future to assess the efficacy of this approach.  To this end, an 
immunodiagnostic test, such as an ELISA, will have to be developed for assessment of immune responses 
elicited towards the Ms01-specific DNA vaccine in ostriches.  Such assays will be carried out with ELISA 
plates coated with whole Ms01 organism or P100 protein.  The P100 gene cloned in this study can be sub-
cloned into a suitable prokaryotic expression vector for this purpose.  Furthermore, the same labeled 
secondary antibody detection system used in this study, i.e. biotinylated rabbit anti-ostrich Ig antibodies, 
can also be used.  If the DNA vaccine is found to provide protection in ostriches against Ms01, a similar 
approach may also be employed for the development of DNA vaccines against the other ostrich-specific 
mycoplasmas Ms02 and Ms03.  The whole-genome sequence data of Ms01 and the approaches developed 
in this study may also be applied in searches for other potential vaccine candidate genes for the 
development of a DNA vaccine against Ms01 in future.  Thus, this study serves as a good platform for the 
future development of vaccines against the ostrich-specific mycoplasmas Ms02 and Ms03. 
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Addendum A Statistical analysis of the ELISA results using SAS 
Kwessie (MS) 
Vaccine trials with poultry mycoplasma vaccines in ostriches on the Kwessie farmstead:  Statistical 
analysis of ELISA data, obtained with MS Antibody Test kits, using the Statistical Analysis System 
(SAS, Cary, NC) program (version 6.2). 
Statistical analysis: 
The General Linear Models (GLM) Procedure 
Class Level Information 
Class Levels Values 
Trt 3 1 2 3 
 
Time 9 0 6 14 21 38 52 62 83 111 
 
 
Number of Observations Read 1268 
Number of Observations Used 1111 
 
Dependent Variable: resp 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 26 36.81960471 1.41613864 65.57 <.0001 
Error 1084 23.41261956 0.02159836   
Corrected Total 1110 60.23222427    
 
R-Squared Coeff Var Root MSE Resp Mean 
0.611294 144.5848 0.146964 0.101645 
 
Source DF Type I SS Mean Square F Value Pr > F 
Trt 2 10.21842232 5.10921116 236.56 <.0001 
Time 8 9.56305445 1.19538181 55.35 <.0001 
Trt*Time 16 17.03812794 1.06488300 49.30 <.0001 
 
The input data follows.  On each page the data is arranged in three columns, each containing the ostrich 
identification number, treatment (Trt), time and response (Resp), read from top to bottom and left to right. 
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Ostrich Trt Time Resp 
360701 2 0 0.006 
360702 2 0 0.026 
360703 2 0 0.002 
360704 2 0 0.008 
360705 2 0 0.009 
360706 2 0 0.006 
360707 2 0 0.006 
360708 2 0 0.008 
360709 2 0 0.037 
360710 2 0 0.026 
360711 2 0 0.044 
360712 2 0 0.024 
360713 2 0 0.032 
360714 2 0 0.038 
360715 2 0 0.019 
360716 2 0 0.043 
360717 2 0 0.024 
360718 2 0 0.028 
360719 2 0 0.038 
360720 2 0 0.022 
360721 2 0 0.027 
360722 2 0 0.043 
360723 2 0 0.033 
360724 2 0 0.021 
360725 2 0 0.02 
360726 2 0 0.029 
360727 2 0 0.033 
360728 2 0 0.034 
360729 2 0 0.019 
360730 2 0 0.034 
360731 2 0 0.02 
360732 2 0 0.01 
360733 2 0 0.012 
360734 2 0 0.03 
360735 2 0 0.06 
360736 2 0 0.034 
360737 2 0 0.013 
360738 2 0 0.031 
360739 2 0 0.017 
360740 2 0 0.022 
360741 2 0 0.02 
360742 2 0 0.032 
360743 2 0 0.044 
360744 2 0 0.03 
360745 2 0 0.071 
360746 2 0 0.034 
360747 2 0 0.038 
360748 2 0 0.022 
360749 2 0 0.042 
360750 2 0 0.026 
360751 3 0 0.014 
360752 3 0 0.01 
360753 3 0 0.016 
360754 3 0 0.029 
360755 3 0 0.003 
360756 3 0 0 
360757 3 0 0 
360758 3 0 0 
360759 3 0 0 
360760 3 0 0.007 
360761 3 0 0 
360762 3 0 0 
360763 3 0 0 
360764 3 0 0 
360765 3 0 0.008 
360766 3 0 0.011 
360767 3 0 0.021 
360768 3 0 0.039 
360769 3 0 0.022 
360770 3 0 0.012 
360771 3 0 0.009 
360772 3 0 0.026 
360773 3 0 0.006 
360774 3 0 0.052 
360775 3 0 0.019 
360776 3 0 0.033 
360777 3 0 0.027 
360778 3 0 0.021 
360779 3 0 0.027 
360780 3 0 0.027 
360781 3 0 0.021 
360782 3 0 0.025 
360783 3 0 0.032 
360784 3 0 0.014 
360785 3 0 0.022 
360786 3 0 0.023 
360787 3 0 0.032 
360788 3 0 0.024 
360789 3 0 0.021 
360790 3 0 0.019 
360791 3 0 0.017 
360792 3 0 0.016 
360793 3 0 0.011 
360794 3 0 0.02 
360795 3 0 0.037 
360796 3 0 0.017 
360797 3 0 0.029 
360798 3 0 0.042 
360799 3 0 0.012 
360800 3 0 0.023 
360801 1 0 0.057 
360802 1 0 0.026 
360803 1 0 0.059 
360804 1 0 0.013 
360805 1 0 0.034 
360806 1 0 0.049 
360807 1 0 0.012 
360808 1 0 0.015 
360809 1 0 0.017 
360810 1 0 0.043 
360811 1 0 0.038 
360812 1 0 0.034 
360813 1 0 0.005 
360814 1 0 0.025 
360815 1 0 0.0320 
360816 1 0 0.02 
360817 1 0 0.026 
360818 1 0 0.039 
360819 1 0 0.036 
360820 1 0 0.037 
360821 1 0 0.042 
360822 1 0 0.029 
360823 1 0 0.053 
360824 1 0 0.048 
360825 1 0 0.032 
360826 1 0 0.044 7 37
360828 1 0 0.035 
360829 1 0 0.044 
360830 1 0 0.042 
360831 1 0 0.047 
360832 1 0 0.058 
360833 1 0 0.018 
360834 1 0 0.037 
360835 1 0 0.016 
360836 1 0 0.03 
360837 1 0 0.018 
360838 1 0 0.031 
360839 1 0 0.062 
360840 1 0 0.015 
360841 1 0 0.02 
360701 2 6 0.023 
360702 2 6 0.018 
360703 2 6 0.029 
360704 2 6 0.023 
360705 2 6 0.032 
360706 2 6 0.017 
360707 2 6 0.019 
360708 2 6 0.023 
360709 2 6 0.019 
360710 2 6 0.025 
360711 2 6 0.026 
360712 2 6 0.014 
360713 2 6 0.024 
360714 2 6 0.002 
360715 2 6 0.005 
360716 2 6 0.021 
360717 2 6 0.016 
360718 2 6 0.023 
360719 2 6 0.022 
360720 2 6 0.041 
360721 2 6 0.04 
360722 2 6 0.02 
360723 2 6 0.015 
360724 2 6 0.028 
360725 2 6 0.009 
360726 2 6 0.026 
360727 2 6 0.011 
360728 2 6 0.015 
360729 2 6 0.014 
360730 2 6 0.023 
360731 2 6 0.047 
360732 2 6 0.056 
360733 2 6 0.027 
360734 2 6 0.025 
360735 2 6 0.019 
360736 2 6 0.032 
360737 2 6 0.018 
360738 2 6 0.012 
360739 2 6 0.011 
360740 2 6 0.027 
360741 2 6 0.031 
360742 2 6 0.027 
360743 2 6 0.019 
360744 2 6 0.02 
360745 2 6 0.047 
360746 2 6 0.026 
360747 2 6 0.013 
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360748 2 6 0.03 
360749 2 6 0.036 
360750 2 6 0.013 
360751 3 6 0.041 
360752 3 6 0.023 
360753 3 6 0.02 
360754 3 6 0.029 
360755 3 6 0.031 
360756 3 6 0.017 
360757 3 6 0.015 
360758 3 6 0.014 
360759 3 6 0.003 
360760 3 6 0 
360761 3 6 0.008 
360762 3 6 0.01 
360763 3 6 0.008 
360764 3 6 0.012 
360765 3 6 0.011 
360766 3 6 0.013 
360767 3 6 0.005 
360768 3 6 0.028 
360769 3 6 0.005 
360770 3 6 0.036 
360771 3 6 0.025 
360772 3 6 0.021 
360773 3 6 0.006 
360774 3 6 0.074 
360775 3 6 0.039 
360776 3 6 0.011 
360777 3 6 0.028 
360778 3 6 0.018 
360779 3 6 0.035 
360780 3 6 0.032 
360781 3 6 0.027 
360782 3 6 0.017 
360783 3 6 0.031 
360784 3 6 0.017 
360785 3 6 0.032 
360786 3 6 0.023 
360787 3 6 0.016 
360788 3 6 0.03 
360789 3 6 0.014 
360790 3 6 0.02 
360791 3 6 0.032 
360792 3 6 0.005 
360793 3 6 0.017 
360794 3 6 0.025 
360795 3 6 0.005 
360796 3 6 0.01 
360797 3 6 0.009 
360798 3 6 0.031 
360799 3 6 0.009 
360800 3 6 0.017 
360801 1 6 0.03 
360802 1 6 0.022 
360803 1 6 0.025 
360804 1 6 0.013 
360805 1 6 0.01 
360806 1 6 0.025 
360807 1 6 0.011 
360808 1 6 0.017 
360809 1 6 0.019 
360810 1 6 0.015 
360811 1 6 0.025 
360812 1 6 0.057 
360813 1 6 0.046 
360814 1 6 0.031 
360815 1 6 0.034 
360816 1 6 0.012 
360817 1 6 0.01 
360818 1 6 0.022 
360819 1 6 0.029 
360820 1 6 0.019 
360821 1 6 0.024 
360822 1 6 0.027 
360823 1 6 0.033 
360824 1 6 0.025 
360825 1 6 0.004 
360826 1 6 0.016 
360827 1 6 0.007 
360828 1 6 0.012 
360829 1 6 0.01 
360830 1 6 . 
360831 1 6 0.008 
360832 1 6 . 
360833 1 6 0.003 
360834 1 6 0.005 
360835 1 6 0.023 
360836 1 6 0.043 
360837 1 6 0.011 
360838 1 6 0.02 
360839 1 6 0.025 
360840 1 6 0.014 
360841 1 6 0.02 
360701 2 14 0.006 
360702 2 14 0.009 
360703 2 14 0.067 
360704 2 14 0.006 
360705 2 14 0.055 
360706 2 14 0.062 
360707 2 14 0.015 
360708 2 14 0.01 
360709 2 14 0.061 
360710 2 14 0.023 
360711 2 14 0.032 
360712 2 14 0.013 
360713 2 14 0.047 
360714 2 14 0.013 
360715 2 14 0.031 
360716 2 14 0.021 
360717 2 14 0.04 
360718 2 14 0.309 
360719 2 14 0.006 
360720 2 14 0.026 
360721 2 14 0.005 
360722 2 14 0.049 
360723 2 14 0.014 
360724 2 14 0.002 
360725 2 14 0.058 
360726 2 14 0.006 
360727 2 14 0.004 
360728 2 14 0.015 
360729 2 14 0.003 
360730 2 14 0.025 
360731 2 14 0.008 
360732 2 14 0.093 
360733 2 14 0.07 4 0.004 
360735 2 14 0.005 
360736 2 14 0.024 
360737 2 14 0 
360738 2 14 0 
360739 2 14 0.007 
360740 2 14 0.015 
360741 2 14 0.008 
360742 2 14 0.271 
360743 2 14 0.025 
360744 2 14 0.013 
360745 2 14 0.092 
360746 2 14 0.016 
360747 2 14 0 
360748 2 14 0.006 
360749 2 14 0 
360750 2 14 0.064 
360751 3 14 0.009 
360752 3 14 0 
360753 3 14 0.002 
360754 3 14 0.003 
360755 3 14 0.019 
360756 3 14 0.024 
360757 3 14 0.024 
360758 3 14 0.007 
360759 3 14 0.021 
360760 3 14 0.019 
360761 3 14 0.005 
360762 3 14 0.029 
360763 3 14 0.013 
360764 3 14 0.016 
360765 3 14 0 
360766 3 14 0.299 
360767 3 14 0.018 
360768 3 14 0.025 
360769 3 14 0.26 
360770 3 14 0.053 
360771 3 14 0.032 
360772 3 14 0.024 
360773 3 14 0.056 
360774 3 14 0.04 
360775 3 14 0.034 
360776 3 14 0.039 
360777 3 14 0.141 
360778 3 14 0.078 
360779 3 14 0.028 
360780 3 14 0.037 
360781 3 14 0.056 
360782 3 14 0.096 
360783 3 14 0.048 
360784 3 14 0.035 
360785 3 14 0.027 
360786 3 14 0.019 
360787 3 14 0.028 
360788 3 14 0.037 
360789 3 14 0.036 
360790 3 14 0.037 
360791 3 14 0.03 
360792 3 14 0.041 
360793 3 14 0.034 
360794 3 14 0.039 
360795 3 14 0.036 
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360796 3 14 0.031 
360797 3 14 0.036 
360798 3 14 0.036 
360799 3 14 0.057 
360800 3 14 0.058 
360801 1 14 0.05 
360802 1 14 0 
360803 1 14 0.034 
360804 1 14 0 
360805 1 14 0 
360806 1 14 0 
360807 1 14 0 
360808 1 14 0 
360809 1 14 0 
360810 1 14 0 
360811 1 14 0 
360812 1 14 0.057 
360813 1 14 0.011 
360814 1 14 0.058 
360815 1 14 0.027 
360816 1 14 0.002 
360817 1 14 0.005 
360818 1 14 0.017 
360819 1 14 0.033 
360820 1 14 0.013 
360821 1 14 0.01 
360822 1 14 0.018 
360823 1 14 0.012 
360824 1 14 0.022 
360825 1 14 0.032 
360826 1 14 0.025 
360827 1 14 0.009 
360828 1 14 0.016 
360829 1 14 0.005 
360830 1 14 0.006 
360831 1 14 0.003 
360832 1 14 0.007 
360833 1 14 0.009 
360834 1 14 0.009 
360835 1 14 0.005 
360836 1 14 0.007 
360837 1 14 0.011 
360838 1 14 0.017 
360839 1 14 0.01 
360840 1 14 0.006 
360841 1 14 0.013 
360701 2 21 0.049 
360702 2 21 0.131 
360703 2 21 0.129 
360704 2 21 0.023 
360705 2 21 0.167 
360706 2 21 0.062 
360707 2 21 0.162 
360708 2 21 0.013 
360709 2 21 0.12 
360710 2 21 0.176 
360711 2 21 0.086 
360712 2 21 0.162 
360713 2 21 0.072 
360714 2 21 0.03 
360715 2 21 0.074 
360716 2 21 0.018 
360717 2 21 0.288 
360718 2 21 0.351 
360719 2 21 0.097 
360720 2 21 0.044 
360721 2 21 0.18 
360722 2 21 0.14 
360723 2 21 0.175 
360724 2 21 0.096 
360725 2 21 0.073 
360726 2 21 0.095 
360727 2 21 0.041 
360728 2 21 0.05 
360729 2 21 0.104 
360730 2 21 0.041 
360731 2 21 0.005 
360732 2 21 1.116 
360733 2 21 0.026 
360734 2 21 0.004 
360735 2 21 0 
360736 2 21 0.016 
360737 2 21 0 
360738 2 21 0.253 
360739 2 21 0.523 
360740 2 21 0.165 
360741 2 21 0.111 
360742 2 21 0.608 
360743 2 21 0.006 
360744 2 21 0.014 
360745 2 21 0.015 
360746 2 21 0.092 
360747 2 21 0.189 
360748 2 21 0.009 
360749 2 21 0.019 
360750 2 21 0.034 
360751 3 21 0.052 
360752 3 21 0.047 
360753 3 21 0.059 
360754 3 21 0.036 
360755 3 21 0.018 
360756 3 21 0.061 
360757 3 21 0.008 
360758 3 21 0.05 
360759 3 21 0.018 
360760 3 21 0.033 
360761 3 21 0.061 
360762 3 21 0.064 
360763 3 21 0.027 
360764 3 21 0.025 
360765 3 21 0.04 
360766 3 21 0.185 
360767 3 21 0.05 
360768 3 21 0.019 
360769 3 21 0.552 
360770 3 21 0.017 
360771 3 21 0.041 
360772 3 21 0.012 
360773 3 21 0.022 
360774 3 21 0.036 
360775 3 21 0.026 
360776 3 21 0.055 
360777 3 21 0.1 
360778 3 21 0.017 
360779 3 21 0.004 
360780 3 21 0.216 
360781 3 21 0.036 2 5
360783 3 21 0.024 
360784 3 21 0.016 
360785 3 21 0.173 
360786 3 21 0.004 
360787 3 21 0.009 
360788 3 21 0.025 
360789 3 21 0.004 
360790 3 21 0.035 
360791 3 21 0.038 
360792 3 21 0.047 
360793 3 21 0.029 
360794 3 21 0.048 
360795 3 21 0.019 
360796 3 21 0.02 
360797 3 21 0.017 
360798 3 21 0.018 
360799 3 21 0.025 
360800 3 21 0.046 
360801 1 21 0.112 
360802 1 21 0.059 
360803 1 21 0.062 
360804 1 21 0.039 
360805 1 21 0.048 
360806 1 21 0.056 
360807 1 21 0.096 
360808 1 21 0.042 
360809 1 21 0.065 
360810 1 21 0.071 
360811 1 21 0.117 
360812 1 21 0.047 
360813 1 21 0.021 
360814 1 21 0.008 
360815 1 21 0.018 
360816 1 21 0.01 
360817 1 21 0.012 
360818 1 21 0.011 
360819 1 21 0.014 
360820 1 21 0.01 
360821 1 21 0.012 
360822 1 21 0.02 
360823 1 21 0.028 
360824 1 21 0.016 
360825 1 21 0.034 
360826 1 21 0.017 
360827 1 21 0.019 
360828 1 21 0.016 
360829 1 21 0.024 
360830 1 21 0.028 
360831 1 21 0.01 
360832 1 21 0.025 
360833 1 21 0.028 
360834 1 21 0.024 
360835 1 21 0.008 
360836 1 21 0.024 
360837 1 21 0.02 
360838 1 21 0.013 
360839 1 21 0.019 
360840 1 21 0.015 
360841 1 21 0.012 
360701 2 38 0.037 
360702 2 38 0.145 
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360703 2 38 0.036 
360704 2 38 0.123 
360705 2 38 0.053 
360706 2 38 0.065 
360707 2 38 0.01 
360708 2 38 0.297 
360709 2 38 0.021 
360710 2 38 0.131 
360711 2 38 0.106 
360712 2 38 0.001 
360713 2 38 0.006 
360714 2 38 0.011 
360715 2 38 0 
360716 2 38 0 
360717 2 38 0.328 
360718 2 38 0.266 
360719 2 38 0.052 
360720 2 38 0.156 
360721 2 38 0.134 
360722 2 38 0.101 
360723 2 38 0.087 
360724 2 38 0.066 
360725 2 38 0.062 
360726 2 38 0.21 
360727 2 38 0.083 
360728 2 38 0.121 
360729 2 38 0.068 
360730 2 38 0.116 
360731 2 38 0.027 
360732 2 38 0.495 
360733 2 38 0.045 
360734 2 38 0.031 
360735 2 38 0.004 
360736 2 38 0.147 
360737 2 38 0.012 
360738 2 38 0.036 
360739 2 38 0.053 
360740 2 38 0.015 
360741 2 38 0.017 
360742 2 38 0.072 
360743 2 38 0.11 
360744 2 38 0.047 
360745 2 38 0.004 
360746 2 38 0.004 
360747 2 38 0.073 
360748 2 38 0.005 
360749 2 38 0.003 
360750 2 38 0.015 
360751 3 38 0.045 
360752 3 38 0.016 
360753 3 38 0.024 
360754 3 38 0.029 
360755 3 38 0.068 
360756 3 38 0.038 
360757 3 38 0.017 
360758 3 38 0.041 
360759 3 38 0.013 
360760 3 38 0.011 
360761 3 38 0.02 
360762 3 38 0.038 
360763 3 38 0.004 
360764 3 38 0.02 
360765 3 38 0.023 
360766 3 38 0.001 
360767 3 38 0.007 
360768 3 38 0.007 
360769 3 38 0.01 
360770 3 38 0.006 
360771 3 38 0 
360772 3 38 0 
360773 3 38 0.004 
360774 3 38 0.047 
360775 3 38 0.018 
360776 3 38 0.028 
360777 3 38 0.026 
360778 3 38 0.055 
360779 3 38 0.035 
360780 3 38 0.027 
360781 3 38 0.014 
360782 3 38 0.016 
360783 3 38 0.036 
360784 3 38 0.055 
360785 3 38 0.112 
360786 3 38 0.02 
360787 3 38 0.034 
360788 3 38 0.017 
360789 3 38 0.007 
360790 3 38 0.011 
360791 3 38 0.006 
360792 3 38 0.002 
360793 3 38 0.012 
360794 3 38 0.004 
360795 3 38 0.014 
360796 3 38 0.022 
360797 3 38 0.024 
360798 3 38 0.021 
360799 3 38 0.008 
360800 3 38 0.213 
360801 1 38 0.036 
360802 1 38 0.016 
360803 1 38 0.039 
360804 1 38 0.033 
360805 1 38 0.027 
360806 1 38 0.033 
360807 1 38 0.027 
360808 1 38 0.012 
360809 1 38 0.024 
360810 1 38 0.032 
360811 1 38 0.024 
360812 1 38 0.015 
360813 1 38 0.01 
360814 1 38 0.017 
360815 1 38 0.007 
360816 1 38 0.006 
360817 1 38 0.024 
360818 1 38 0.009 
360819 1 38 0.008 
360820 1 38 0.004 
360821 1 38 0.005 
360822 1 38 0.029 
360823 1 38 0.031 
360824 1 38 0.024 
360825 1 38 0.031 
360826 1 38 0.017 
360827 1 38 0.031 
360828 1 38 0.008 
360829 1 38 0.03 30 2
360831 1 38 0.012 
360832 1 38 0.031 
360833 1 38 0.053 
360834 1 38 0.016 
360835 1 38 0.073 
360836 1 38 0.017 
360837 1 38 0.001 
360838 1 38 0.015 
360839 1 38 0 
360840 1 38 0.002 
360841 1 38 0.005 
360701 2 52 0.455 
360702 2 52 0.93 
360703 2 52 0.315 
360704 2 52 0.777 
360705 2 52 0.965 
360706 2 52 1.222 
360707 2 52 0.385 
360708 2 52 0.649 
360709 2 52 . 
360710 2 52 . 
360711 2 52 . 
360712 2 52 1.191 
360713 2 52 0.418 
360714 2 52 0.504 
360715 2 52 0.17 
360716 2 52 . 
360717 2 52 0.681 
360718 2 52 1.153 
360719 2 52 . 
360720 2 52 0.339 
360721 2 52 0.487 
360722 2 52 0.558 
360723 2 52 1.111 
360724 2 52 . 
360725 2 52 0.273 
360726 2 52 0.377 
360727 2 52 . 
360728 2 52 0.518 
360729 2 52 0.79 
360730 2 52 0.989 
360731 2 52 0.165 
360732 2 52 1.089 
360733 2 52 . 
360734 2 52 0.721 
360735 2 52 . 
360736 2 52 1.387 
360737 2 52 1.037 
360738 2 52 1.126 
360739 2 52 . 
360740 2 52 0.179 
360741 2 52 0.321 
360742 2 52 1.171 
360743 2 52 1.381 
360744 2 52 0.426 
360745 2 52 0.195 
360746 2 52 2.056 
360747 2 52 . 
360748 2 52 . 
360749 2 52 . 
360750 2 52 0.516 
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360751 3 52 0.036 
360752 3 52 0.02 
360753 3 52 0.078 
360754 3 52 0.049 
360755 3 52 0.209 
360756 3 52 0.031 
360757 3 52 . 
360758 3 52 0.033 
360759 3 52 0.009 
360760 3 52 0.025 
360761 3 52 . 
360762 3 52 0.028 
360763 3 52 . 
360764 3 52 0.042 
360765 3 52 0.09 
360766 3 52 0.013 
360767 3 52 . 
360768 3 52 0.072 
360769 3 52 0.062 
360770 3 52 0.007 
360771 3 52 0.006 
360772 3 52 0.012 
360773 3 52 0.028 
360774 3 52 . 
360775 3 52 0.028 
360776 3 52 0.01 
360777 3 52 0.013 
360778 3 52 0.038 
360779 3 52 0.019 
360780 3 52 . 
360781 3 52 0.004 
360782 3 52 0.001 
360783 3 52 . 
360784 3 52 0.012 
360785 3 52 0.005 
360786 3 52 0 
360787 3 52 . 
360788 3 52 0.001 
360789 3 52 . 
360790 3 52 . 
360791 3 52 0 
360792 3 52 0.008 
360793 3 52 0.006 
360794 3 52 0.037 
360795 3 52 . 
360796 3 52 0.023 
360797 3 52 0.191 
360798 3 52 0.005 
360799 3 52 0.028 
360800 3 52 0.014 
360801 1 52 0.059 
360802 1 52 . 
360803 1 52 0.046 
360804 1 52 . 
360805 1 52 . 
360806 1 52 0.035 
360807 1 52 0.053 
360808 1 52 0.043 
360809 1 52 0.048 
360810 1 52 0.023 
360811 1 52 0.056 
360812 1 52 0.054 
360813 1 52 0.065 
360814 1 52 0.014 
360815 1 52 0.02 
360816 1 52 0.031 
360817 1 52 . 
360818 1 52 0.035 
360819 1 52 0.077 
360820 1 52 . 
360821 1 52 0.033 
360822 1 52 0.091 
360823 1 52 0.042 
360824 1 52 0.05 
360825 1 52 0.042 
360826 1 52 0.065 
360827 1 52 0.011 
360828 1 52 0.017 
360829 1 52 0.026 
360830 1 52 . 
360831 1 52 0.031 
360832 1 52 0.024 
360833 1 52 0.037 
360834 1 52 . 
360835 1 52 0.022 
360836 1 52 . 
360837 1 52 0.02 
360838 1 52 0.042 
360839 1 52 0.024 
360840 1 52 0.054 
360841 1 52 0.01 
360701 2 62 0.15 
360702 2 62 0.86 
360703 2 62 0.481 
360704 2 62 0.869 
360705 2 62 1.033 
360706 2 62 1.518 
360707 2 62 0.733 
360708 2 62 0.516 
360709 2 62 . 
360710 2 62 . 
360711 2 62 . 
360712 2 62 0.976 
360713 2 62 0.363 
360714 2 62 0.92 
360715 2 62 0.136 
360716 2 62 . 
360717 2 62 0.583 
360718 2 62 1.103 
360719 2 62 . 
360720 2 62 0.52 
360721 2 62 0.485 
360722 2 62 0.456 
360723 2 62 1.308 
360724 2 62 . 
360725 2 62 0.107 
360726 2 62 0.327 
360727 2 62 . 
360728 2 62 0.552 
360729 2 62 1.282 
360730 2 62 1.414 
360731 2 62 0.322 
360732 2 62 . 
360733 2 62 0.424 
360734 2 62 0.6 
360735 2 62 0.574 
360736 2 62 . 7 1.186 
360738 2 62 0.701 
360739 2 62 . 
360740 2 62 0.29 
360741 2 62 0.236 
360742 2 62 0.857 
360743 2 62 1.156 
360744 2 62 0.344 
360745 2 62 0.366 
360746 2 62 1.488 
360747 2 62 . 
360748 2 62 . 
360749 2 62 . 
360750 2 62 . 
360751 3 62 0 
360752 3 62 0 
360753 3 62 0.002 
360754 3 62 0.024 
360755 3 62 0.047 
360756 3 62 0.065 
360757 3 62 . 
360758 3 62 . 
360759 3 62 0.029 
360760 3 62 0.026 
360761 3 62 . 
360762 3 62 0.012 
360763 3 62 . 
360764 3 62 0.023 
360765 3 62 0.012 
360766 3 62 . 
360767 3 62 . 
360768 3 62 0.001 
360769 3 62 0.041 
360770 3 62 0.022 
360771 3 62 0.034 
360772 3 62 0.018 
360773 3 62 0.011 
360774 3 62 . 
360775 3 62 0.009 
360776 3 62 0.014 
360777 3 62 0.019 
360778 3 62 0.01 
360779 3 62 0.011 
360780 3 62 . 
360781 3 62 0.003 
360782 3 62 0.022 
360783 3 62 . 
360784 3 62 0.012 
360785 3 62 0.048 
360786 3 62 0.016 
360787 3 62 . 
360788 3 62 0.016 
360789 3 62 . 
360790 3 62 . 
360791 3 62 0.022 
360792 3 62 0.008 
360793 3 62 0.009 
360794 3 62 0.005 
360795 3 62 . 
360796 3 62 0.004 
360797 3 62 0.002 
360798 3 62 0.009 
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360799 3 62 0.02 
360800 3 62 0.035 
360801 1 62 . 
360802 1 62 0.014 
360803 1 62 . 
360804 1 62 . 
360805 1 62 . 
360806 1 62 0.023 
360807 1 62 . 
360808 1 62 0.008 
360809 1 62 0.049 
360810 1 62 0.016 
360811 1 62 0.088 
360812 1 62 0.008 
360813 1 62 0.008 
360814 1 62 0.021 
360815 1 62 0.015 
360816 1 62 0.011 
360817 1 62 . 
360818 1 62 0.027 
360819 1 62 0.008 
360820 1 62 . 
360821 1 62 0.022 
360822 1 62 0.046 
360823 1 62 0.031 
360824 1 62 0.032 
360825 1 62 0.019 
360826 1 62 0.033 
360827 1 62 0.028 
360828 1 62 0.022 
360829 1 62 0.031 
360830 1 62 . 
360831 1 62 . 
360832 1 62 0.048 
360833 1 62 0.041 
360834 1 62 . 
360835 1 62 0.041 
360836 1 62 . 
360837 1 62 0.04 
360838 1 62 0.033 
360839 1 62 0.046 
360840 1 62 0.012 
360841 1 62 0.022 
360701 2 83 0.194 
360702 2 83 0.518 
360703 2 83  
360704 2 83 0.465 
360705 2 83 . 
360706 2 83 0.998 
360707 2 83 0.244 
360708 2 83 0.287 
360709 2 83 . 
360710 2 83 . 
360711 2 83 1.03 
360712 2 83 0.612 
360713 2 83 0.098 
360714 2 83 0.588 
360715 2 83 0.065 
360716 2 83 . 
360717 2 83 0.407 
360718 2 83 0.533 
360719 2 83 . 
360720 2 83 0.277 
360721 2 83 0.242 
360722 2 83 0.041 
360723 2 83 0.636 
360724 2 83 0.095 
360725 2 83 0.065 
360726 2 83 . 
360727 2 83 . 
360728 2 83 0.302 
360729 2 83 1.241 
360730 2 83 . 
360731 2 83 0.119 
360732 2 83 0.878 
360733 2 83 . 
360734 2 83 0.243 
360735 2 83 0.133 
360736 2 83 1.062 
360737 2 83 0.699 
360738 2 83 0.147 
360739 2 83 . 
360740 2 83 0.123 
360741 2 83 0.084 
360742 2 83 0.313 
360743 2 83 0.599 
360744 2 83 0.148 
360745 2 83 . 
360746 2 83 0.294 
360747 2 83 . 
360748 2 83 0.391 
360749 2 83 . 
360750 2 83 0.058 
360751 3 83 0.028 
360752 3 83 . 
360753 3 83 0.015 
360754 3 83 0.048 
360755 3 83 0.03 
360756 3 83 0.033 
360757 3 83 . 
360758 3 83 . 
360759 3 83 0.039 
360760 3 83 0.036 
360761 3 83 0.015 
360762 3 83 0.058 
360763 3 83 . 
360764 3 83 0.029 
360765 3 83 . 
360766 3 83 . 
360767 3 83 0.015 
360768 3 83 0.018 
360769 3 83 0.047 
360770 3 83 0.071 
360771 3 83 0.025 
360772 3 83 0.031 
360773 3 83 0.061 
360774 3 83 . 
360775 3 83 0.048 
360776 3 83 0.064 
360777 3 83 0.054 
360778 3 83 0.058 
360779 3 83 . 
360780 3 83 . 
360781 3 83 0.061 
360782 3 83 0.048 
360783 3 83 . 
360784 3 83 0.033 5 55
360786 3 83 0.033 
360787 3 83 . 
360788 3 83 0.044 
360789 3 83 . 
360790 3 83 . 
360791 3 83 0.022 
360792 3 83 . 
360793 3 83 . 
360794 3 83 0.068 
360795 3 83 0.028 
360796 3 83 0.08 
360797 3 83 0.083 
360798 3 83 . 
360799 3 83 0.033 
360800 3 83 . 
360801 1 83 0.068 
360802 1 83 . 
360803 1 83 0.049 
360804 1 83 . 
360805 1 83 0.027 
360806 1 83 0.096 
360807 1 83 0.047 
360808 1 83 0.044 
360809 1 83 0.038 
360810 1 83 0.089 
360811 1 83 0.072 
360812 1 83 0.054 
360813 1 83 0.037 
360814 1 83 0.068 
360815 1 83 0 
360816 1 83 0.042 
360817 1 83 . 
360818 1 83 . 
360819 1 83 0.068 
360820 1 83 . 
360821 1 83 0 
360822 1 83 0.051 
360823 1 83 . 
360824 1 83 0.067 
360825 1 83 0.019 
360826 1 83 0.027 
360827 1 83 0.041 
360828 1 83 0.029 
360829 1 83 0.033 
360830 1 83 0.031 
360831 1 83 . 
360832 1 83 0.034 
360833 1 83 . 
360834 1 83 . 
360835 1 83 . 
360836 1 83 . 
360837 1 83 . 
360838 1 83 . 
360839 1 83 0.025 
360840 1 83 0.024 
360841 1 83 . 
360701 2 111 . 
360702 2 111 0.203 
360703 2 111 . 
360704 2 111 0.17 
360705 2 111 0.235 
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360706 2 111 0.361 
360707 2 111 0.091 
360708 2 111 0.265 
360709 2 111 . 
360710 2 111 . 
360711 2 111 0.623 
360712 2 111 0.229 
360713 2 111 0.01 
360714 2 111 0.111 
360715 2 111 0.032 
360716 2 111 . 
360717 2 111 0.178 
360718 2 111 . 
360719 2 111 . 
360720 2 111 0.157 
360721 2 111 0.103 
360722 2 111 0.121 
360723 2 111 0.285 
360724 2 111 0.107 
360725 2 111 0.022 
360726 2 111 . 
360727 2 111 . 
360728 2 111 0.149 
360729 2 111 0.495 
360730 2 111 . 
360731 2 111 0.122 
360732 2 111 0.687 
360733 2 111 0.122 
360734 2 111 0.169 
360735 2 111 0.228 
360736 2 111 0.902 
360737 2 111 0.327 
360738 2 111 0.07 
360739 2 111 . 
360740 2 111 0.085 
360741 2 111 0.029 
360742 2 111 0.18 
360743 2 111 0.414 
360744 2 111 0.18 
360745 2 111 . 
360746 2 111 0.164 
360747 2 111 . 
360748 2 111 0.595 
360749 2 111 . 
360750 2 111 0.082 
360751 3 111 . 
360752 3 111 . 
360753 3 111 0.029 
360754 3 111 0.02 
360755 3 111 0.031 
360756 3 111 0.024 
360757 3 111 0.02 
360758 3 111 . 
360759 3 111 0.043 
360760 3 111 0.043 
360761 3 111 0.015 
360762 3 111 0.041 
360763 3 111 . 
360764 3 111 0.045 
360765 3 111 . 
360766 3 111 . 
360767 3 111 0.041 
360768 3 111 0.015 
360769 3 111 0.038 
360770 3 111 0.017 
360771 3 111 0.024 
360772 3 111 0.024 
360773 3 111 0.115 
360774 3 111 . 
360775 3 111 0.047 
360776 3 111 0.03 
360777 3 111 0.028 
360778 3 111 0.053 
360779 3 111 . 
360780 3 111 . 
360781 3 111 0.011 
360782 3 111 0.009 
360783 3 111 . 
360784 3 111 0.011 
360785 3 111 0.011 
360786 3 111 0.016 
360787 3 111 0.008 
360788 3 111 0.005 
360789 3 111 . 
360790 3 111 . 
360791 3 111 0.015 
360792 3 111 . 
360793 3 111 0.008 
360794 3 111 0.019 
360795 3 111 . 
360796 3 111 0.011 
360797 3 111 0 
360798 3 111 . 
360799 3 111 0 
360800 3 111 . 1 1 0.111 
360802 1 111 . 
360803 1 111 0.016 
360804 1 111 . 
360805 1 111 0.007 
360806 1 111 0.018 
360807 1 111 0.061 
360808 1 111 0.01 
360809 1 111 0.07 
360810 1 111 0.074 
360811 1 111 0.037 
360812 1 111 0.019 
360813 1 111 0.05 
360814 1 111 0.037 
360815 1 111 0.034 
360816 1 111 0.073 
360817 1 111 . 
360818 1 111 . 
360819 1 111 0.031 
360820 1 111 . 
360821 1 111 0.031 
360822 1 111 0.07 
360823 1 111 0.037 
360824 1 111 0.058 
360825 1 111 0.027 
360826 1 111 0.047 
360827 1 111 0.028 
360828 1 111 0.047 
360829 1 111 0.048 
360830 1 111 0.058 
360831 1 111 . 
360832 1 111 0.031 
360833 1 111 . 
360834 1 111 . 
360835 1 111 0.071 
360836 1 111 . 
360837 1 111 0.049 
360838 1 111 . 
360839 1 111 0.007 
360840 1 111 0.027 
360841 1 111 . 
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Kwessie (MG) 
Vaccine trials with poultry mycoplasma vaccines in ostriches on the Kwessie farmstead:  Statistical 
analysis of ELISA data, obtained with MG Antibody Test kits, using the Statistical Analysis System 
(SAS, Cary, NC) program (version 6.2). 
Statistical analysis: 
The General Linear Models (GLM) Procedure 
Class Level Information 
Class Levels Values 
Trt 3 1 2 3 
 
Time 9 0 6 14 21 38 52 62 83 111 
 
 
Number of Observations Read 1269 
Number of Observations Used 1110 
 
Dependent Variable: Resp 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 26 163.7116441 6.2966017 121.53 <.0001 
Error 1083 56.1119499 0.0518116   
Corrected Total 1109 219.8235940    
 
R-Squared Coeff Var Root MSE Resp Mean 
0.744741 85.04034 0.227622 0.267663 
 
Source DF Type I SS Mean Square F Value Pr > F 
Trt 2 85.21597202 42.60798601 822.36 <.0001 
Time 8 27.98438409 3.49804801 67.51 <.0001 
Trt*Time 16 50.51128795 3.15695550 60.93 <.0001 
 
The input data follows.  On each page the data is arranged in three columns, each containing the ostrich 
identification number, treatment (Trt), time and response (Resp), read from top to bottom and left to right. 
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Ostrich Trt Time Resp 
360701 2 0 0.079 
360702 2 0 0.084 
360703 2 0 0.083 
360704 2 0 0.084 
360705 2 0 0.081 
360706 2 0 0.065 
360707 2 0 0.074 
360708 2 0 0.066 
360709 2 0 0.048 
360710 2 0 0.053 
360711 2 0 0.055 
360712 2 0 0.073 
360713 2 0 0.073 
360714 2 0 0.101 
360715 2 0 0.089 
360716 2 0 0.100 
360717 2 0 0.074 
360718 2 0 0.068 
360719 2 0 0.079 
360720 2 0 0.091 
360721 2 0 0.063 
360722 2 0 0.087 
360723 2 0 0.09 
360724 2 0 0.078 
360725 2 0 0.059 
360726 2 0 0.078 
360727 2 0 0.087 
360728 2 0 0.098 
360729 2 0 0.078 
360730 2 0 0.089 
360731 2 0 0.088 
360732 2 0 0.066 
360733 2 0 0.054 
360734 2 0 0.076 
360735 2 0 0.104 
360736 2 0 0.066 
360737 2 0 0.053 
360738 2 0 0.082 
360739 2 0 0.079 
360740 2 0 0.084 
360741 2 0 0.06 
360742 2 0 0.093 
360743 2 0 0.04 
360744 2 0 0.044 
360745 2 0 0.064 
360746 2 0 0.067 
360747 2 0 0.07 
360748 2 0 0.082 
360749 2 0 0.096 
360750 2 0 0.079 
360751 3 0 0.075 
360752 3 0 0.058 
360753 3 0 0.045 
360754 3 0 0.049 
360755 3 0 0.066 
360756 3 0 0.066 
360757 3 0 0.098 
360758 3 0 0.093 
360759 3 0 0.069 
360760 3 0 0.078 
360761 3 0 0.093 
360762 3 0 0.095 
360763 3 0 0.063 
360764 3 0 0.08 
360765 3 0 0.05 
360766 3 0 0.066 
360767 3 0 0.105 
360768 3 0 0.108 
360769 3 0 0.059 
360770 3 0 0.078 
360771 3 0 0.063 
360772 3 0 0.07 
360773 3 0 0.066 
360774 3 0 0.11 
360775 3 0 0.085 
360776 3 0 0.115 
360777 3 0 0.124 
360778 3 0 0.065 
360779 3 0 0.082 
360780 3 0 0.106 
360781 3 0 0.093 
360782 3 0 0.088 
360783 3 0 0.077 
360784 3 0 0.05 
360785 3 0 0.072 
360786 3 0 0.083 
360787 3 0 0.089 
360788 3 0 0.067 
360789 3 0 0.069 
360790 3 0 0.063 
360791 3 0 0.058 
360792 3 0 0.076 
360793 3 0 0.055 
360794 3 0 0.087 
360795 3 0 0.078 
360796 3 0 0.056 
360797 3 0 0.067 
360798 3 0 0.077 
360799 3 0 0.069 
360800 3 0 0.053 
360801 1 0 0.086 
360802 1 0 0.055 
360803 1 0 0.071 
360804 1 0 0.058 
360805 1 0 0.091 
360806 1 0 0.071 
360807 1 0 0.07 
360808 1 0 0.061 
360809 1 0 0.067 
360810 1 0 0.063 
360811 1 0 0.084 
360812 1 0 0.061 
360813 1 0 0.067 
360814 1 0 0.062 
360815 1 0 0.077 
360816 1 0 0.081 
360817 1 0 0.083 
360818 1 0 0.087 
360819 1 0 0.09 
360820 1 0 0.076 
360821 1 0 0.067 
360822 1 0 0.067 
360823 1 0 0.1 
360824 1 0 0.081 
360825 1 0 0.071 
360826 1 0 0.074 7 7
360828 1 0 0.091 
360829 1 0 0.084 
360830 1 0 0.054 
360831 1 0 0.094 
360832 1 0 0.062 
360833 1 0 0.082 
360834 1 0 0.086 
360835 1 0 0.073 
360836 1 0 0.075 
360837 1 0 0.099 
360838 1 0 0.082 
360839 1 0 0.114 
360840 1 0 0.072 
360841 1 0 0.061 
360701 2 6 0.063 
360702 2 6 0.067 
360703 2 6 0.085 
360704 2 6 0.108 
360705 2 6 0.093 
360706 2 6 0.083 
360707 2 6 0.079 
360708 2 6 0.088 
360709 2 6 0.084 
360710 2 6 0.071 
360711 2 6 0.087 
360712 2 6 0.046 
360713 2 6 0.069 
360714 2 6 0.077 
360715 2 6 0.117 
360716 2 6 0.079 
360717 2 6 0.061 
360718 2 6 0.063 
360719 2 6 0.091 
360720 2 6 0.09 
360721 2 6 0.083 
360722 2 6 0.062 
360723 2 6 0.042 
360724 2 6 0.048 
360725 2 6 0.077 
360726 2 6 0.074 
360727 2 6 0.077 
360728 2 6 0.084 
360729 2 6 0.065 
360730 2 6 0.082 
360731 2 6 0.078 
360732 2 6 0.102 
360733 2 6 0.076 
360734 2 6 0.055 
360735 2 6 0.03 
360736 2 6 0.078 
360737 2 6 0.061 
360738 2 6 0.075 
360739 2 6 0.093 
360740 2 6 0.128 
360741 2 6 0.081 
360742 2 6 0.083 
360743 2 6 0.058 
360744 2 6 0.062 
360745 2 6 0.105 
360746 2 6 0.06 
360747 2 6 0.072 
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360748 2 6 0.072 
360749 2 6 0.071 
360750 2 6 0.077 
360751 3 6 0.106 
360752 3 6 0.107 
360753 3 6 0.105 
360754 3 6 0.115 
360755 3 6 0.059 
360756 3 6 0.056 
360757 3 6 0.067 
360758 3 6 0.064 
360759 3 6 0.074 
360760 3 6 0.077 
360761 3 6 0.119 
360762 3 6 0.094 
360763 3 6 0.066 
360764 3 6 0.086 
360765 3 6 0.086 
360766 3 6 0.074 
360767 3 6 0.122 
360768 3 6 0.137 
360769 3 6 0.065 
360770 3 6 0.088 
360771 3 6 0.069 
360772 3 6 0.073 
360773 3 6 0.065 
360774 3 6 0.113 
360775 3 6 0.087 
360776 3 6 0.076 
360777 3 6 0.125 
360778 3 6 0.081 
360779 3 6 0.115 
360780 3 6 0.093 
360781 3 6 0.074 
360782 3 6 0.051 
360783 3 6 0.053 
360784 3 6 0.041 
360785 3 6 0.041 
360786 3 6 0.051 
360787 3 6 0.056 
360788 3 6 0.054 
360789 3 6 0.052 
360790 3 6 0.043 
360791 3 6 0.071 
360792 3 6 0.055 
360793 3 6 0.066 
360794 3 6 0.059 
360795 3 6 0.058 
360796 3 6 0.053 
360797 3 6 0.06 
360798 3 6 0.061 
360799 3 6 0.046 
360800 3 6 0.058 
360801 1 6 0.061 
360802 1 6 0.066 
360803 1 6 0.09 
360804 1 6 0.051 
360805 1 6 0.059 
360806 1 6 0.066 
360807 1 6 0.074 
360808 1 6 0.072 
360809 1 6 0.075 
360810 1 6 0.05 
360811 1 6 0.067 
360812 1 6 0.07 
360813 1 6 0.063 
360814 1 6 0.065 
360815 1 6 0.056 
360816 1 6 0.056 
360817 1 6 0.032 
360818 1 6 0.053 
360819 1 6 0.07 
360820 1 6 0.061 
360821 1 6 0.065 
360822 1 6 0.05 
360823 1 6 0.057 
360824 1 6 0.074 
360825 1 6 0.079 
360826 1 6 0.074 
360827 1 6 0.091 
360828 1 6 0.089 
360829 1 6 0.091 
360830 1 6 . 
360831 1 6 0.08 
360832 1 6 . 
360833 1 6 0.075 
360834 1 6 0.108 
360835 1 6 0.09 
360836 1 6 0.105 
360837 1 6 0.041 
360838 1 6 0.046 
360839 1 6 0.075 
360840 1 6 0.063 
360841 1 6 0.062 
360701 2 14 0.024 
360702 2 14 0.057 
360703 2 14 0.04 
360704 2 14 0.052 
360705 2 14 0.058 
360706 2 14 0.036 
360707 2 14 0.042 
360708 2 14 0.03 
360709 2 14 0.048 
360710 2 14 0.062 
360711 2 14 0.062 
360712 2 14 0.04 
360713 2 14 0.04 
360714 2 14 0.062 
360715 2 14 0.071 
360716 2 14 0.014 
360717 2 14 0 
360718 2 14 0 
360719 2 14 0 
360720 2 14 0.012 
360721 2 14 0.016 
360722 2 14 0.013 
360723 2 14 0.018 
360724 2 14 0.012 
360725 2 14 0.005 
360726 2 14 0.002 
360727 2 14 0.003 
360728 2 14 0.025 
360729 2 14 0.002 
360730 2 14 0.006 
360731 2 14 0.003 
360732 2 14 0.041 
360733 2 14 0.03 4 0.022 
360735 2 14 0.037 
360736 2 14 0.046 
360737 2 14 0.014 
360738 2 14 0.039 
360739 2 14 0.056 
360740 2 14 0.048 
360741 2 14 0.038 
360742 2 14 0.04 
360743 2 14 0.037 
360744 2 14 0.033 
360745 2 14 0.041 
360746 2 14 0.048 
360747 2 14 0.022 
360748 2 14 0.048 
360749 2 14 0.031 
360750 2 14 0.047 
360751 3 14 0.223 
360752 3 14 0.066 
360753 3 14 0.044 
360754 3 14 0.075 
360755 3 14 0.07 
360756 3 14 0.102 
360757 3 14 0.066 
360758 3 14 0.218 
360759 3 14 0.2 
360760 3 14 0.03 
360761 3 14 0.068 
360762 3 14 0.8 
360763 3 14 0.301 
360764 3 14 0.035 
360765 3 14 0.055 
360766 3 14 0.609 
360767 3 14 0.22 
360768 3 14 0.121 
360769 3 14 0.622 
360770 3 14 0.293 
360771 3 14 0.289 
360772 3 14 0.078 
360773 3 14 0.42 
360774 3 14 0.202 
360775 3 14 0.306 
360776 3 14 0.313 
360777 3 14 0.554 
360778 3 14 0.21 
360779 3 14 0.234 
360780 3 14 0.469 
360781 3 14 1.056 
360782 3 14 0.956 
360783 3 14 0.13 
360784 3 14 0.116 
360785 3 14 0.148 
360786 3 14 0.213 
360787 3 14 0.434 
360788 3 14 0.212 
360789 3 14 0.081 
360790 3 14 0.369 
360791 3 14 0.143 
360792 3 14 0.226 
360793 3 14 0.102 
360794 3 14 0.211 
360795 3 14 0.127 
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360796 3 14 0.148 
360797 3 14 0.053 
360798 3 14 0.171 
360799 3 14 0.357 
360800 3 14 0.22 
360801 1 14 0.025 
360802 1 14 0.045 
360803 1 14 0.034 
360804 1 14 0.039 
360805 1 14 0.072 
360806 1 14 0.066 
360807 1 14 0.054 
360808 1 14 0.038 
360809 1 14 0.039 
360810 1 14 0.035 
360811 1 14 0.077 
360812 1 14 0.043 
360813 1 14 0.035 
360814 1 14 0.038 
360815 1 14 0.030 
360816 1 14 0.04 
360817 1 14 0.045 
360818 1 14 0.047 
360819 1 14 0.047 
360820 1 14 0.057 
360821 1 14 0.054 
360822 1 14 0.045 
360823 1 14 0.034 
360824 1 14 0.044 
360825 1 14 0.087 
360826 1 14 0.057 
360827 1 14 0.046 
360828 1 14 0.037 
360829 1 14 0.041 
360830 1 14 0.039 
360831 1 14 0.033 
360832 1 14 0.036 
360833 1 14 0.03 
360834 1 14 0.038 
360835 1 14 0.043 
360836 1 14 0.049 
360837 1 14 0 
360838 1 14 0.003 
360839 1 14 0.009 
360840 1 14 0 
360841 1 14 0 
360701 2 21 0.02 
360702 2 21 0.034 
360703 2 21 0.034 
360704 2 21 0.023 
360705 2 21 0.018 
360706 2 21 0.018 
360707 2 21 0.033 
360708 2 21 0.846 
360709 2 21 0.126 
360710 2 21 0.026 
360711 2 21 0.036 
360712 2 21 0.015 
360713 2 21 0.027 
360714 2 21 0.017 
360715 2 21 0.033 
360716 2 21 0.064 
360717 2 21 0.074 
360718 2 21 0.051 
360719 2 21 0.073 
360720 2 21 0.066 
360721 2 21 0.05 
360722 2 21 0.07 
360723 2 21 0.097 
360724 2 21 0.191 
360725 2 21 0.053 
360726 2 21 0.09 
360727 2 21 0.117 
360728 2 21 0.083 
360729 2 21 0.074 
360730 2 21 0.049 
360731 2 21 0.063 
360732 2 21 0.093 
360733 2 21 0.111 
360734 2 21 0.053 
360735 2 21 0.083 
360736 2 21 0.053 
360737 2 21 0.067 
360738 2 21 0.062 
360739 2 21 0.069 
360740 2 21 0.055 
360741 2 21 0.081 
360742 2 21 0.096 
360743 2 21 0.067 
360744 2 21 0.063 
360745 2 21 0.048 
360746 2 21 0.05 
360747 2 21 0.063 
360748 2 21 0.17 
360749 2 21 0.071 
360750 2 21 0.023 
360751 3 21 1.256 
360752 3 21 0.566 
360753 3 21 0.489 
360754 3 21 0.23 
360755 3 21 1.459 
360756 3 21 1.69 
360757 3 21 0.918 
360758 3 21 1.273 
360759 3 21 0.977 
360760 3 21 0.713 
360761 3 21 0.411 
360762 3 21 0.904 
360763 3 21 0.545 
360764 3 21 0.203 
360765 3 21 0.195 
360766 3 21 1.770 
360767 3 21 1.189 
360768 3 21 1.08 
360769 3 21 1.436 
360770 3 21 0.391 
360771 3 21 1.251 
360772 3 21 0.054 
360773 3 21 0.622 
360774 3 21 1.084 
360775 3 21 1.008 
360776 3 21 0.35 
360777 3 21 0.647 
360778 3 21 0.561 
360779 3 21 0.401 
360780 3 21 0.078 
360781 3 21 0.808 2 1
360783 3 21 1.485 
360784 3 21 0.379 
360785 3 21 0.574 
360786 3 21 0.17 
360787 3 21 1.516 
360788 3 21 1.814 
360789 3 21 0.709 
360790 3 21 0.644 
360791 3 21 0.59 
360792 3 21 1.652 
360793 3 21 0.148 
360794 3 21 0.51 
360795 3 21 0.119 
360796 3 21 0.811 
360797 3 21 0.062 
360798 3 21 1.345 
360799 3 21 0.668 
360800 3 21 0.863 
360801 1 21 0.077 
360802 1 21 0.059 
360803 1 21 0.037 
360804 1 21 0.016 
360805 1 21 0.013 
360806 1 21 0.019 
360807 1 21 0.03 
360808 1 21 0.028 
360809 1 21 0.013 
360810 1 21 0.032 
360811 1 21 0.035 
360812 1 21 0.09 
360813 1 21 0.021 
360814 1 21 0.024 
360815 1 21 0.049 
360816 1 21 0.059 
360817 1 21 0.071 
360818 1 21 0.048 
360819 1 21 0.05 
360820 1 21 0.056 
360821 1 21 0.049 
360822 1 21 0.067 
360823 1 21 0.057 
360824 1 21 0.085 
360825 1 21 0.072 
360826 1 21 0.056 
360827 1 21 0.048 
360828 1 21 0.061 
360829 1 21 0.066 
360830 1 21 0.079 
360831 1 21 0.063 
360832 1 21 0.057 
360833 1 21 0.054 
360834 1 21 0.085 
360835 1 21 0.045 
360836 1 21 0.075 
360837 1 21 0.058 
360838 1 21 0.059 
360839 1 21 0.091 
360840 1 21 0.058 
360841 1 21 0.055 
360701 2 38 0.021 
360702 2 38 0.023 
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360703 2 38 0.014 
360704 2 38 0.031 
360705 2 38 0.05 
360706 2 38 0.048 
360707 2 38 0.025 
360708 2 38 0.031 
360709 2 38 0.05 
360710 2 38 0.047 
360711 2 38 0.048 
360712 2 38 0.067 
360713 2 38 0.055 
360714 2 38 0.031 
360715 2 38 0.036 
360716 2 38 0.033 
360717 2 38 0.031 
360718 2 38 0.099 
360719 2 38 0.108 
360720 2 38 0.063 
360721 2 38 0.144 
360722 2 38 0.057 
360723 2 38 0.081 
360724 2 38 0.1 
360725 2 38 0.058 
360726 2 38 0.055 
360727 2 38 0.081 
360728 2 38 0.062 
360729 2 38 0.051 
360730 2 38 0.037 
360731 2 38 0.037 
360732 2 38 0.059 
360733 2 38 0.047 
360734 2 38 0.061 
360735 2 38 0.044 
360736 2 38 0.053 
360737 2 38 0.02 
360738 2 38 0.03 
360739 2 38 0.052 
360740 2 38 0.049 
360741 2 38 0.014 
360742 2 38 0.001 
360743 2 38 0.069 
360744 2 38 0.012 
360745 2 38 0.094 
360746 2 38 0 
360747 2 38 0 
360748 2 38 0.001 
360749 2 38 0.008 
360750 2 38 0.004 
360751 3 38 0.657 
360752 3 38 1.231 
360753 3 38 0.409 
360754 3 38 0.102 
360755 3 38 1.376 
360756 3 38 0.886 
360757 3 38 0.797 
360758 3 38 1.536 
360759 3 38 1.133 
360760 3 38 1.201 
360761 3 38 0.595 
360762 3 38 1.518 
360763 3 38 0.076 
360764 3 38 0.735 
360765 3 38 0.505 
360766 3 38 0.601 
360767 3 38 0.242 
360768 3 38 0.881 
360769 3 38 0.599 
360770 3 38 0.515 
360771 3 38 0.881 
360772 3 38 0.008 
360773 3 38 0.555 
360774 3 38 0.525 
360775 3 38 0.509 
360776 3 38 0.153 
360777 3 38 0.681 
360778 3 38 0.788 
360779 3 38 0.407 
360780 3 38 1.077 
360781 3 38 0.189 
360782 3 38 0.671 
360783 3 38 0.65 
360784 3 38 0.805 
360785 3 38 0.522 
360786 3 38 0.298 
360787 3 38 1.03 
360788 3 38 1.293 
360789 3 38 0.41 
360790 3 38 0.839 
360791 3 38 0.363 
360792 3 38 1.102 
360793 3 38 0.176 
360794 3 38 0.105 
360795 3 38 0.76 
360796 3 38 0.527 
360797 3 38 0.133 
360798 3 38 0.635 
360799 3 38 0.653 
360800 3 38 0.025 
360801 1 38 0.04 
360802 1 38 0.623 
360803 1 38 0.056 
360804 1 38 0.034 
360805 1 38 0.018 
360806 1 38 0.066 
360807 1 38 0.042 
360808 1 38 0.031 
360809 1 38 0.033 
360810 1 38 0.017 
360811 1 38 0.029 
360812 1 38 0.048 
360813 1 38 0.019 
360814 1 38 0.029 
360815 1 38 0.037 
360816 1 38 0.025 
360817 1 38 0.03 
360818 1 38 0.031 
360819 1 38 0.025 
360820 1 38 0.042 
360821 1 38 0.029 
360822 1 38 0.038 
360823 1 38 0.064 
360824 1 38 0.02 
360825 1 38 0.029 
360826 1 38 0.02 
360827 1 38 0.033 
360828 1 38 0.016 
360829 1 38 0.037 30 22
360831 1 38 0.001 
360832 1 38 0.033 
360833 1 38 0.079 
360834 1 38 0.059 
360835 1 38 0.048 
360836 1 38 0.046 
360837 1 38 0.033 
360838 1 38 0.042 
360839 1 38 0.031 
360840 1 38 0.033 
360841 1 38 0.014 
360701 2 52 0.067 
360702 2 52 0.073 
360703 2 52 0.107 
360704 2 52 0.063 
360705 2 52 0.037 
360706 2 52 0.061 
360707 2 52 0.021 
360708 2 52 0.078 
360709 2 52 . 
360710 2 52 . 
360711 2 52 . 
360712 2 52 0.131 
360713 2 52 0.035 
360714 2 52 0.049 
360715 2 52 0.037 
360716 2 52 . 
360717 2 52 0.084 
360718 2 52 0.044 
360719 2 52 . 
360720 2 52 0.051 
360721 2 52 0.049 
360722 2 52 0.052 
360723 2 52 0.079 
360724 2 52 . 
360725 2 52 0.033 
360726 2 52 0.073 
360727 2 52 . 
360728 2 52 0.057 
360729 2 52 0.056 
360730 2 52 0.018 
360731 2 52 0.069 
360732 2 52 0.052 
360733 2 52 . 
360734 2 52 0.064 
360735 2 52 . 
360736 2 52 0.024 
360737 2 52 0.014 
360738 2 52 0.053 
360739 2 52 . 
360740 2 52 0.033 
360741 2 52 0.069 
360742 2 52 0.036 
360743 2 52 0.048 
360744 2 52 0 
360745 2 52 0.011 
360746 2 52 0.017 
360747 2 52 . 
360748 2 52 . 
360749 2 52 . 
360750 2 52 0 
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360751 3 52 0.505 
360752 3 52 1.491 
360753 3 52 1.485 
360754 3 52 0.374 
360755 3 52 0.052 
360756 3 52 1.406 
360757 3 52 . 
360758 3 52 1.755 
360759 3 52 1.026 
360760 3 52 1.212 
360761 3 52 . 
360762 3 52 1.742 
360763 3 52 . 
360764 3 52 1.351 
360765 3 52 0.031 
360766 3 52 0.691 
360767 3 52 . 
360768 3 52 0.942 
360769 3 52 1.854 
360770 3 52 0.978 
360771 3 52 1.402 
360772 3 52 0.077 
360773 3 52 0.865 
360774 3 52 . 
360775 3 52 1.27 
360776 3 52 1.076 
360777 3 52 1.211 
360778 3 52 1.245 
360779 3 52 1.823 
360780 3 52 . 
360781 3 52 0.574 
360782 3 52 1.694 
360783 3 52 . 
360784 3 52 1.516 
360785 3 52 1.284 
360786 3 52 0.767 
360787 3 52 . 
360788 3 52 1.218 
360789 3 52 . 
360790 3 52 . 
360791 3 52 1.373 
360792 3 52 1.558 
360793 3 52 1.311 
360794 3 52 1.511 
360795 3 52 . 
360796 3 52 1.576 
360797 3 52 1.399 
360798 3 52 1.602 
360799 3 52 1.987 
360800 3 52 1.678 
360801 1 52 0 
360802 1 52 . 
360803 1 52 0 
360804 1 52 . 
360805 1 52 . 
360806 1 52 0 
360807 1 52 0 
360808 1 52 0 
360809 1 52 0 
360810 1 52 0 
360811 1 52 0 
360812 1 52 0 
360813 1 52 0 
360814 1 52 0.067 
360815 1 52 0.054 
360816 1 52 0.054 
360817 1 52 . 
360818 1 52 0.073 
360819 1 52 0.058 
360820 1 52 . 
360821 1 52 0.058 
360822 1 52 0.057 
360823 1 52 0.12 
360824 1 52 0.072 
360825 1 52 0.11 
360826 1 52 0.111 
360827 1 52 0.058 
360828 1 52 0.056 
360829 1 52 0.083 
360830 1 52 . 
360831 1 52 0.061 
360832 1 52 0.073 
360833 1 52 0.101 
360834 1 52 . 
360835 1 52 0.06 
360836 1 52 . 
360837 1 52 0.054 
360838 1 52 0.077 
360839 1 52 0.089 
360840 1 52 0.154 
360841 1 52 0.056 
360701 2 62 0.079 
360702 2 62 0.052 
360703 2 62 0.072 
360704 2 62 0.085 
360705 2 62 0.108 
360706 2 62 0.041 
360707 2 62 . 
360708 2 62 0.064 
360709 2 62 . 
360710 2 62 . 
360711 2 62 . 
360712 2 62 0.06 
360713 2 62 0.035 
360714 2 62 0.029 
360715 2 62 0.073 
360716 2 62 . 
360717 2 62 0.054 
360718 2 62 0.037 
360719 2 62 . 
360720 2 62 0.042 
360721 2 62 0.031 
360722 2 62 0.037 
360723 2 62 0.037 
360724 2 62 . 
360725 2 62 0.024 
360726 2 62 0.034 
360727 2 62 . 
360728 2 62 0.024 
360729 2 62 0.053 
360730 2 62 0.038 
360731 2 62 0.021 
360732 2 62 . 
360733 2 62 0.037 
360734 2 62 0.027 
360735 2 62 0.068 
360736 2 62 . 7 0.042 
360738 2 62 0.83 
360739 2 62 . 
360740 2 62 0.041 
360741 2 62 0.027 
360742 2 62 0.09 
360743 2 62 0.055 
360744 2 62 0.056 
360745 2 62 0.059 
360746 2 62 0.048 
360747 2 62 . 
360748 2 62 . 
360749 2 62 . 
360750 2 62 . 
360751 3 62 0.789 
360752 3 62 1.331 
360753 3 62 1.521 
360754 3 62 0.768 
360755 3 62 1.604 
360756 3 62 1.52 
360757 3 62 . 
360758 3 62 . 
360759 3 62 1.214 
360760 3 62 1.343 
360761 3 62 . 
360762 3 62 1.897 
360763 3 62 . 
360764 3 62 1.622 
360765 3 62 1.232 
360766 3 62 . 
360767 3 62 . 
360768 3 62 1.016 
360769 3 62 1.566 
360770 3 62 0.842 
360771 3 62 1.553 
360772 3 62 0.175 
360773 3 62 1.603 
360774 3 62 . 
360775 3 62 1.18 
360776 3 62 1.13 
360777 3 62 1.563 
360778 3 62 1.495 
360779 3 62 1.973 
360780 3 62 . 
360781 3 62 0.612 
360782 3 62 1.515 
360783 3 62 . 
360784 3 62 1.602 
360785 3 62 1.761 
360786 3 62 0.932 
360787 3 62 . 
360788 3 62 1.046 
360789 3 62 . 
360790 3 62 . 
360791 3 62 1.287 
360792 3 62 1.551 
360793 3 62 1.294 
360794 3 62 1.058 
360795 3 62 . 
360796 3 62 1.338 
360797 3 62 1.615 
360798 3 62 0.989 
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360799 3 62 1.748 
360800 3 62 1.573 
360801 1 62 . 
360802 1 62 0.059 
360803 1 62 . 
360804 1 62 . 
360805 1 62 . 
360806 1 62 0.048 
360807 1 62 . 
360808 1 62 0.147 
360809 1 62 0.085 
360810 1 62 0.051 
360811 1 62 0.1 
360812 1 62 0.049 
360813 1 62 0.112 
360814 1 62 0.114 
360815 1 62 0.032 
360816 1 62 0.031 
360817 1 62 . 
360818 1 62 0.026 
360819 1 62 0.066 
360820 1 62 . 
360821 1 62 0.127 
360822 1 62 0.082 
360823 1 62 0.061 
360824 1 62 0.081 
360825 1 62 0.06 
360826 1 62 0.092 
360827 1 62 0.071 
360828 1 62 0.031 
360829 1 62 0.048 
360830 1 62 . 
360831 1 62 . 
360832 1 62 0.071 
360833 1 62 0.056 
360834 1 62 . 
360835 1 62 0.057 
360836 1 62 . 
360837 1 62 0.055 
360838 1 62 0.056 
360839 1 62 0.11 
360840 1 62 0.094 
360841 1 62 0.064 
360701 2 83 0.088 
360702 2 83 0.089 
360703 2 83 . 
360704 2 83 0.078 
360705 2 83 . 
360706 2 83 0.108 
360707 2 83 0.054 
360708 2 83 0.081 
360709 2 83 . 
360710 2 83 . 
360711 2 83 0.076 
360712 2 83 0.047 
360713 2 83 0.056 
360714 2 83 0.046 
360715 2 83 0.064 
360716 2 83 . 
360717 2 83 0.054 
360718 2 83 0.079 
360719 2 83 . 
360720 2 83 0.138 
360721 2 83 0.099 
360722 2 83 0.079 
360723 2 83 0.052 
360724 2 83 0.081 
360725 2 83 0.065 
360726 2 83 . 
360727 2 83 . 
360728 2 83 0.087 
360729 2 83 0.119 
360730 2 83 . 
360731 2 83 0.063 
360732 2 83 0.077 
360733 2 83 . 
360734 2 83 0.073 
360735 2 83 0.156 
360736 2 83 0.118 
360737 2 83 0.085 
360738 2 83 0.088 
360739 2 83 . 
360740 2 83 0.063 
360741 2 83 0.06 
360742 2 83 0.087 
360743 2 83 0.058 
360744 2 83 0.04 
360745 2 83 . 
360746 2 83 0.07 
360747 2 83 . 
360748 2 83 0.062 
360749 2 83 . 
360750 2 83 0.114 
360751 3 83 0.338 
360752 3 83 . 
360753 3 83 0.408 
360754 3 83 0.244 
360755 3 83 0.573 
360756 3 83 1.035 
360757 3 83 . 
360758 3 83 . 
360759 3 83 0.277 
360760 3 83 1.146 
360761 3 83 1.062 
360762 3 83 0.618 
360763 3 83 . 
360764 3 83 1.541 
360765 3 83 . 
360766 3 83 . 
360767 3 83 1.372 
360768 3 83 0.431 
360769 3 83 1.384 
360770 3 83 0.664 
360771 3 83 1.197 
360772 3 83 0.087 
360773 3 83 1.006 
360774 3 83 . 
360775 3 83 0.382 
360776 3 83 0.254 
360777 3 83 1.05 
360778 3 83 1.164 
360779 3 83 . 
360780 3 83 . 
360781 3 83 0.393 
360782 3 83 0.403 
360783 3 83 . 
360784 3 83 0.858 5 2 376
360786 3 83 0.376 
360787 3 83 . 
360788 3 83 0.843 
360789 3 83 . 
360790 3 83 . 
360791 3 83 0.634 
360792 3 83 . 
360793 3 83 . 
360794 3 83 0.64 
360795 3 83 0.845 
360796 3 83 0.706 
360797 3 83 1.016 
360798 3 83 . 
360799 3 83 1.274 
360800 3 83 . 
360801 1 83 0.095 
360802 1 83 . 
360803 1 83 0.101 
360804 1 83 . 
360805 1 83 0.069 
360806 1 83 0.193 
360807 1 83 0.082 
360808 1 83 0.084 
360809 1 83 0.132 
360810 1 83 0.105 
360811 1 83 0.113 
360812 1 83 0.149 
360813 1 83 0.079 
360814 1 83 0.153 
360815 1 83 0.111 
360816 1 83 0.102 
360817 1 83 . 
360818 1 83 . 
360819 1 83 0.156 
360820 1 83 . 
360821 1 83 0.087 
360822 1 83 0.166 
360823 1 83 . 
360824 1 83 0.134 
360825 1 83 0.107 
360826 1 83 0.087 
360827 1 83 0.074 
360828 1 83 0.064 
360829 1 83 0.072 
360830 1 83 0.103 
360831 1 83 . 
360832 1 83 0.061 
360833 1 83 . 
360834 1 83 . 
360835 1 83 . 
360836 1 83 . 
360837 1 83 . 
360838 1 83 . 
360839 1 83 0.076 
360840 1 83 0.056 
360841 1 83 . 
360701 2 111 . 
360702 2 111 0.08 
360703 2 111 . 
360704 2 111 0.054 
360705 2 111 0.05 
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360706 2 111 0.057 
360707 2 111 0.067 
360708 2 111 0.055 
360709 2 111 . 
360710 2 111 . 
360711 2 111 0.036 
360712 2 111 0.05 
360713 2 111 0.063 
360714 2 111 0.06 
360715 2 111 0.097 
360716 2 111 . 
360717 2 111 0.039 
360718 2 111 . 
360719 2 111 . 
360720 2 111 0.011 
360721 2 111 0.027 
360722 2 111 0.017 
360723 2 111 0.039 
360724 2 111 0.061 
360725 2 111 0.027 
360726 2 111 . 
360727 2 111 . 
360728 2 111 0.078 
360729 2 111 0.166 
360730 2 111 . 
360731 2 111 0.032 
360732 2 111 0.05 
360733 2 111 0.043 
360734 2 111 0.048 
360735 2 111 0.079 
360736 2 111 0.061 
360737 2 111 0.04 
360738 2 111 0.056 
360739 2 111 . 
360740 2 111 0.061 
360741 2 111 0.055 
360742 2 111 0.064 
360743 2 111 0.046 
360744 2 111 0.058 
360745 2 111 . 
360746 2 111 0.051 
360747 2 111 . 
360748 2 111 0.053 
360749 2 111 . 
360750 2 111 0.065 
360751 3 111 . 
360752 3 111 . 
360753 3 111 1.35 
360754 3 111 0.489 
360755 3 111 1.549 
360756 3 111 1.288 
360757 3 111 0.535 
360758 3 111 . 
360759 3 111 0.849 
360760 3 111 1.752 
360761 3 111 1.226 
360762 3 111 1.513 
360763 3 111 . 
360764 3 111 1.771 
360765 3 111 . 
360766 3 111 . 
360767 3 111 1.2 
360768 3 111 0.826 
360769 3 111 1.674 
360770 3 111 0.661 
360771 3 111 1.753 
360772 3 111 0.081 
360773 3 111 0.056 
360774 3 111 . 
360775 3 111 0.738 
360776 3 111 1.382 
360777 3 111 1.58 
360778 3 111 1.31 
360779 3 111 . 
360780 3 111 . 
360781 3 111 0.279 
360782 3 111 0.76 
360783 3 111 . 
360784 3 111 1.157 
360785 3 111 1.796 
360786 3 111 0.589 
360787 3 111 0.049 
360788 3 111 0.968 
360789 3 111 . 
360790 3 111 . 
360791 3 111 1.147 
360792 3 111 . 
360793 3 111 1.162 
360794 3 111 1.115 
360795 3 111 . 
360796 3 111 1.454 
360797 3 111 1.803 
360798 3 111 . 
360799 3 111 1.919 
360800 3 111 . 1 1 0 1 
360802 1 111 . 
360803 1 111 0.092 
360804 1 111 . 
360805 1 111 0.049 
360806 1 111 0.045 
360807 1 111 0.044 
360808 1 111 0.038 
360809 1 111 0.071 
360810 1 111 0.066 
360811 1 111 0.052 
360812 1 111 0.039 
360813 1 111 0.056 
360814 1 111 0.063 
360815 1 111 0.047 
360816 1 111 0.049 
360817 1 111 . 
360818 1 111 . 
360819 1 111 0.033 
360820 1 111 . 
360821 1 111 0.069 
360822 1 111 0.044 
360823 1 111 0.068 
360824 1 111 0.078 
360825 1 111 0.064 
360826 1 111 0.067 
360827 1 111 0.044 
360828 1 111 0.062 
360829 1 111 0.172 
360830 1 111 0.081 
360831 1 111 . 
360832 1 111 0.068 
360833 1 111 . 
360834 1 111 . 
360835 1 111 0.099 
360836 1 111 . 
360837 1 111 0.046 
360838 1 111 . 
360839 1 111 0.064 
360840 1 111 0.057 
360841 1 111 . 
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Schoeman (MS) 
Vaccine trials with poultry mycoplasma vaccines in ostriches on the Schoeman farmstead:  Statistical 
analysis of ELISA data, obtained with MS Antibody Test kits, using the Statistical Analysis System 
(SAS, Cary, NC) program (version 6.2). 
Statistical analysis: 
The General Linear Models (GLM) Procedure 
Class Level Information 
Class Levels Values 
3 1 2 3 
 
Trt 
Time 7 0 7 27 34 45 53 83 
 
 
Number of Observations Read 546 
Number of Observations Used 484 
 
Dependent Variable: resp 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 20 6.28050221 0.31402511 15.49 <.0001 
Error 463 9.38741951 0.02027520   
Corrected Total 483 15.66792172    
 
R-Squared Coeff Var Root MSE Resp Mean 
0.400851 168.8652 0.142391 0.084322 
 
Source DF Type I SS Mean Square F Value Pr > F 
Trt 2 2.08139789 1.04069894 51.33 <.0001 
Time 6 1.78833006 0.29805501 14.70 <.0001 
Trt*Time 12 2.410774426 0.20089786 9.91 <.0001 
 
The input data follows.  On each page the data is arranged in three columns, each containing the ostrich 
identification number, treatment (Trt), time and response (Resp), read from top to bottom and left to right. 
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Ostrich Trt Time Resp 
353655 1 0 0.035 
353656 1 0 0.038 
353657 1 0 0.041 
353658 1 0 0.034 
353659 1 0 0.03 
353660 1 0 0.013 
353661 2 0 0 
353662 2 0 0 
353663 2 0 0 
353664 2 0 0.026 
353665 2 0 0 
353666 2 0 0.029 
353667 2 0 0.033 
353668 2 0 0.05 
353669 2 0 0.031 
353670 2 0 0.031 
353671 2 0 . 
353672 2 0 0.023 
353673 2 0 0.018 
353674 2 0 0.021 
353675 2 0 0.009 
353676 2 0 0.040 
353677 2 0 0.033 
353678 2 0 0.04 
353679 2 0 0.06 
353680 2 0 0.026 
353681 2 0 0.066 
353682 2 0 0.043 
353683 2 0 0.046 
353684 2 0 0.044 
353685 2 0 0.047 
353686 2 0 0.057 
353687 2 0 0.021 
353688 2 0 0.03 
353689 2 0 0.021 
353690 2 0 0.019 
353691 3 0 0 
353692 3 0 0.028 
353693 3 0 0.026 
353694 3 0 0.04 
353695 3 0 0.048 
353696 3 0 0.04 
353697 3 0 0.042 
353698 3 0 0.023 
353699 3 0 0.02 
353700 3 0 0.037 
353701 3 0 0.024 
353702 3 0 0.014 
353703 3 0 0.033 
353704 3 0 0.033 
353705 3 0 0.022 
353706 3 0 0.033 
353707 3 0 0.025 
353708 3 0 0.04 
353709 3 0 0.049 
353710 3 0 0.026 
353711 3 0 0.016 
353712 3 0 0.014 
353713 3 0 0.036 
353714 3 0 0.012 
353715 3 0 0.018 
353716 3 0 0.009 
353717 3 0 0.009 
353718 3 0 0.026 
353719 3 0 0.012 
353720 3 0 0.024 
353721 1 0 0.001 
353722 1 0 0.025 
353723 1 0 0.016 
353724 1 0 0.043 
353725 1 0 0.02 
353726 1 0 0.022 
353727 1 0 0.043 
353728 1 0 0.028 
353729 1 0 0.01 
353730 1 0 0.011 
353731 1 0 0 
353732 1 0 0.006 
353655 1 7 0.012 
353656 1 7 0.025 
353657 1 7 0 
353658 1 7 0.032 
353659 1 7 0.034 
353660 1 7 0.028 
353661 2 7 0.003 
353662 2 7 0 
353663 2 7 0.001 
353664 2 7 0 
353665 2 7 0.046 
353666 2 7 0.025 
353667 2 7 0.012 
353668 2 7 . 
353669 2 7 0.014 
353670 2 7 0.012 
353671 2 7 0.004 
353672 2 7 0 
353673 2 7 0.008 
353674 2 7 0 
353675 2 7 0.028 
353676 2 7 0.013 
353677 2 7 0.008 
353678 2 7 0.007 
353679 2 7 0.015 
353680 2 7 0.011 
353681 2 7 0.047 
353682 2 7 0.037 
353683 2 7 0.021 
353684 2 7 0.037 
353685 2 7 0.032 
353686 2 7 0.027 
353687 2 7 . 
353688 2 7 0.025 
353689 2 7 0.027 
353690 2 7 . 
353691 3 7 0 
353692 3 7 . 
353693 3 7 0.01 
353694 3 7 0.019 
353695 3 7 0.037 
353696 3 7 0.018 
353697 3 7 0.024 
353698 3 7 0.02 
353699 3 7 0.013 
353700 3 7 0.017 
353701 3 7 . 
353702 3 7 0.015 353703 3 7 0.001 
353704 3 7 0.017 
353705 3 7 0.02 
353706 3 7 0.020 
353707 3 7 0.014 
353708 3 7 0.014 
353709 3 7 0.033 
353710 3 7 0.036 
353711 3 7 0.021 
353712 3 7 0.015 
353713 3 7 0.015 
353714 3 7 0.034 
353715 3 7 0.036 
353716 3 7 0.023 
353717 3 7 0.022 
353718 3 7 0.029 
353719 3 7 0.034 
353720 3 7 0.02 
353721 1 7 0.022 
353722 1 7 0.028 
353723 1 7 0.006 
353724 1 7 0.011 
353725 1 7 0.025 
353726 1 7 0.021 
353727 1 7 0.02 
353728 1 7 0.018 
353729 1 7 0.016 
353730 1 7 0 
353731 1 7 0.006 
353732 1 7 0 
353655 1 27 0.013 
353656 1 27 0.058 
353657 1 27 0.07 
353658 1 27 0.014 
353659 1 27 . 
353660 1 27 0.004 
353661 2 27 . 
353662 2 27 0.021 
353663 2 27 0.007 
353664 2 27 0 
353665 2 27 . 
353666 2 27 0 
353667 2 27 0 
353668 2 27 0.006 
353669 2 27 0.024 
353670 2 27 0.026 
353671 2 27 0.049 
353672 2 27 0.028 
353673 2 27 0.131 
353674 2 27 0.022 
353675 2 27 0.064 
353676 2 27 0.055 
353677 2 27 . 
353678 2 27 0.027 
353679 2 27 0.013 
353680 2 27 0.033 
353681 2 27 0.008 
353682 2 27 0.091 
353683 2 27 0.18 
353684 2 27 0.045 
353685 2 27 0.036 
353686 2 27 0.025 
Stellenbosch University  https://scholar.sun.ac.za
  
94
 
353687 2 27 0.068 
353688 2 27 0.026 
353689 2 27 0.114 
353690 2 27 0.158 
353691 3 27 0 
353692 3 27 0.011 
353693 3 27 0.023 
353694 3 27 0.06 
353695 3 27 0.047 
353696 3 27 0.021 
353697 3 27 . 
353698 3 27 0.047 
353699 3 27 0.039 
353700 3 27 0.036 
353701 3 27 . 
353702 3 27 0.017 
353703 3 27 0.007 
353704 3 27 0.044 
353705 3 27 0.015 
353706 3 27 0.01 
353707 3 27 0.029 
353708 3 27 0.006 
353709 3 27 . 
353710 3 27 . 
353711 3 27 0.005 
353712 3 27 0.008 
353713 3 27 0.038 
353714 3 27 0 
353715 3 27 0.01 
353716 3 27 . 
353717 3 27 0.062 
353718 3 27 0.004 
353719 3 27 0.041 
353720 3 27 0.022 
353721 1 27 0.076 
353722 1 27 0 
353723 1 27 0 
353724 1 27 0 
353725 1 27 0 
353726 1 27 0.033 
353727 1 27 0 
353728 1 27 0.035 
353729 1 27 0.003 
353730 1 27 0 
353731 1 27 0 
353732 1 27 0 
353655 1 34 0.045 
353656 1 34 0.048 
353657 1 34 . 
353658 1 34 0.076 
353659 1 34 0.024 
353660 1 34 0.029 
353661 2 34 0.039 
353662 2 34 0.044 
353663 2 34 0.861 
353664 2 34 0.036 
353665 2 34 . 
353666 2 34 0.028 
353667 2 34 0.044 
353668 2 34 0.406 
353669 2 34 0.037 
353670 2 34 0.102 
353671 2 34 0.102 
353672 2 34 0.115 
353673 2 34 0.207 
353674 2 34 0.067 
353675 2 34 0.072 
353676 2 34 0.052 
353677 2 34 . 
353678 2 34 0.041 
353679 2 34 0.044 
353680 2 34 0.05 
353681 2 34 0.021 
353682 2 34 0.067 
353683 2 34 0.209 
353684 2 34 0.063 
353685 2 34 0.136 
353686 2 34 0.067 
353687 2 34 0.181 
353688 2 34 0.069 
353689 2 34 0.043 
353690 2 34 0.559 
353691 3 34 0.024 
353692 3 34 . 
353693 3 34 0.031 
353694 3 34 0.016 
353695 3 34 0.037 
353696 3 34 0.016 
353697 3 34 . 
353698 3 34 0.012 
353699 3 34 0.026 
353700 3 34 0.021 
353701 3 34 . 
353702 3 34 0.055 
353703 3 34 0.006 
353704 3 34 0.015 
353705 3 34 0.01 
353706 3 34 . 
353707 3 34 0.01 
353708 3 34 0.024 
353709 3 34 0.039 
353710 3 34 0.031 
353711 3 34 0.041 
353712 3 34 0.028 
353713 3 34 0.048 
353714 3 34 0.042 
353715 3 34 0.04 
353716 3 34 0.044 
353717 3 34 0.268 
353718 3 34 0.02 
353719 3 34 0.04 
353720 3 34 0.047 
353721 1 34 0.02 
353722 1 34 0.038 
353723 1 34 0.017 
353724 1 34 0.061 
353725 1 34 . 
353726 1 34 0.053 
353727 1 34 0.042 
353728 1 34 0.052 
353729 1 34 0.033 
353730 1 34 0.05 
353731 1 34 . 
353732 1 34 0.022 
353655 1 45 0.012 
353656 1 45 0.013 
353657 1 45 0 353658 1 45 0.023 
353659 1 45 . 
353660 1 45 0.016 
353661 2 45 0 
353662 2 45 0.251 
353663 2 45 0.834 
353664 2 45 0.02 
353665 2 45 . 
353666 2 45 0.42 
353667 2 45 0.11 
353668 2 45 1.469 
353669 2 45 0.032 
353670 2 45 0.34 
353671 2 45 0.068 
353672 2 45 0.288 
353673 2 45 0.729 
353674 2 45 0.172 
353675 2 45 0.047 
353676 2 45 0.469 
353677 2 45 . 
353678 2 45 0.92 
353679 2 45 0.047 
353680 2 45 0.062 
353681 2 45 0.031 
353682 2 45 0.475 
353683 2 45 1.015 
353684 2 45 . 
353685 2 45 0.568 
353686 2 45 0.068 
353687 2 45 0.541 
353688 2 45 0.688 
353689 2 45 0.088 
353690 2 45 . 
353691 3 45 0.031 
353692 3 45 0.023 
353693 3 45 0.005 
353694 3 45 0.017 
353695 3 45 0.041 
353696 3 45 0.028 
353697 3 45 . 
353698 3 45 0.03 
353699 3 45 0.06 
353700 3 45 0.037 
353701 3 45 . 
353702 3 45 0.028 
353703 3 45 0.005 
353704 3 45 0.056 
353705 3 45 . 
353706 3 45 0.042 
353707 3 45 0.021 
353708 3 45 0.022 
353709 3 45 0.074 
353710 3 45 0.013 
353711 3 45 0.015 
353712 3 45 0.013 
353713 3 45 0.029 
353714 3 45 0.113 
353715 3 45 0.09 
353716 3 45 . 
353717 3 45 0.06 
353718 3 45 0.073 
353719 3 45 0.021 
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353720 3 45 0.044 
353721 1 45 0.004 
353722 1 45 0.056 
353723 1 45 0 
353724 1 45 0.007 
353725 1 45 . 
353726 1 45 0.017 
353727 1 45 0.029 
353728 1 45 0.034 
353729 1 45 0.013 
353730 1 45 0 
353731 1 45 0 
353732 1 45 0 
353655 1 53 0.01 
353656 1 53 . 
353657 1 53 . 
353658 1 53 0.014 
353659 1 53 . 
353660 1 53 0.007 
353661 2 53 0.217 
353662 2 53 0.319 
353663 2 53 0.91 
353664 2 53 0.048 
353665 2 53 . 
353666 2 53 0.426 
353667 2 53 0.129 
353668 2 53 1.271 
353669 2 53 0.486 
353670 2 53 0.19 
353671 2 53 0.139 
353672 2 53 0.245 
353673 2 53 1.08 
353674 2 53 . 
353675 2 53 0.156 
353676 2 53 0.868 
353677 2 53 . 
353678 2 53 0.457 
353679 2 53 0.101 
353680 2 53 0.088 
353681 2 53 0.076 
353682 2 53 0.662 
353683 2 53 0.454 
353684 2 53 0.086 
353685 2 53 0.257 
353686 2 53 0.077 
353687 2 53 0.836 
353688 2 53 0.749 
353689 2 53 0.064 
353690 2 53 . 
353691 3 53 0.03 
353692 3 53 . 
353693 3 53 0.046 
353694 3 53 0.048 
353695 3 53 0.079 
353696 3 53 0.019 
353697 3 53 . 
353698 3 53 0.046 
353699 3 53 0.041 
353700 3 53 0.087 
353701 3 53 . 
353702 3 53 0.006 
353703 3 53 0.006 
353704 3 53 0.011 
353705 3 53 0.019 
353706 3 53 . 
353707 3 53 0.02 
353708 3 53 0.011 
353709 3 53 0.037 
353710 3 53 0.007 
353711 3 53 0.036 
353712 3 53 0.008 
353713 3 53 0.018 
353714 3 53 0.009 
353715 3 53 0.018 
353716 3 53 0.036 
353717 3 53 0.341 
353718 3 53 0.011 
353719 3 53 0.048 
353720 3 53 0.064 
353721 1 53 0.001 
353722 1 53 0.016 
353723 1 53 0.004 
353724 1 53 0.023 
353725 1 53 . 
353726 1 53 0.021 
353727 1 53 0.008 
353728 1 53 0.021 
353729 1 53 0.02 
353730 1 53 0.024 
353731 1 53 0.053 
353732 1 53 0.055 
353655 1 83 0.075 
353656 1 83 . 
353657 1 83 0.013 
353658 1 83 0.016 
353659 1 83 . 
353660 1 83 0.015 
353661 2 83 0.158 
353662 2 83 0.25 
353663 2 83 0.17 
353664 2 83 . 
353665 2 83 . 
353666 2 83 0.376 
353667 2 83 0.034 
353668 2 83 0.313 
353669 2 83 0.183 
353670 2 83 0.177 
353671 2 83 0.124 
353672 2 83 . 
353673 2 83 0.064 
353674 2 83 . 
353675 2 83 0.141 
353676 2  
83
. 
353677 2 83 . 
353678 2 83 0.121 
353679 2 83 0.05 
353680 2 83 0.03 353681 2 83 0.057 
353682 2 83 0.174 
353683 2 83 0.111 
353684 2 83 0.109 
353685 2 83 . 
353686 2 83 0.083 
353687 2 83 1.221 
353688 2 83 0.267 
353689 2 83 0.045 
353690 2 83 0.36 
353691 3 83 0.049 
353692 3 83 0.084 
353693 3 83 0.06 
353694 3 83 0.023 
353695 3 83 . 
353696 3 83 0.034 
353697 3 83 . 
353698 3 83 0.045 
353699 3 83 0.084 
353700 3 83 0.044 
353701 3 83 . 
353702 3 83 0.054 
353703 3 83 0.036 
353704 3 83 0.041 
353705 3 83 0.046 
353706 3 83 . 
353707 3 83 0.088 
353708 3 83 0.068 
353709 3 83 0.059 
353710 3 83 0.057 
353711 3 83 0.037 
353712 3 83 0.072 
353713 3 83 0.097 
353714 3 83 0.1 
353715 3 83 . 
353716 3 83 0.06 
353717 3 83 0.074 
353718 3 83 0.12 
353719 3 83 0.154 
353720 3 83 0.029 
353721 1 83 0.049 
353722 1 83 0.084 
353723 1 83 0.073 
353724 1 83 0.086 
353725 1 83 . 
353726 1 83 0.034 
353727 1 83 0.155 
353728 1 83 0.075 
353729 1 83 0.075 
353730 1 83 . 
353731 1 83 0.097 
353732 1 83 0.067 
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Schoeman (MG) 
 
Vaccine trials with poultry mycoplasma vaccines in ostriches on the Schoeman farmstead:  Statistical 
analysis of ELISA data, obtained with MG Antibody Test kits, using the Statistical Analysis System 
(SAS, Cary, NC) program (version 6.2). 
Statistical analysis: 
The General Linear Models (GLM) Procedure 
Class Level Information 
Class Levels Values 
3 1 2 3 
 
Trt 
Time 7 0 7 27 34 45 53 83 
 
 
Number of Observations Read 546 
Number of Observations Used 484 
 
Dependent Variable: Resp 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 20 62.94947986 3.14747399 72.86 <.0001 
Error 463 20.00172520 0.04320027   
Corrected Total 483 82.95120507    
 
R-Squared Coeff Var Root MSE Resp Mean 
0.758874 80.35612 0.207847 0.258657 
 
Source DF Type I SS Mean Square F Value Pr > F 
Trt 2 29.69179881 14.84589941 343.65 <.0001 
Time 6 13.98058427 2.33009738 53.94 <.0001 
Trt*Time 12 19.27709678 1.60642473 37.19 <.0001 
 
The input data follows.  On each page the data is arranged in three columns, each containing the ostrich 
identification number, treatment (Trt), time and response (Resp), read from top to bottom and left to right. 
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Ostrich Trt Time Resp 
353655 1 0 0.09 
353656 1 0 0.022 
353657 1 0 0.049 
353658 1 0 0.007 
353659 1 0 0.014 
353660 1 0 0.015 
353661 2 0 0.021 
353662 2 0 0.016 
353663 2 0 0.028 
353664 2 0 0.098 
353665 2 0 0.009 
353666 2 0 0.047 
353667 2 0 0.04 
353668 2 0 0.022 
353669 2 0 0.022 
353670 2 0 0.009 
353671 2 0 . 
353672 2 0 0.003 
353673 2 0 0.001 
353674 2 0 0.026 
353675 2 0 0 
353676 2 0 0.062 
353677 2 0 0.057 
353678 2 0 0.08 
353679 2 0 0.085 
353680 2 0 0.061 
353681 2 0 0.119 
353682 2 0 0.064 
353683 2 0 0.088 
353684 2 0 0.093 
353685 2 0 0.079 
353686 2 0 0.116 
353687 2 0 0.064 
353688 2 0 0.061 
353689 2 0 0.054 
353690 2 0 0.05 
353691 3 0 0 
353692 3 0 0 
353693 3 0 0.027 
353694 3 0 0.047 
353695 3 0 0.016 
353696 3 0 0.015 
353697 3 0 0.013 
353698 3 0 0.012 
353699 3 0 0 
353700 3 0 0 
353701 3 0 0 
353702 3 0 0 
353703 3 0 0.012 
353704 3 0 0.09 
353705 3 0 0.089 
353706 3 0 0.081 
353707 3 0 0.097 
353708 3 0 0.12 
353709 3 0 0.094 
353710 3 0 0.043 
353711 3 0 0.062 
353712 3 0 0.055 
353713 3 0 0.084 
353714 3 0 0.075 
353715 3 0 0.051 
353716 3 0 0.072 
353717 3 0 0.017 
353718 3 0 0.098 
353719 3 0 0.122 
353720 3 0 0.088 
353721 1 0 0.016 
353722 1 0 0.041 
353723 1 0 0.002 
353724 1 0 0.026 
353725 1 0 0.08 
353726 1 0 0.056 
353727 1 0 0.048 
353728 1 0 0.039 
353729 1 0 0.059 
353730 1 0 0.055 
353731 1 0 0.023 
353732 1 0 0.035 
353655 1 7 0.074 
353656 1 7 0.029 
353657 1 7 0.039 
353658 1 7 0.023 
353659 1 7 0.039 
353660 1 7 0.024 
353661 2 7 0.028 
353662 2 7 0.042 
353663 2 7 0.028 
353664 2 7 0.035 
353665 2 7 0.053 
353666 2 7 0.105 
353667 2 7 0.056 
353668 2 7 . 
353669 2 7 0.051 
353670 2 7 0.035 
353671 2 7 0.063 
353672 2 7 0.026 
353673 2 7 0.058 
353674 2 7 0.024 
353675 2 7 0.024 
353676 2 7 0.038 
353677 2 7 0.068 
353678 2 7 0.047 
353679 2 7 0.004 
353680 2 7 0.033 
353681 2 7 0.087 
353682 2 7 0.044 
353683 2 7 0.043 
353684 2 7 0.099 
353685 2 7 0.053 
353686 2 7 0.081 
353687 2 7 . 
353688 2 7 0.09 
353689 2 7 0.059 
353690 2 7 . 
353691 3 7 0.062 
353692 3 7 . 
353693 3 7 0.051 
353694 3 7 0.042 
353695 3 7 0.01 
353696 3 7 0.015 
353697 3 7 0.016 
353698 3 7 0.027 
353699 3 7 0.014 
353700 3 7 0.021 
353701 3 7 . 
353702 3 7 0.011 
353703 3 7 0.011 
353704 3 7 0.004 
353705 3 7 0.007 
353706 3 7 0.076 
353707 3 7 0.055 
353708 3 7 0.094 
353709 3 7 0.138 
353710 3 7 0.047 
353711 3 7 0.08 
353712 3 7 0.056 
353713 3 7 0.111 
353714 3 7 0.061 
353715 3 7 0.067 
353716 3 7 0.073 
353717 3 7 0.047 
353718 3 7 0.068 
353719 3 7 0.06 
353720 3 7 0.073 
353721 1 7 0.023 
353722 1 7 0.014 
353723 1 7 0.015 
353724 1 7 0.018 
353725 1 7 0.026 
353726 1 7 0.028 
353727 1 7 0.031 
353728 1 7 0.062 
353729 1 7 0.067 
353730 1 7 0.024 
353731 1 7 0.024 
353732 1 7 0.045 
353655 1 27 0.073 
353656 1 27 0.079 
353657 1 27 0.013 
353658 1 27 0.028 
353659 1 27 . 
353660 1 27 0.027 
353661 2 27 . 
353662 2 27 0.001 
353663 2 27 0 
353664 2 27 0.02 
353665 2 27 . 
353666 2 27 0 
353667 2 27 0.009 
353668 2 27 0.035 
353669 2 27 0 
353670 2 27 0 
353671 2 27 0 
353672 2 27 0 
353673 2 27 0 
353674 2 27 0 
353675 2 27 0.001 
353676 2 27 0.058 
353677 2 27 . 
353678 2 27 0.076 
353679 2 27 0.089 
353680 2 27 0.07 
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353681 2 27 0.043 
353682 2 27 0.061 
353683 2 27 0.066 
353684 2 27 0.142 
353685 2 27 0.081 
353686 2 27 0.054 
353687 2 27 0.054 
353688 2 27 0.084 
353689 2 27 0.057 
353690 2 27 0.054 
353691 3 27 0.628 
353692 3 27 0.194 
353693 3 27 0.333 
353694 3 27 0.616 
353695 3 27 1.046 
353696 3 27 0.597 
353697 3 27 . 
353698 3 27 0.873 
353699 3 27 0.886 
353700 3 27 0.125 
353701 3 27 . 
353702 3 27 0.133 
353703 3 27 0.278 
353704 3 27 0.846 
353705 3 27 1.035 
353706 3 27 0.97 
353707 3 27 0.675 
353708 3 27 0.282 
353709 3 27 . 
353710 3 27 . 
353711 3 27 1.974 
353712 3 27 0.346 
353713 3 27 0.535 
353714 3 27 0.803 
353715 3 27 0.49 
353716 3 27 . 
353717 3 27 0.447 
353718 3 27 0.369 
353719 3 27 0.387 
353720 3 27 0.772 
353721 1 27 0.037 
353722 1 27 0.035 
353723 1 27 0.033 
353724 1 27 0.016 
353725 1 27 0.011 
353726 1 27 0.009 
353727 1 27 0.013 
353728 1 27 0.015 
353729 1 27 0.034 
353730 1 27 0.017 
353731 1 27 0.081 
353732 1 27 0.001 
353655 1 34 0.07 
353656 1 34 0.009 
353657 1 34 . 
353658 1 34 0.042 
353659 1 34 0.003 
353660 1 34 0.009 
353661 2 34 0 
353662 2 34 0 
353663 2 34 0.003 
353664 2 34 0.003 
353665 2 34 . 
353666 2 34 0 
353667 2 34 0 
353668 2 34 0 
353669 2 34 0.052 
353670 2 34 0.059 
353671 2 34 0 
353672 2 34 0 
353673 2 34 0 
353674 2 34 0 
353675 2 34 0 
353676 2 34 0.048 
353677 2 34 . 
353678 2 34 0.053 
353679 2 34 0.052 
353680 2 34 0.087 
353681 2 34 0.065 
353682 2 34 0.065 
353683 2 34 0.086 
353684 2 34 0.191 
353685 2 34 0.114 
353686 2 34 0.089 
353687 2 34 0.126 
353688 2 34 0.056 
353689 2 34 0.058 
353690 2 34 0.03 
353691 3 34 0.504 
353692 3 34 . 
353693 3 34 0.729 
353694 3 34 0.819 
353695 3 34 1.001 
353696 3 34 0.877 
353697 3 34 . 
353698 3 34 0.815 
353699 3 34 0.534 
353700 3 34 0.219 
353701 3 34 . 
353702 3 34 0.562 
353703 3 34 0.539 
353704 3 34 0.188 
353705 3 34 0.804 
353706 3 34 . 
353707 3 34 0.304 
353708 3 34 0.042 
353709 3 34 0 
353710 3 34 0.790 
353711 3 34 1.55 
353712 3 34 0.547 
353713 3 34 0.767 
353714 3 34 0.84 
353715 3 34 0.843 
353716 3 34 1.266 
353717 3 34 0.674 
353718 3 34 0.643 
353719 3 34 0.707 
353720 3 34 0.573 
353721 1 34 0.008 
353722 1 34 0.054 
353723 1 34 0.023 
353724 1 34 0.021 
353725 1 34 . 
353726 1 34 0 
353727 1 34 0.017 
353728 1 34 0.087 
353729 1 34 0.051 30 15
353731 1 34 . 
353732 1 34 0.014 
353655 1 45 0.045 
353656 1 45 0.041 
353657 1 45 0.028 
353658 1 45 0.074 
353659 1 45 . 
353660 1 45 0.06 
353661 2 45 0.052 
353662 2 45 0.183 
353663 2 45 0.06 
353664 2 45 0.103 
353665 2 45 . 
353666 2 45 0.082 
353667 2 45 0.046 
353668 2 45 0.087 
353669 2 45 0.072 
353670 2 45 0.132 
353671 2 45 0.106 
353672 2 45 0.093 
353673 2 45 0.067 
353674 2 45 0.169 
353675 2 45 0.07 
353676 2 45 0.097 
353677 2 45 . 
353678 2 45 0.102 
353679 2 45 0.053 
353680 2 45 0.07 
353681 2 45 0.062 
353682 2 45 0.072 
353683 2 45 0.057 
353684 2 45 . 
353685 2 45 0.12 
353686 2 45 0.05 
353687 2 45 0.078 
353688 2 45 0.104 
353689 2 45 0.102 
353690 2 45 . 
353691 3 45 0.727 
353692 3 45 1.11 
353693 3 45 1.276 
353694 3 45 1.482 
353695 3 45 0.784 
353696 3 45 1.327 
353697 3 45 . 
353698 3 45 0.59 
353699 3 45 1.042 
353700 3 45 1.429 
353701 3 45 . 
353702 3 45 1.698 
353703 3 45 1.649 
353704 3 45 0.629 
353705 3 45 . 
353706 3 45 0.721 
353707 3 45 0.481 
353708 3 45 1.231 
353709 3 45 0.137 
353710 3 45 1.061 
353711 3 45 1.276 
353712 3 45 1.745 
353713 3 45 1.847 
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353714 3 45 0.02 
353715 3 45 1.584 
353716 3 45 . 
353717 3 45 1.055 
353718 3 45 1.022 
353719 3 45 0.466 
353720 3 45 1.572 
353721 1 45 0.025 
353722 1 45 0.079 
353723 1 45 0.014 
353724 1 45 0.029 
353725 1 45 . 
353726 1 45 0.025 
353727 1 45 0.09 
353728 1 45 0.128 
353729 1 45 0.092 
353730 1 45 0.039 
353731 1 45 0.046 
353732 1 45 0.047 
353655 1 53 0.035 
353656 1 53 . 
353657 1 53 . 
353658 1 53 0.07 
353659 1 53 . 
353660 1 53 0.068 
353661 2 53 0.056 
353662 2 53 0.125 
353663 2 53 0.279 
353664 2 53 0.095 
353665 2 53 . 
353666 2 53 0.036 
353667 2 53 0.071 
353668 2 53 0.047 
353669 2 53 0.085 
353670 2 53 0.072 
353671 2 53 0.053 
353672 2 53 0.031 
353673 2 53 0.093 
353674 2 53 . 
353675 2 53 0.079 
353676 2 53 0.07 
353677 2 53 . 
353678 2 53 0.107 
353679 2 53 0.018 
353680 2 53 0.048 
353681 2 53 0.078 
353682 2 53 0.085 
353683 2 53 0.076 
353684 2 53 0.052 
353685 2 53 0.141 
353686 2 53 0.047 
353687 2 53 0.14 
353688 2 53 0.079 
353689 2 53 0.037 
353690 2 53 . 
353691 3 53 0.955 
353692 3 53 . 
353693 3 53 0.935 
353694 3 53 1.365 
353695 3 53 1.236 
353696 3 53 1.132 
353697 3 53 . 
353698 3 53 1.638 
353699 3 53 1.194 
353700 3 53 1.322 
353701 3 53 . 
353702 3 53 1.304 
353703 3 53 1.918 
353704 3 53 0.699 
353705 3 53 0.651 
353706 3 53 . 
353707 3 53 0.699 
353708 3 53 1.377 
353709 3 53 0.112 
353710 3 53 1.277 
353711 3 53 1.08 
353712 3 53 1.436 
353713 3 53 1.731 
353714 3 53 1.308 
353715 3 53 1.68 
353716 3 53 1.669 
353717 3 53 1.112 
353718 3 53 1.351 
353719 3 53 0.31 
353720 3 53 1.513 
353721 1 53 0.037 
353722 1 53 0.086 
353723 1 53 0.027 
353724 1 53 0.103 
353725 1 53 . 
353726 1 53 0.121 
353727 1 53 0.073 
353728 1 53 0.423 
353729 1 53 0 
353730 1 53 0.015 
353731 1 53 0.289 
353732 1 53 0.044 
353655 1 83 0.087 
353656 1 83 . 
353657 1 83 0.066 
353658 1 83 0.068 
353659 1 83 . 
353660 1 83 0.46 
353661 2 83 0.123 
353662 2 83 0.217 
353663 2 83 0.086 
353664 2 83 . 
353665 2 83 . 
353666 2 83 0.094 
353667 2 83 0.069 
353668 2 83 0.108 
353669 2 83 0.137 
353670 2 83 0.114 
353671 2 83 0.162 
353672 2 83 . 
353673 2 83 0.171 
353674 2 83 . 
353675 2 83 0.102 
353676 2 83 . 
353677 2 83 . 
353678 2 83 0.067 
353679 2 83 0.077 
353680 2 83 0.072 
353681 2 83 0.163 
353682 2 83 0.1 
353683 2 83 0.101 
353684 2 83 0.125 5 . 
353686 2 83 0.105 
353687 2 83 0.089 
353688 2 83 0.147 
353689 2 83 0.06 
353690 2 83 0.119 
353691 3 83 0.445 
353692 3 83 0.315 
353693 3 83 1.157 
353694 3 83 0.433 
353695 3 83 . 
353696 3 83 0.3 
353697 3 83 . 
353698 3 83 0.441 
353699 3 83 0.791 
353700 3 83 0.307 
353701 3 83 . 
353702 3 83 0.962 
353703 3 83 0.965 
353704 3 83 0.462 
353705 3 83 0.411 
353706 3 83 . 
353707 3 83 0.439 
353708 3 83 0.247 
353709 3 83 0.121 
353710 3 83 0.76 
353711 3 83 0.546 
353712 3 83 0.344 
353713 3 83 0.358 
353714 3 83 0.465 
353715 3 83 . 
353716 3 83 0.455 
353717 3 83 0.226 
353718 3 83 0.336 
353719 3 83 0.179 
353720 3 83 0.336 
353721 1 83 0.082 
353722 1 83 0.089 
353723 1 83 0.126 
353724 1 83 0.196 
353725 1 83 . 
353726 1 83 0.061 
353727 1 83 0.056 
353728 1 83 0.25 
353729 1 83 0.098 
353730 1 83 . 
353731 1 83 0.382 
353732 1 83 0.131 
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SD-like sequence Initiation codon 
site 1 
Signal peptide II  
recognition site and lipoprotein attachment site
Oligopeptide binding domain
-35 box -10 box 
Addendum B  Nucleotide/amino acid sequence of the P100 gene of Ms01 
The nucleotide and translated amino acid sequences of the P100 gene of Ms01 before modification by 
SDM.  Indicated on the sequence are the consensus translation promoter areas in green, the translation 
initiation and termination codons in blue, as well as the signal peptide II recognition site with the cystein 
lipoprotein attachment site in bold, and the highly conserved Walker A and B motifs in grey.  Also 
indicated are the ten sites destined for modification by SDM in yellow. 
 
1     TAG TGT ATT ATC GGT TTA TAA ATT ATT TAA TTT ATA ACA TAC ACA   45 
                                                
 
46    CAT TAG GAG AAA AAA ATG AAA AAA aGC GCA AGA CTT TTA TTA TTA   90 
                          Met Lys Lys Ser Ala Arg Leu Leu Leu Leu    
 
91    GGT GCT TTA CCA TTA GCA GCC TTA GCA GCT CCA TTA GTT GCT GCG   135 
      Gly Ala Leu Pro Leu Ala Ala Leu Ala Ala Pro Leu Val Ala Ala    
 
136   GCA TGT AAT AGT AAA TCA GCC CCT TCG CAG AAC ACT GCT TTA GCT   180 
      Ala Cys Asn Ser Lys Ser Ala Pro Ser Gln Asn Thr Ala Leu Ala    
 
181   AAA CAG CAG TTC GTT ACT GAA ATA AAC GCA ACA CCA ACA TTT GAT   225 
      Lys Gln Gln Phe Val Thr Glu Ile Asn Ala Thr Pro Thr Phe Asp    
 
226   GCT TAT ACA TAT GAT AGT TCA GCT TCA TAT GGT GGA TAT TCT TCA   270 
      Ala Tyr Thr Tyr Asp Ser Ser Ala Ser Tyr Gly Gly Tyr Ser Ser    
 
271   AAT GCT AGC TAC CAA CAC ACA TCA GGT ATG TTA GTT AGA GAA CAA   315 
      Asn Ala Ser Tyr Gln His Thr Ser Gly Met Leu Val Arg Glu Gln    
 
316   GGT GTT AAT GAA ATT CAA ATT GAT ACA GTG ACC TCA GAC ACT GGA   360 
      Gly Val Asn Glu Ile Gln Ile Asp Thr Val Thr Ser Asp Thr Gly    
 
361   AAA GTT TCA AAC TAT ATT ACT AAA CCA GCT TTC TCA AAA TAT ACA   405 
      Lys Val Ser Asn Tyr Ile Thr Lys Pro Ala Phe Ser Lys Tyr Thr    
 
406   TTA TCA TTA GCA AAA GCT GTA GTT TTA ACT TTA ACA GAT GGC ACA   450 
      Leu Ser Leu Ala Lys Ala Val Val Leu Thr Leu Thr Asp Gly Thr    
 
451   GTT GTA GTT TAC GAT AAT GAT GAT GCT GAA GTT GTT CCT GCA CCA   495 
      Val Val Val Tyr Asp Asn Asp Asp Ala Glu Val Val Pro Ala Pro    
 
496   GAT TTA ACT TAT GTA GAT GCT GCA GGT GAA ACT AAA AAA GCT TAT   540 
      Asp Leu Thr Tyr Val Asp Ala Ala Gly Glu Thr Lys Lys Ala Tyr    
 
541   TCA TCA GCA TAT CAA AGA TTA AGT TCA GCA AAT TCA AAA TCA ATT   585 
      Ser Ser Ala Tyr Gln Arg Leu Ser Ser Ala Asn Ser Lys Ser Ile    
 
586   AAT AGT CAA GAA TTT GCA GAA AAC TTG AAA AAA GCT AAA ACA TTA   630 
      Asn Ser Gln Glu Phe Ala Glu Asn Leu Lys Lys Ala Lys Thr Leu    
 
631   CAA TAT GTA CTT AAA GAC AAT TTA AAA TGA GTA AAT TCA AAA GGT   675 
      Gln Tyr Val Leu Lys Asp Asn Leu Lys End Val Asn Ser Lys Gly    
 
676   GAA GAA ACT AAA TAT CAA ATT GTT CCT AAA GAT TTC TAT TAT TCA   720 
      Glu Glu Thr Lys Tyr Gln Ile Val Pro Lys Asp Phe Tyr Tyr Ser    
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site 2 
site 3 
721   TGA CTA AGA ACA AAT CAA ACA ATT GGT AAT GTT CGT CAT GAT GAA   765 
      End Leu Arg Thr Asn Gln Thr Ile Gly Asn Val Arg His Asp Glu    
 
766   GAA AAA AGT GGA GGT TCA GAA CAA TTA GAC AAT GAA GTT AGA GAT   810 
      Glu Lys Ser Gly Gly Ser Glu Gln Leu Asp Asn Glu Val Arg Asp    
 
811   GCA TTA GCA AGA CCT AAC AGT CGT GTA TTT ACA GAT ACA AGT GAA   855 
      Ala Leu Ala Arg Pro Asn Ser Arg Val Phe Thr Asp Thr Ser Glu    
 
856   TAC TCA AAT GAA TAT GTT TTA AAA ATC TTT GGT TTA GAT ACA GTA   900 
      Tyr Ser Asn Glu Tyr Val Leu Lys Ile Phe Gly Leu Asp Thr Val    
 
901   AAA TTA AAT GAA GAA AGT GAA TTC GTT AAA AAA GTT GCT CCA AGT   945 
      Lys Leu Asn Glu Glu Ser Glu Phe Val Lys Lys Val Ala Pro Ser    
 
946   GCA AAT TTA GGA GAT GTA ACA GCT GTA ACC TTC CAA GGA TTA ACA   990 
      Ala Asn Leu Gly Asp Val Thr Ala Val Thr Phe Gln Gly Leu Thr    
 
991   GGT GAA GGT GCT AAA GTT CAA ATG AAT CAA TTT TTT GAT CAA TTA   1035 
      Gly Glu Gly Ala Lys Val Gln Met Asn Gln Phe Phe Asp Gln Leu    
 
1036  ATG CAT GAC TAT ACA TTC TAT CCA GCT CCA TCA CAA TAC ATT GAT   1080 
      Met His Asp Tyr Thr Phe Tyr Pro Ala Pro Ser Gln Tyr Ile Asp    
 
1081  GAT ATG AAT GCA ACA AAT GGT TAC AAA TTA ACT AAT TAC CAA GGC   1125 
      Asp Met Asn Ala Thr Asn Gly Tyr Lys Leu Thr Asn Tyr Gln Gly    
 
1126  GAT GTA ACT GAT AAA GTT TCT GCA CTA GAA ACT AAA TCA AAA GCA   1170 
      Asp Val Thr Asp Lys Val Ser Ala Leu Glu Thr Lys Ser Lys Ala    
 
1171  ATG GAT AAA AGT AAA TTA ACT GCT AAA TTA GGT GTT TAC TGA TAT   1215 
      Met Asp Lys Ser Lys Leu Thr Ala Lys Leu Gly Val Tyr End Tyr    
 
1216  GGT GTA ACA GCA AAT AGT ACA TTG TAT TCA GGA CCA TAC TAT GCA   1260 
      Gly Val Thr Ala Asn Ser Thr Leu Tyr Ser Gly Pro Tyr Tyr Ala    
 
1261  CAA GGC TTT GTA AGT GGT CAA TCA GAA ATA TTT AAA AAG AAT ACT   1305 
      Gln Gly Phe Val Ser Gly Gln Ser Glu Ile Phe Lys Lys Asn Thr    
 
1306  CAC TTT GCA GAA AAA GCC TTT GCA GAA TCT AAA AAT ACA GTT AAT   1350 
      His Phe Ala Glu Lys Ala Phe Ala Glu Ser Lys Asn Thr Val Asn    
 
1351  GAA aTT ATT ACA AAC TAT CAA CAA AAA ACC TTA AGC CCT GAA GAA   1395 
      Glu Ile Ile Thr Asn Tyr Gln Gln Lys Thr Leu Ser Pro Glu Glu    
 
1396  TTT AAT ACA AAC ATC TTT AAC TTA TAT AGA CAA GGT ACT ACA TCA   1440 
      Phe Asn Thr Asn Ile Phe Asn Leu Tyr Arg Gln Gly Thr Thr Ser    
 
1441  ACT ACT CCA TAT TCA TCA TTA ACT GAA GCT CAA AAA CAA ATC GTT   1485 
      Thr Thr Pro Tyr Ser Ser Leu Thr Glu Ala Gln Lys Gln Ile Val    
 
1486  AAC CAA GAC CCA CAA GGA TTT GGT ATT AGA TTA TTC AAA AGA GAA   1530 
      Asn Gln Asp Pro Gln Gly Phe Gly Ile Arg Leu Phe Lys Arg Glu    
 
1531  AAT ACT AAT TCA GCT CCT TAT GAT ATA ATC CAA ACT CCA TTT GTG   1575 
      Asn Thr Asn Ser Ala Pro Tyr Asp Ile Ile Gln Thr Pro Phe Val    
 
1576  TTT AAC AAT GTT ACT GCA GAT TAC TCA TTT AAC GAT GCT TAT GCT   1620 
      Phe Asn Asn Val Thr Ala Asp Tyr Ser Phe Asn Asp Ala Tyr Ala    
 
 
1621  CAA TTA ATG TAT GGT AAA ACA ATA GAA GAA TTA AAA GCC GGA AAA   1665 
      Gln Leu Met Tyr Gly Lys Thr Ile Glu Glu Leu Lys Ala Gly Lys    
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site 4 
site 5 
site 6 
site 7 
site 8 
Walker B motif
Walker A motif
 
1666  GGT ACA GGA GAT GCT TAT ATT TAC GGA ACA GGT TTA AGT TTT AGA   1710 
      Gly Thr Gly Asp Ala Tyr Ile Tyr Gly Thr Gly Leu Ser Phe Arg    
 
1711  ACT TTA TTA CAA GCT GCA ATT AAC TGA AAT ACA GTA GCA GAT GTA   1755 
      Thr Leu Leu Gln Ala Ala Ile Asn End Asn Thr Val Ala Asp Val    
 
1756  AGA ACA AAC GGT GTT TCA GAA GCT TGA TTG GCG AAA TTA GCC GAT   1800 
      Arg Thr Asn Gly Val Ser Glu Ala End Leu Ala Lys Leu Ala Asp    
 
1801  GGT GGT AAT ATT GGT GGA AAA GAC CAA GAA TCA TCA GCA GAA AAA   1845 
      Gly Gly Asn Ile Gly Gly Lys Asp Gln Glu Ser Ser Ala Glu Lys    
 
1846  aCA CCA TTT GAT GTA AAA GAT AAA ATT AAT GCA TTG AAA GCT GTA   1890 
      Thr Pro Phe Asp Val Lys Asp Lys Ile Asn Ala Leu Lys Ala Val    
 
1891  AAT AAA GAT AAA CAA TTA GTG GAC TTC GGT GGC AAT TTA GGA AAA   1935 
      Asn Lys Asp Lys Gln Leu Val Asp Phe Gly Gly Asn Leu Gly Lys    
 
1936  GAT CTA AAC CCA TCA GAA AAC GAT GCT GCT GTT AGA GAC AGA TCT   1980 
      Asp Leu Asn Pro Ser Glu Asn Asp Ala Ala Val Arg Asp Arg Ser    
 
1981  AAT GTC AAC GAC AAA ATA AAA TCA GCT GGT TAT GAA AAA ATT AAA   2025 
      Asn Val Asn Asp Lys Ile Lys Ser Ala Gly Tyr Glu Lys Ile Lys    
 
2026  GAA GCT GTA AAA GCA TTA TTA GAT GAG TTT GAA AGA ACA CAT CAA   2070 
      Glu Ala Val Lys Ala Leu Leu Asp Glu Phe Glu Arg Thr His Gln    
 
2071  AAT GTT AGA CCG GCA GAT GGT AAA TAT AGA TTC ACT TCA TTC TAT   2115 
      Asn Val Arg Pro Ala Asp Gly Lys Tyr Arg Phe Thr Ser Phe Tyr    
 
2116  CCA TTT ATT AAT CAA TCA AAA GAA TTT GGT GAA TCA TTA AAA TTT   2160 
      Pro Phe Ile Asn Gln Ser Lys Glu Phe Gly Glu Ser Leu Lys Phe    
 
2161  GTT AAA GAG GCT ATA GAA GGA TTA GAT TCT AGA ATT CAA TTA GAT   2205 
      Val Lys Glu Ala Ile Glu Gly Leu Asp Ser Arg Ile Gln Leu Asp    
 
2206  TTA GTA TTC TTT ACT GAT AAT AAA GAT CCT AAT TAT GTT GCA TAT   2250 
      Leu Val Phe Phe Thr Asp Asn Lys Asp Pro Asn Tyr Val Ala Tyr    
 
2251  ATA AAC CAA GGA GCA AAT GGA ACA AGA AAC GTT GGT TGA AGT TAT   2295 
      Ile Asn Gln Gly Ala Asn Gly Thr Arg Asn Val Gly End Ser Tyr    
 
2296  GAC TAT AAC TCA ATA GGT TCA GGT TAT GAT GGT TTA TCA TGA AAT   2340 
      Asp Tyr Asn Ser Ile Gly Ser Gly Tyr Asp Gly Leu Ser End Asn    
 
2341  TGA CCA TTA TTC CCA ACT CTA ATT AAA ATT GGT GTT GAA AAA GAT   2385 
      End Pro Leu Phe Pro Thr Leu Ile Lys Ile Gly Val Glu Lys Asp    
 
2386  AGT CAT CCA GAA TTT GCT ACT GCA TTT CCA AGA ATC GCT AAA TTA   2430 
      Ser His Pro Glu Phe Ala Thr Ala Phe Pro Arg Ile Ala Lys Leu    
 
2431  GCA GAA GAT TTA TTA GCT TAT CAA GAA CAA CCA GGT CAC GAA TTT   2475 
      Ala Glu Asp Leu Leu Ala Tyr Gln Glu Gln Pro Gly His Glu Phe    
 
2476  GTA TCT TCA GTA CCA TTT AAA GAA TTA TAC AAA GTA GAA CCA AGA   2520 
      Val Ser Ser Val Pro Phe Lys Glu Leu Tyr Lys Val Glu Pro Arg    
 
2521  AGA TAC ACA GTA TTG CCT ACT CTA TTA GCT TCA AAT GTT ACA AAA   2565 
      Arg Tyr Thr Val Leu Pro Thr Leu Leu Ala Ser Asn Val Thr Lys    
 
2566  AAT TCT GTA ACA GAT AAA TAT GAG CTT GTT TTA ACA GAA AAA AAT   2610 
      Asn Ser Val Thr Asp Lys Tyr Glu Leu Val Leu Thr Glu Lys Asn    
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site 9 
site 10 
Termination codon 
 
2611  AGA CCA ATA CCT TAT AAA CCA CAA GGT AAT AAG CAA GTA ACT GAT   2655 
      Arg Pro Ile Pro Tyr Lys Pro Gln Gly Asn Lys Gln Val Thr Asp    
 
2656  ATT TAT CAA TAC TCA GCG GTT TTC TGA AAC CAA TAC GTA GCA GAC   2700 
      Ile Tyr Gln Tyr Ser Ala Val Phe End Asn Gln Tyr Val Ala Asp    
 
2701  AAA ACA AAT GAT TAT TTA ACT GAA TTA ATG GAA GAA CTA ACA ACA   2745 
      Lys Thr Asn Asp Tyr Leu Thr Glu Leu Met Glu Glu Leu Thr Thr    
 
2746  TTT TTA GGT ATT GAA TAT TCA TCA GCA ACT ATA ACA AAA GCA AAA   2790 
      Phe Leu Gly Ile Glu Tyr Ser Ser Ala Thr Ile Thr Lys Ala Lys    
 
2791  GAT TCA TTT GTT AAC GTT TTA GTA CAA AAA GGT TAT GTA GCA CCT   2835 
      Asp Ser Phe Val Asn Val Leu Val Gln Lys Gly Tyr Val Ala Pro    
 
2836  TAC ACA GTA AAT AAT AGT GTT GAC ATG TAT GTT GAT TGA AGA ATC   2880 
      Tyr Thr Val Asn Asn Ser Val Asp Met Tyr Val Asp End Arg Ile    
 
2881  AAT AAA TAA   2889 
      Asn Lys End  
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Addendum C Alignment of the P100 gene in Ms01 after SDM 
 
Alignments done in BioEdit of the P100 gene in Ms01 as obtained by sequencing after the modification 
of each of the ten TGA codons to TGG codons by site-directed mutagenesis. 
 
                       10        20        30        40        50        60        70        80        90       100                   
              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     ~~~~~~ATGAAAAAAaGCGCAAGACTTTTATTATTAGGTGCTTTACCATTAGCAGCCTTAGCAGCTCCATTAGTTGCTGCGGCATGTAATAGTAAATCAG  
SDM site 1    ACGCGT..............................................................................................  
SDM site 2    ACGCGT..............................................................................................  
SDM site 3    ACGCGT..............................................................................................  
SDM site 4    ACGCGT..............................................................................................  
SDM site 5    ACGCGT..............................................................................................  
SDM site 6    ACGCGT..............................................................................................  
SDM site 7&8  ACGCGT..............................................................................................  
SDM site 9    ACGCGT..............................................................................................  
SDM site 10   ACGCGT..............................................................................................  
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ms01 P100     CCCCTTCGCAGAACACTGCTTTAGCTAAACAGCAGTTCGTTACTGAAATAAACGCAACACCAACATTTGATGCTTATACATATGATAGTTCAGCTTCATA  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
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ms01 P100     TGGTGGATATTCTTCAAATGCTAGCTACCAACACACATCAGGTATGTTAGTTAGAGAACAAGGTGTTAATGAAATTCAAATTGATACAGTGACCTCAGAC  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
SDM site 10   ....................................................................................................  
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              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     ACTGGAAAAGTTTCAAACTATATTACTAAACCAGCTTTCTCAAAATATACATTATCATTAGCAAAAGCTGTAGTTTTAACTTTAACAGATGGCACAGTTG  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
SDM site 10   ....................................................................................................  
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              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     TAGTTTACGATAATGATGATGCTGAAGTTGTTCCTGCACCAGATTTAACTTATGTAGATGCTGCAGGTGAAACTAAAAAAGCTTATTCATCAGCATATCA  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
SDM site 10   ....................................................................................................  
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              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     AAGATTAAGTTCAGCAAATTCAAAATCAATTAATAGTCAAGAATTTGCAGAAAACTTGAAAAAAGCTAAAACATTACAATATGTACTTAAAGACAATTTA  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
SDM site 10   ....................................................................................................  
 
                      610       620       630       640       650       660       670       680       690       700          
              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     AAATGAGTAAATTCAAAAGGTGAAGAAACTAAATATCAAATTGTTCCTAAAGATTTCTATTATTCATGACTAAGAACAAATCAAACAATTGGTAATGTTC  
SDM site 1    .....G..............................................................................................  
SDM site 2    .....G..............................................................G...............................  
SDM site 3    .....G..............................................................G...............................  
SDM site 4    .....G..............................................................G...............................  
SDM site 5    .....G..............................................................G...............................  
SDM site 6    .....G..............................................................G...............................  
SDM site 7&8  .....G..............................................................G...............................  
SDM site 9    .....G..............................................................G...............................  
SDM site 10   .....G..............................................................G...............................  
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                      710       720       730       740       750       760       770       780       790       800          
              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     GTCATGATGAAGAAAAAAGTGGAGGTTCAGAACAATTAGACAATGAAGTTAGAGATGCATTAGCAAGACCTAACAGTCGTGTATTTACAGATACAAGTGA  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
SDM site 10   ....................................................................................................  
 
                      810       820       830       840       850       860       870       880       890       900          
              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     ATACTCAAATGAATATGTTTTAAAAATCTTTGGTTTAGATACAGTAAAATTAAATGAAGAAAGTGAATTCGTTAAAAAAGTTGCTCCAAGTGCAAATTTA  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
SDM site 10   ....................................................................................................  
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              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     GGAGATGTAACAGCTGTAACCTTCCAAGGATTAACAGGTGAAGGTGCTAAAGTTCAAATGAATCAATTTTTTGATCAATTAATGCATGACTATACATTCT  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
SDM site 10   ....................................................................................................  
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ms01 P100     ATCCAGCTCCATCACAATACATTGATGATATGAATGCAACAAATGGTTACAAATTAACTAATTACCAAGGCGATGTAACTGATAAAGTTTCTGCACTAGA  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
SDM site 10   ....................................................................................................  
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              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     AACTAAATCAAAAGCAATGGATAAAAGTAAATTAACTGCTAAATTAGGTGTTTACTGATATGGTGTAACAGCAAATAGTACATTGTATTCAGGACCATAC  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    .........................................................G..........................................  
SDM site 4    .........................................................G..........................................  
SDM site 5    .........................................................G..........................................  
SDM site 6    .........................................................G..........................................  
SDM site 7&8  .........................................................G..........................................  
SDM site 9    .........................................................G..........................................  
SDM site 10   .........................................................G..........................................  
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ms01 P100     TATGCACAAGGCTTTGTAAGTGGTCAATCAGAAATATTTAAAAAGAATACTCACTTTGCAGAAAAAGCCTTTGCAGAATCTAAAAATACAGTTAATGAAa  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
SDM site 10   ....................................................................................................  
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              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     TTATTACAAACTATCAACAAAAAACCTTAAGCCCTGAAGAATTTAATACAAACATCTTTAACTTATATAGACAAGGTACTACATCAACTACTCCATATTC  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
SDM site 10   ....................................................................................................  
 
                      1410      1420      1430      1440      1450      1460      1470      1480      1490      1500         
              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     ATCATTAACTGAAGCTCAAAAACAAATCGTTAACCAAGACCCACAAGGATTTGGTATTAGATTATTCAAAAGAGAAAATACTAATTCAGCTCCTTATGAT  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
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                      1510      1520      1530      1540      1550      1560      1570      1580      1590      1600         
              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
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ms01 P100     ATAATCCAAACTCCATTTGTGTTTAACAATGTTACTGCAGATTACTCATTTAACGATGCTTATGCTCAATTAATGTATGGTAAAACAATAGAAGAATTAA  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
SDM site 10   ....................................................................................................  
 
                      1610      1620      1630      1640      1650      1660      1670      1680      1690      1700         
              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     AAGCCGGAAAAGGTACAGGAGATGCTTATATTTACGGAACAGGTTTAAGTTTTAGAACTTTATTACAAGCTGCAATTAACTGAAATACAGTAGCAGATGT  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ..................................................................................G.................  
SDM site 5    ..................................................................................G.................  
SDM site 6    ..................................................................................G.................  
SDM site 7&8  ..................................................................................G.................  
SDM site 9    ..................................................................................G.................  
SDM site 10   ..................................................................................G.................  
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ms01 P100     AAGAACAAACGGTGTTTCAGAAGCTTGATTGGCGAAATTAGCCGATGGTGGTAATATTGGTGGAAAAGACCAAGAATCATCAGCAGAAAAAaCACCATTT  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ...........................G........................................................................  
SDM site 6    ...........................G........................................................................  
SDM site 7&8  ...........................G........................................................................  
SDM site 9    ...........................G........................................................................  
SDM site 10   ...........................G........................................................................  
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              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     GATGTAAAAGATAAAATTAATGCATTGAAAGCTGTAAATAAAGATAAACAATTAGTGGACTTCGGTGGCAATTTAGGAAAAGATCTAAACCCATCAGAAA  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
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ms01 P100     ACGATGCTGCTGTTAGAGACAGATCTAATGTCAACGACAAAATAAAATCAGCTGGTTATGAAAAAATTAAAGAAGCTGTAAAAGCATTATTAGATGAGTT  
SDM site 1    ....................................................................................................  
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ms01 P100     TGAAAGAACACATCAAAATGTTAGACCGGCAGATGGTAAATATAGATTCACTTCATTCTATCCATTTATTAATCAATCAAAAGAATTTGGTGAATCATTA  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
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              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     AAATTTGTTAAAGAGGCTATAGAAGGATTAGATTCTAGAATTCAATTAGATTTAGTATTCTTTACTGATAATAAAGATCCTAATTATGTTGCATATATAA  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
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SDM site 4    ....................................................................................................  
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ms01 P100     ACCAAGGAGCAAATGGAACAAGAAACGTTGGTTGAAGTTATGACTATAACTCAATAGGTTCAGGTTATGATGGTTTATCATGAAATTGACCATTATTCCC  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ..................................G.................................................................  
SDM site 7&8  ..................................G...............................................G.....G...........  
SDM site 9    ..................................G...............................................G.....G...........  
SDM site 10   ..................................G...............................................G.....G...........  
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ms01 P100     AACTCTAATTAAAATTGGTGTTGAAAAAGATAGTCATCCAGAATTTGCTACTGCATTTCCAAGAATCGCTAAATTAGCAGAAGATTTATTAGCTTATCAA  
SDM site 1    ....................................................................................................  
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SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
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ms01 P100     GAACAACCAGGTCACGAATTTGTATCTTCAGTACCATTTAAAGAATTATACAAAGTAGAACCAAGAAGATACACAGTATTGCCTACTCTATTAGCTTCAA  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
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ms01 P100     ATGTTACAAAAAATTCTGTAACAGATAAATATGAGCTTGTTTTAACAGAAAAAAATAGACCAATACCTTATAAACCACAAGGTAATAAGCAAGTAACTGA  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
SDM site 3    ....................................................................................................  
SDM site 4    ....................................................................................................  
SDM site 5    ....................................................................................................  
SDM site 6    ....................................................................................................  
SDM site 7&8  ....................................................................................................  
SDM site 9    ....................................................................................................  
SDM site 10   ....................................................................................................  
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              ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ms01 P100     TATTTATCAATACTCAGCGGTTTTCTGAAACCAATACGTAGCAGACAAAACAAATGATTATTTAACTGAATTAATGGAAGAACTAACAACATTTTTAGGT  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
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ms01 P100     ATTGAATATTCATCAGCAACTATAACAAAAGCAAAAGATTCATTTGTTAACGTTTTAGTACAAAAAGGTTATGTAGCACCTTACACAGTAAATAATAGTG  
SDM site 1    ....................................................................................................  
SDM site 2    ....................................................................................................  
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ms01 P100     TTGACATGTATGTTGATTGAAGAATCAATAAATAA        
SDM site 1    ...................................GTCGAC  
SDM site 2    ...................................GTCGAC  
SDM site 3    ...................................GTCGAC  
SDM site 4    ...................................GTCGAC  
SDM site 5    ...................................GTCGAC  
SDM site 6    ...................................GTCGAC  
SDM site 7&8  ...................................GTCGAC  
SDM site 9    ...................................GTCGAC  
SDM site 10   ...................G...............GTCGAC  
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